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Abstract 
 
Amyloidosis is a group of disorders in which specific soluble proteins convert 
into insoluble extracellular fibrillar deposits. Certain mutations in 
amyloid-prone proteins result in aggressive forms of the disease. 
β2-microglobulin (β2m), a cell surface protein and transthyretin (TTR), a 
normal plasma protein, are inherently amyloidogenic. In patients undergoing 
long-term dialysis, ineffective clearance of β2m from the plasma results in 
sustained increase of its concentration and its deposition as amyloid. 
Wild-type TTR is the amyloid precursor in senile systemic amyloidosis, a 
cause of heart failure in the elderly, and various different mutations in the 
human TTR gene cause the autosomal dominant conditions familial amyloid 
polyneuropathy and familial amyloid cardiomyopathy.  
The D76N β2m variant causes highly penetrant hereditary systemic 
amyloidosis. Similarly, the S52P TTR variant also causes aggressive 
amyloidosis which is characterised by prominent cardiac ATTR deposits. 
Animal models for Aβ2m amyloidosis and ATTR amyloidosis have long been 
sought to enable a better understanding of disease mechanisms and for 
validation of diagnostic methods and treatments, but previous attempts to 
model these diseases in vivo have met with limited or no success. The aims 
of this project were to generate mouse models of: (1) Aβ2m amyloidosis and 
(2) cardiac ATTR amyloidosis by transgenic expression of these highly 
amyloidogenic variants. 
In the work presented here, hβ2mD76N transgenic mice and hTTRS52P 
transgenic mice were generated. Despite expressing high plasma 
concentrations of the amyloidogenic proteins, the mice did not spontaneously 
develop amyloidosis. After priming amyloid deposition with pre-formed 
amyloid fibrils, the hβ2mD76N transgenic mice failed to develop amyloid 
deposits. It is notable that most of the β2m circulates bound in a complex, 
potentially limiting the availability of free β2m monomers for conversion into 
fibrils. In the hTTRS52P transgenic mice, priming of amyloid deposition with 
amyloid fibrils led to consistent and reproducible development of cardiac 
ATTR amyloidosis.  
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1 Introduction 
 
1.1 Amyloidosis 
The biological functions of proteins are directly linked to their specific three-
dimensional structures. Normally, incorrectly folded proteins trigger complex 
biological responses causing degradation of such proteins. However, failure 
of these systems can cause a loss of protein function or overabundance and 
aggregation of misfolded proteins, resulting in protein misfolding disorders. 
Amyloidoses represent the largest group of misfolding diseases where 
specific proteins convert from their soluble functional state into amyloid, a 
highly organised insoluble fibrillar material, deposited in extracellular spaces 
causing the disruption of tissue structure and function (Sipe et al., 2014). 
More than 30 proteins have been identified to form amyloid in humans (Sipe 
et al., 2014), with the number increasing every year. Classification of the 
amyloidoses is based on the precursor protein that forms the amyloid fibrils 
and the distribution of amyloid deposition (Sipe et al., 2014). Amyloidosis can 
be local, where the amyloid is restricted to a particular organ or tissue of 
precursor protein synthesis, or systemic with the amyloid present in any 
viscera, blood vessel walls and connective tissue. These two can be further 
grouped into acquired or hereditary amyloidoses (Pepys, 2006). Acquired 
amyloidosis is often a complication of a pre-existing primary disease that 
produces an amyloidogenic abnormal protein (e.g. the monoclonal 
immunoglobulin light (L) chains of AL amyloidosis) or prolonged production of 
a normal protein that is capable of being converted into amyloid (e.g. serum 
amyloid A (SAA) protein in AA amyloidosis). Hereditary amyloidosis is caused 
by mutant genes encoding variant proteins whose structure makes them 
particularly amyloidogenic (e.g. mutations in the gene for transthyretin (TTR) 
in ATTR amyloidosis). 
In amyloidosis, the presence of amyloid deposits is the cause of the clinical 
manifestations of the disease. Protein misfolding into amyloid also 
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accompanies other disease, e.g. Aβ peptide within the brain in Alzheimer’s 
disease (Glenner and Wong, 1984, Lu et al., 2013, Haass and Selkoe, 1993), 
islet amyloid polypeptide (IAPP) in the pancreatic Islets of Langerhans in type 
2 diabetes mellitus (Melato et al., 1977, Jurgens et al., 2011); but these are 
not classified as amyloidosis, because it is not established that amyloid 
causes these diseases. 
 
 
1.2 Amyloid and amyloid fibrils 
Amyloid refers to a highly organised, insoluble fibrillar material that is 
deposited mainly in the extracellular spaces of organs and tissues as a result 
of changes in protein folding (Pepys, 2006). Amyloid can form from 
disordered proteins that lack a well-defined tertiary structure or from partial 
unfolding of proteins that normally have well-defined tertiary structure (Chiti 
and Dobson, 2006). Once amyloid deposition has been initiated, and with 
continued production and abundance of the precursor protein, amyloid fibrils 
formation persistently progresses. Amyloid deposits are remarkably stable 
and inert, and natural clearance mechanisms are very inefficient (Pepys, 
2001, Gillmore et al., 2001). However, amyloid deposits are in a state of 
dynamic turnover and can regress if new fibril formation is halted (Tan and 
Pepys, 1994, Hawkins et al., 1993). Mechanisms of natural regression are 
unknown. 
The identification of amyloid depends on its ability to bind the dye Congo red 
and exhibit green, yellow or orange birefringence when the stained deposits 
are viewed under polarised light (Puchtler H, 1962). The optical effect is a 
result of alignment of the dye molecules along the fibrils. Congo red staining 
is not a very sensitive test and requires an adequate amount of amyloid, 
technically correct staining, high quality microscope and adequate observer 
experience. 
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Isolated amyloid fibrils can be imagined in vitro using transmission electron 
microscopy or atomic force microscopy. These imaging techniques revealed 
that all amyloid fibrils are straight, rigid, non-branching and consist of a 
number (usually 5 or 6) of protofilaments, each of which is about 2-5 nm in 
diameter (Serpell et al., 2000). These protofilaments twist together to form 
rope-like fibrils that are 7-13 nm wide (Serpell et al., 2000). X-ray diffraction 
analyses have shown that in each protofilaments, the protein molecules are 
arranged so that the peptide chain forms β-strand that run perpendicularly to 
the fibril long axis, regardless of the protein from which they are formed 
(Sunde et al., 1997). A schematic picture of an amyloid fibril is shown in figure 
1.1. Apart from Congo red, the amyloid fibrils also bind thioflavin T but this 
binding is less specific (Nilsson, 2004) and other detection techniques are 
under investigation (Sjolander et al., 2016). 
 
 
 
Figure 1.1: Amyloid fibrils 
Amyloid fibrils viewed under electron microscope (left) and their schematic 
structure (right). The mature amyloid fibril is formed from twisted 
protofilaments. Each protofilament is formed of β-strand peptide chain running  
perpendicularly to the fibril long axis. 
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The amyloidoses differ in the protein precursors aggregating into amyloid 
fibrils, the tissue and organs involved in amyloid deposition and consequently 
in the clinical features. Different amyloidoses (as defined by precursor 
protein) have different characteristic patterns of deposition. In systemic 
amyloidosis, the damage mostly occurs at tissue distant from the site of the 
precursor protein synthesis (Pepys, 2006). The process of fibril formation in 
extracellular spaces results in displacement of parenchymal tissue by amyloid 
deposits, causing tissue damage and organ dysfunction (Pepys, 2006). 
 
 
1.2.1 Amyloid fibril formation 
Amyloid formation in vivo occurs with normal wild-type proteins and with 
genetically variant amyloidogenic proteins. However, amyloid deposits do not 
appear immediately in any case and amyloidosis is extremely rare in children 
and young adults (Pepys, 2006). There is always a lag phase, often of many 
years, before the deposition of clinically significant amyloid (Pepys, 2006). 
The lag phase is believed to be the time required for formation of “nuclei” or 
“seeds” which then act as templates for amyloid-fibril growth (Serio et al., 
2000, Kisilevsky, 2000). Once the seeds are formed, a process which occurs 
stochastically in vivo, amyloid formation is autocatalytic and progressive, 
given the continued supply and/or abundance of the precursor protein. In 
animal models of amyloidosis, the lag phase can be greatly shortened by 
administration of an amyloid-containing tissue extract (Baltz et al., 1986a, Hol 
et al., 1986) or by isolated amyloid fibrils (Liu et al., 2007, Johan et al., 1998). 
In vitro, purified proteins can be converted into amyloid-like fibrils without any 
additional biological molecules, although the conditions under which this 
conversion happens are usually not physiological and require e.g. low pH, 
high temperature and/or organic solvents, which promote the proteins partial 
unfolding (Myers et al., 2006b, Picotti et al., 2007, Lashuel et al., 1998, 
Verdone et al., 2002). The possibility to form amyloid fibrils in vitro has led to 
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extensive experiments of protein fibrillogenesis studying the underlying 
mechanisms of such processes. From the outcomes of such experiments, it is 
generally believed that the conversion of a soluble monomeric peptide into 
insoluble mature amyloid fibrils involves a partially unfolded intermediate that 
is thermodynamically unfavourable and rapidly progresses to the stable 
amyloid form (Litvinovich et al., 1998, Kelly, 1998, Teplow, 1998, Quintas et 
al., 2001). The studies on kinetics of this transition then proposed the above 
mentioned nucleation dependent model, when a heterogeneous “nucleus” is 
formed consisting of oligomeric misfolded protein. Such seed then acts as a 
template in the polymerization step when normally folded monomeric 
polypeptides bind to the nucleus forming wide variety of structures from small 
soluble oligomers to large amyloid fibrils (Kisilevsky, 2000). Seeding with 
natural or synthetic pre-formed fibrils accelerates fibrillogenesis in vitro 
(Myers et al., 2006a). 
During the fibril formation, several multimeric or polymeric non-fibrillar 
structures have been identified. These include very early species called 
oligomers (dimers, trimers, teteramers) and later beaded-like structures up to 
200 nm in length called protofibrils (Walsh et al., 1999, Harper et al., 1997, 
Walsh et al., 1997, Ionescu-Zanetti et al., 1999). These are believed to be 
soluble intermediates in the formation of mature, insoluble amyloid fibres. 
 
 
1.2.2 Amyloid associated molecules 
Each type of amyloid is characterised by the amyloid-precursor protein that 
forms the core. Irrespective of the amyloid protein, there are common 
additional non-fibrillar constituents found in all amyloid deposits in vivo but 
their function in not fully understood. These minor constituents include 
glycosaminoglycans (Pras et al., 1971), serum amyloid P (Baltz et al., 1986b), 
apolipoprotein E (Wisniewski and Frangione, 1992). 
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Glycosaminoglycans (GAGs) are linear polysaccharides ubiquitously present 
in all mammalian organs and tissues, mostly in extracellular spaces and on 
the cell surface. GAGs – mostly heparan sulphate, chondroitin sulphate and 
dermatan sulphate have been co-purified and ultrastructurally co-localised 
with various amyloid fibrils (Nelson et al., 1991, Magnus et al., 1992). They 
may contribute to amyloid fibrillogenesis and stabilization of the fibril structure 
(Pras et al., 1971, Nelson et al., 1991, Madine et al., 2013). 
Serum amyloid P component (SAP), a normal circulating plasma protein, is a 
member of the pentraxin protein family, that is secreted and catabolised by 
hepatocytes (Hutchinson et al., 1994). SAP reversibly binds to all amyloid 
deposits in vivo and accounts for up to 15% of their mass (Pepys et al., 
1979). It has been shown that SAP stabilizes amyloid fibrils and protects them 
from degradation by proteases and phagocytic cells in vitro (Tennent et al., 
1995) and contributes to amyloidogenesis in vivo (Botto et al., 1997). The 
occurrence of SAP in all types of amyloid and the binding of SAP to amyloid 
has found its use in diagnosis and quantitative monitoring of amyloid deposits 
by intravenous injections of radioactively labelled SAP (SAP scintigraphy) 
(Hawkins et al., 1990a), which is introduced below. 
 
 
1.2.3 Pathogenicity of amyloid 
The physical presence of amyloid deposits in extracellular spaces results in 
displacement of parenchymal tissue causing a disruption of tissue structure 
and function, and organ dysfunction. Increasing amyloid load increases the 
severity of the disease and stabilization or regression of amyloid deposits is 
associated with clinical stability or improvement of amyloidosis patients 
(Pepys, 2006).  
Recently, the cytotoxicity of amyloid fibrils and pre-fibrillar amyloid deposits 
has been debated. It has been suggested by in vitro studies that pre-fibrillar 
intermediates have a cytotoxic effect on cells of the affected tissue inducing 
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oxidative stress and cell apoptosis (Bucciantini et al., 2004, Lorenzo et al., 
1994, Reixach et al., 2004, Walsh et al., 2002). In a mouse model, the site of 
amorphous TTR aggregates coincided with an increase of oxidative stress in 
the tissue which may be caused by cytotoxic effects of the TTR aggregates 
on surrounding cells (Sousa et al., 2002). Thus, although amyloid is inert, and 
amyloidosis is defined by the presence of mature amyloid deposits, cytotoxic 
pre-fibrillar material may in some cases contribute to clinical disease. 
 
 
1.3 Epidemiology of amyloidosis 
Although more than 30 different amyloid proteins cause amyloidosis, 5 types 
of amyloidosis account for ~95 % of all amyloidoses (Wechalekar et al., 2016, 
Takahashi et al., 2016, Aguirre et al., 2016) – immunoglobulin light chain (AL) 
amyloidosis, serum amyloid A (AA) amyloidosis, transthyretin (ATTR) 
amyloidosis, β2-microglobulin (Aβ2m) amyloidosis and fibrinogen A α-chain 
(AFib) amyloidosis. Characteristics of the common types of amyloidoses are 
shown in Table 1.1. Death certificates from the UK indicate that amyloidosis is 
a cause of death in 0.58 per 1000 individuals (Pinney et al., 2013a). The 
incidence of amyloidosis in the UK is ~0.4 per 100 000 population with the 
incidence peak at age 60-79 years (Pinney et al., 2013a). 
Patterns of referrals have changed considerably over the last 20 years in the 
National Amyloidosis Centre (NAC) in the UK (Wechalekar et al., 2016)  – the 
frequency of AL amyloidosis has remained stable (67 % of all cases – as a 
proportion of total referrals per year), a substantial decrease has been seen in 
AA amyloidosis (from 32 % to 6.8 % of all cases) which probably reflects 
improvement of treatment of inflammatory arthropathies, whereas wild-type 
ATTR amyloidosis-related cardiomyopathy has increased greatly (from 0.2 % 
to more than 6.4 %) (Wechalekar et al., 2016). 
 
 
25 
 
 
Fibril 
protein Precursor protein 
Acquired or 
Hereditary 
Patients seen 
in the UK-NAC Underlying disorder 
Main target 
organs 
AL Immunoglobulin light chain (L) Acquired 4067 (68%) Plasma cell dyscrasia H, K, L, PN 
AA Serum amyloid A (SAA) Acquired 633 (12%) Inflammatory disorders K, (late – L, H) 
ATTR Transthyretin (TTR), wild-type Acquired 168 (3.2%) Not known H 
 Transthyretin (TTR), variants Hereditary 339 (6.6%) Mutations in TTR gene PN, H 
AFib Fibrinogen A (Fib), variants Hereditary 87 (1.7%) Mutations in Fib gene K 
ALect2 Leukocyte chemotactic factor-2 (Lect2) Acquired 16 (0.3%) Not known K, L 
AApoAI Apolipoprotein AI (ApoAI), variants Hereditary 40 (0.8%) Mutations in ApoAI gene K, L 
ALys Lysozyme (Lys), variants Hereditary 17 (0.3%) Mutations in Lys gene L, K 
AGel Gelsolin (Gel), variants Hereditary 4 (0.1%) Mutations in Gel gene PN 
Aβ2m β2-microglobulin (β2m), wild-type Acquired 93 (1.8%) Long-term dialysis MS system 
 β2-microglobulin (β2m), variant Hereditary - Mutation in β2m gene PN, A, S, L, H 
 
Table 1.1: Characteristics of the common types of systemic amyloidoses 
Frequency of different amyloid types among 5100 individuals with amyloidosis 
assessed in the National Amyloidosis Centre (NAC) in the UK from 1987 to 2012. 
Amyloid fibril protein is designated letter A and followed by the abbreviation of the 
precursor protein name. H=heart, K=kidney, L=liver, PN=peripheral nervous system, 
MS=muscular-skeletal system, A=adrenal, S=spleen. (Amended from Wechalekar et 
al., 2016.)  
 
 
1.4 Types and clinical features of systemic 
amyloidoses 
Amyloidoses are heterogeneous affecting multiple organs and the clinical 
features of systemic amyloidosis are rarely specific to one type of 
amyloidosis. Moreover, some types of amyloidoses invariably affect a specific 
organ (e.g. wild-type ATTR amyloidosis always affects the heart) whereas 
involvement of a specific organ ranges from absent to severe in other types of 
amyloidosis (Wechalekar et al., 2016). In this section, the involvement of 
major organs in different types of amyloidoses is introduced. 
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Heart is the most common organ involved in amyloidosis and cardiac 
amyloidosis is the most prominent cause of morbidity and mortality in 
amyloidosis (Wechalekar et al., 2016, Takahashi et al., 2016). The most 
common forms of cardiac amyloidosis are the AL and ATTR types. In AL 
amyloidosis, cardiac amyloid occurs in ~50 % of patients (Merlini, 2012, Patel 
and Hawkins, 2015). Cardiac involvement is the dominant feature in wild-type 
ATTR amyloidosis and some hereditary ATTR amyloidoses (Patel and 
Hawkins, 2015), although in some TTR variants cardiac amyloid is 
uncommon (e.g. V30M) or not reported (Connors et al., 2003). Amyloid in the 
heart is also a common feature in apolipoprotein A-I (ApoAI) amyloidosis 
(Patel and Hawkins, 2015). Amyloid deposition in the heart results in 
progressive thickening of ventricular walls, increases myocardial stiffness and 
ventricular filling pressure, which leads to atrial enlargement and atrial 
fibrillation and can cause systemic embolic events (Feng et al., 2007). The 
most common types of death in cardiac amyloidosis are progressive heart 
failure and arrhythmia (Selvanayagam et al., 2007). 
The kidneys are most commonly involved in AA, AL, AFib and ApoAI 
amyloidoses (Lachmann et al., 2007, Merlini et al., 2014, Wechalekar et al., 
2016, Gregorini et al., 2005, Stangou et al., 2010) and renal amyloid is often a 
source of morbidity. The clinical manifestation of renal amyloid is proteinuria 
or renal dysfunction, with varying degrees of renal insufficiency. Amyloid can 
be found anywhere in the kidney but deposition in the glomeruli predominates 
(Dember, 2006). Renal impairment tends to progress more rapidly when the 
amyloid is deposited in the glomeruli of the kidney than in the interstitium of 
the kidney tubules (Dember, 2006). 
Autonomic and peripheral nerves are another major sites involved in AL 
amyloidosis, some hereditary forms of ATTR amyloidosis, ApoAI amyloidosis 
and hereditary β2m amyloidosis (Wechalekar et al., 2016, Sousa et al., 1993, 
Valleix et al., 2012, Adams, 2001). Peripheral neuropathy is usually axonal 
and begins with loss of sensation of cold and heat and with feeling of pins and 
needles. The sensory neuropathy is followed by motor neuropathy with loss of 
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extensor function of toes and feet causing unstable walking (Carr et al., 
2016). Autonomic neuropathy is manifested by urinary incontinence, sweat 
abnormalities, diarrhoea alternating with constipation, erectile dysfunction, 
orthostatic hypotension (Gertz et al., 2015). 
Carpal tunnel syndrome is a common complication of ATTR amyloidosis and 
acquired β2m amyloidosis (Kopec et al., 2011, Sekijima et al., 2011). It results 
from compression of median nerve and its entrapment in the carpal tunnel by 
amyloid deposits. 
Amyloid deposits in the liver are very common in AL amyloidosis, in later 
stages of AA amyloidosis, in ApoAI amyloidosis and AFib amyloidosis 
(Lachmann et al., 2007, Wechalekar et al., 2016, Janssens et al., 2010). The 
clinical manifestations of hepatic amyloid are mild. Accumulation of amyloid 
may increase the rigidity of the liver parenchyma resulting in higher liver 
stiffness (Janssens et al., 2010). Amyloid is also commonly found in spleen in 
systemic amyloidosis but usually asymptomatic. An atraumatic rupture of 
amyloidotic spleen has been reported but is extremely rare (Renzulli et al., 
2009). 
Gastrointestinal involvement is common in systemic amyloidosis and about 
30-60 % of patients develop gastrointestinal symptoms (Friedman and 
Janowitz, 1998, Petre et al., 2008). Amyloid in the tongue is a characteristic of 
AL amyloidosis and is present in 10-23 % patients with AL amyloidosis (Kyle 
and Gertz, 1995). Hereditary ATTR amyloidosis often manifests with 
gastrointestinal symptoms but these may occur due to autonomic 
polyneuropathy. 
Amyloid deposits in fat tissue are almost universal but asymptomatic 
(Westermark and Stenkvist, 1973). 
Although the amino acid sequence of proteins and the sustained supply of the 
relevant protein dictate the potential of a protein to form amyloid, the 
mechanisms that influence the preferential site of amyloid deposition are not 
yet understood. Genetic and/or environmental factors also play an important 
role in susceptibility to amyloid formation. This is apparent for example in 
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cases when the same V30M variant TTR, responsible for familial amyloid 
polyneuropathy has a later onset and lower penetrance in the Swedish form 
of the disease (Sousa et al., 1993, Hellman et al., 2008) than in the 
Portuguese and Japanese populations, in which the onset is much earlier and 
the penetrance is much higher (Tawara et al., 1983, Plante-Bordeneuve et al., 
2003). 
 
 
1.5 Diagnosis of amyloidosis 
Amyloidoses are complicated to diagnose because of different organs 
systems involvement and the localisation of amyloid deposits varies 
according to the amyloidogenic protein. They are often diagnosed in 
advanced stage of the disease because amyloidosis is only considered when 
the various more common causes of the symptoms have been ruled out. The 
diagnosis of amyloidosis includes careful clinical evaluation, confirmation of 
amyloid deposition, identification of amyloid type, assessment of the 
underlying amyloidogenic disorder, and evaluation of the extent of amyloidotic 
organ involvement. Family history is also important for diagnosis of hereditary 
amyloidosis. 
The diagnosis of amyloid relies on histological analysis of affected organ 
biopsies stained with the dye Congo red after which the amyloid appears red 
under bright field illumination and turns orange, yellow or green with polarised 
light (Figure 1.2). Biopsy of subcutaneous fat is often used for histological 
diagnosis of amyloid (Westermark and Stenkvist, 1973).  
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Figure 1.2: Identification of amyloid by Congo red 
Amyloid in a tissue specimen binds the dye Congo red. In a light microscope, 
the amyloid appears red under bright field (A) and turns green/orange when a 
polarization filter is applied (B). AA amyloid in mouse spleen. 
 
 
Immunohistochemical staining of tissue containing amyloid is the most widely 
available method to identify the specific amyloid fibril protein (Schonland et 
al., 2012). Mass spectrometry of amyloidotic material is now also used for 
fibril typing. This analysis involves laser microdissection and capture of 
Congo red-positive material from fixed tissue section with a laser-capture 
microscope. Computer algorithms then match the material to a protein 
reference database (Vrana et al., 2009, Gilbertson et al., 2015). This is 
technically challenging and requires validation in each laboratory before 
routine clinical use (Wechalekar et al., 2016). When hereditary systemic 
amyloidosis is suspected, gene sequencing is performed. 
In AL and AA amyloidoses, identification of the underlying disorder is an 
important step in diagnosis. Measurement of free immunoglobulin light chain 
in serum is required to detect monoclonal protein underlying AL amyloidosis 
(Palladini et al., 2009) and is informative in 95 % of cases (Lachmann et al., 
2003). In AA amyloidosis, identification of the underlying inflammatory 
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disorder responsible for elevated levels of the amyloidogenic serum amyloid 
A (SAA) protein is needed. However, sometimes the cause of elevated SAA 
levels is not known. 
 
SAP scintigraphy, a non-invasive method using radiolabelled SAP as a 
specific tracer for amyloid, is used to evaluate the amyloid load in vivo 
(Hawkins et al., 1988, Hawkins et al., 1990a). SAP, a normal plasma protein, 
binds avidly to all amyloid of human systemic amyloidoses and becomes 
concentrated at the sites of amyloid deposition. The fact that there is constant 
equilibrium between the circulating and the amyloid-bound SAP and that the 
amount of amyloid-bound SAP correlates with the quantity of amyloid present 
in the tissues (Baltz et al., 1986b) led to the development of a specific and 
quantitative in vivo tracing method for systemic amyloid deposition (Hawkins 
et al., 1990a). This clinical method uses intravenously administered 
radiolabelled 125I-human SAP (125I-hSAP) which is distributed between the 
plasma and the amyloid deposits. 125I-hSAP which retains in the body bound 
to amyloid then enables screening of the amyloid burden in amyloidosis 
patients (Figure 1.3). It has been shown that SAP scintigraphy is a safe and 
non-invasive technique providing information on the presence, distribution, 
extent and regression of amyloid deposits of all types which can be used 
repeatedly (Hawkins et al., 1993). Major limitation of this technique is that it is 
unable to image amyloid in the moving heart. SAP scintigraphy is only 
available in NAC in London and in the University of Groningen in the 
Netherlands (Wechalekar et al., 2016). 
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Figure 1.3: SAP scintigraphy scans from a patient with AL amyloidosis 
SAP scintigraphy scans from a patient with AL amyloidosis. In 2005, heavy 
amyloid deposits were seen on the scan in liver and spleen. In 2009, after a 
good response to treatment, a considerable regression of the deposits were 
observed. In 2011, the scan showed a relapse with amyloid deposits in the 
kidneys (Pepys et al., 2012). 
 
 
Cardiac amyloidosis is commonly assessed by echocardiography revealing 
ventricular wall thickening and diastolic dysfunction. Cardiac magnetic 
resonance imaging (MRI) is more precise and reproducible than 
echocardiogram (Maceira et al., 2005). Cardiac MRI can give accurate 
anatomical information, including the wall thickness and allows quantification 
of the myocardial interstitial volume fraction, which is greatly expanded in 
amyloidosis (Banypersad et al., 2013). Recently, it has been observed that 
scintigraphy with 99m-technetium (99mTc) labelled phosphate derivatives used 
commonly as a bone nuclear tracer, detects amyloid in some cases. 
Interestingly, the bone tracer is highly sensitive for ATTR amyloid and some 
AL amyloid (Puille et al., 2002). This method has been studied in order to 
validate its use for evaluation of cardiac amyloid (Perugini et al., 2005, Puille 
et al., 2002, Hutt et al., 2014). 
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1.6 Treatment of amyloidosis 
Supportive care to maintain organ function is crucial for all types of 
amyloidosis. Liver transplantation to remove the hepatic source of the 
genetically variant amyloidogenic protein has been performed in selective 
patients with ATTR, AApoAI and AFib amyloidoses (Wechalekar et al., 2016). 
To date, the most effective treatment of systemic amyloidosis is focused on 
the reduction in the supply of the amyloid fibril precursor protein so that 
amyloid deposition ceases and regression of existing amyloid deposits can 
occur (Pepys, 2006) However, this is not yet possible for some types of 
amyloidosis (Wechalekar et al., 2016). The treatment of the most common 
types of amyloidoses is briefly introduced. 
Treatment of AL amyloidosis involves chemotherapy that targets the 
underlying clonal plasma cell dyscrasia which leads to a rapid reduction in 
production of amyloidogenic light chains by the B-cells, limiting progressive 
damage to amyloidotic organs (Comenzo et al., 2012). However, treatment 
toxicity on amyloidotic organs with reduced function requires frequent 
assessment and a possible rapid change in treatment. Although the survival 
in patients with AL amyloidosis has increased over the past few years, nearly 
25 % of all patients still die of disease-related complications within a few 
months of diagnosis (Wechalekar et al., 2016). Chemotherapy followed by 
autologous stem cell transplant has shown very good results leading to 
improvement in organ function and survival of AL amyloidosis patients 
(Dispenzieri et al., 2013, Cibeira et al., 2011). No particular treatment 
combination has yet been shown to reduce early cardiac deaths in AL patient 
with advanced progression of the disease (Wechalekar et al., 2013). 
In AA amyloidosis, the crucial step in management of the disease is a 
reduction of SAA production with treatment of the underlying inflammatory 
disorder causing the elevated concentrations of circulating SAA (Lachmann et 
al., 2007). 
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Other promising strategies in treatment of systemic amyloidosis which are in 
development are based on the prevention of amyloid formation. This may be 
achieved by stabilization of the fibril precursor protein in order to inhibit its 
misfolding which is of particular interest in transthyretin amyloidosis and this 
strategy is discussed in transthyretin amyloidosis chapter together with 
RNA-inhibiting therapies targeting the synthesis of TTR. Tetracyclines, and in 
particular Doxycycline have been shown to inhibit fibril formation and disrupt 
amyloid fibrils in vitro (Giorgetti et al., 2011, De Luigi et al., 2008) and 
experiments in animal models suggested similar effects in vivo (Aitken et al., 
2010, Cardoso and Saraiva, 2006). On the basis of these studies, clinical 
trials designed to evaluate the efficacy, tolerability and safety of doxycycline 
are under investigation showing beneficial effects on stabilization of the 
disease progression in ATTR amyloidosis (Obici et al., 2012), AL amyloidosis 
(Wechalekar et al., 2015) and pain relief in Aβ2m amyloidosis (Montagna et 
al., 2013). 
Another approach in treatment of amyloidosis is interfering with the 
interactions between amyloidogenic protein and additional molecules 
contributing to fibril aggregation. Inhibition of the interaction between GAGs 
and amyloid fibrils (Kisilevsky et al., 2007) is a possible approach to treatment 
of amyloidosis, and Eprodisate which acts in this way has been reported to 
slow the decline of renal function in AA amyloidosis (Dember et al., 2007). 
Recently, a novel immunotherapeutic approach of directly targeting amyloid 
deposit for removal has been reported (Bodin et al., 2010). This strategy uses 
antibody that targets SAP, a common non-fibrillar component of amyloid 
deposits which binds to all amyloid fibrils (Pepys et al., 1979). The use of SAP 
as the target means that the same treatment is, in principle, suitable for all 
types of amyloid. In order to prevent immune complex formation between 
circulating SAP and the therapeutic antibody, the circulating SAP protein is 
depleted using the drug CPHPC (Pepys et al., 2002, Gillmore et al., 2010). 
CPHPC cross-links the SAP pentamers to form decamers that are rapidly 
cleared by the liver (Pepys et al., 2002)  SAP remaining in the amyloid then 
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provides a specific target for the antibody. In mouse models of AA 
amyloidosis, this treatment approach resulted in activation of complement on 
the deposits thereby attracting and engaging macrophages which then fused 
to multinucleated giant cells capable of engulfing and rapidly clearing 
amyloidosis masses (Bodin et al., 2010, Simons et al., 2013). These results 
led to human phase I clinical trial of anti-SAP antibody treatment, which has 
reported extremely promising results with rapid reduction in liver amyloid 
deposits (Richards et al., 2015). Data on efficacy in cardiac and renal disease 
are awaited (Richards et al., 2015, Wechalekar et al., 2016). 
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1.7 β2-microglobulin amyloidosis 
 
1.7.1 β2-microglobulin 
β2-microglobulin (β2m) is a 11.7 kDa protein ubiquitously expressed by all 
nucleated cells. It was first described in 1968 by Bergaard and Bearn who 
isolated the protein from urine of patients with renal proximal tubular disorders 
(Berggard and Bearn, 1968). Subsequent amino-acid sequence studies of 
β2m revealed its similarity with an immunoglobulin polypeptide chain 
(Peterson et al., 1972) leading to a discovery that β2m is an integral part of 
histocompatibility antigens on a cell surface (Grey et al., 1973, Peterson et 
al., 1974). Evidence was then provided that murine histocompatibility antigen 
also contains a polypeptide subunit analogous to its human β2m counterpart 
(Rask et al., 1974). β2m and its role in immune system as a part of major 
histocompatibility complex (MHC) class I molecules expressed by all 
nucleated cells has been since well characterised. 
 
1.7.1.1 β2-microglobulin and MHC class I 
MHC class I is a plasma membrane heterodimer capable of binding and 
presenting peptides from intracellular proteins to cytotoxic CD8+ 
T-lymphocytes. Peptides derived from normal cellular self-proteins are 
ignored by the CD8+ T-lymphocytes (Jardetzky et al., 1991), whereas 
peptides derived from mutated proteins or from pathogenic proteins trigger an 
adaptive immune response trough binding to CD8+ T-cells presented by MHC 
class I. MHC class I also play an important role in innate immunity through 
natural killer (NK) cells. NK cells have the ability to recognize and non-
specifically kill cells lacking self MHC class I molecules, e.g. tumour cells 
(Bessoles et al., 2014, Kim et al., 2005). 
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Figure 1.4: MHC class I molecule 
MHC class I molecules are present on the membrane distant surface of all nucleated 
cells. The complex consists of two polypeptide chains – heavy chain made of three 
domains (α1, α2, α3) and a non-covalently associated light chain, β2-microglobulin. 
The heavy chain binds the peptide fragment and so determines the antigen 
specificity, β2-microglobulin stabilizes the complex on the cell surface. 
 
 
The MHC class I molecule is a heterodimer composed of a 47 kDa heavy 
chain glycoprotein and a non-covalently associated 11.7 kDa β2m protein. 
The complex folds and assembles in the endoplasmatic reticulum (ER), 
where the newly synthesized heavy chain interacts with β2m protein through 
the assistance of chaperones calnexin (Diedrich et al., 2001, Degen et al., 
1992), calreticulin (Sadasivan et al., 1996), tapasin (Ortmann et al., 1997) and 
the thiol oxidoreductase ERp57 (Morrice and Powis, 1998). These 
chaperones together with the heavy chain, β2m and a transporter protein TAP 
(Ortmann et al., 1994) form a MHC class I loading complex (Cresswell et al., 
1999). The release of the MHC class I dimer from the loading complex is 
induced when an antigenic peptide binds to the peptide-binding side of the 
MHC class I (Knittler et al., 1999, Jackson et al., 1994). 
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The peptides presented by MHC class I come from defective ribosomal 
translation products (Yewdell et al., 1996) and from functional mature proteins 
(Colbert et al., 2013), both degraded by proteasomes in cytosol. The peptides 
are actively transported from the cytosol into the ER by the Transporter 
Associated with antigen Processing (TAP) (Shepherd et al., 1993). TAP 
interacts with MHC class I loading complex, allowing peptides to reach the 
MHC class I peptide-binding groove (Sadasivan et al., 1996). 
The fully assembled peptide-MHC class I complex then leaves ER via the 
Golgi apparatus to the plasma membrane where the bound peptide is 
exposed extracellularly, accessible to CD8+ T-lymphocytes (Swain, 1983). 
β2m bound to the heavy chain domain stabilizes the complex on the cell 
surface but is not directly involved in the interaction with the MHC-bound 
peptide fragment (Otten et al., 1992) (Figure 1.4). 
The importance of β2m in the MHC class I assembly and transport to the cell 
surface was shown in transgenic mice with disrupted β2m gene. These mice 
lack MHC class I antigens on the cell surface and are deficient in CD4- CD8+ 
T-cells (Zijlstra et al., 1990, Koller et al., 1990). 
The type of bound peptide, the binding affinity of such peptides and 
interactions with T-cells, play a role in MHC class I turnover (Tsomides et al., 
1991, Eberl et al., 1996). After the dissociation of the peptide from the MHC 
class I on the cell surface, the complex is destabilised, β2m is released into 
the circulation and the membrane-bound heavy chains are endocytically 
internalised and destroyed in lysosomes (Cresswell et al., 1974, Machold and 
Ploegh, 1996).  
 
1.7.1.2 β2-microglobulin associated with other membrane 
molecules 
Similar to its function in MHC class I, β2m is non-covalently bound to a CD1 
heavy chain and is essential for processing and the surface transport of CD1 
complex (Bauer et al., 1997). CD1 molecules comprise a group of 
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transmembrane glycoproteins expressed on thymocytes and antigen 
presenting cells including dendritic cells, epithelial cells and B-cells (Calabi 
and Milstein, 1986, Small et al., 1987) which present antigenic lipids for 
natural killer T cells (Beckman et al., 1994). The assembly of CD1 complex 
takes place in the ER with the assistance of chaperones also involved in the 
formation of MHC class I loading complex – calnexin, calreticulin and ERp57 
(Kang and Cresswell, 2002). 
β2m is also a part of an IgG-Fc receptor (FcRn). Similarly to MHC class I,  
β2m is a light chain non-covalently bound to a FcRn-heavy chain (Simister 
and Mostov, 1989).  FcRn is involved in the transfer of temporary passive 
immunity from mother to the foetus (Story et al., 1994, Israel et al., 1995) and 
binds IgG and albumin and rescues both from degradation by an intracellular 
recycling mechanism (Junghans and Anderson, 1996, Chaudhury et al., 
2003). In β2m knock-out mice, new born pups show lower IgG serum levels at 
birth than their littermates expressing the endogenous β2m (Israel et al., 
1995) and adult β2m knock-out mice have a higher IgG turnover, resulting in 
lower IgG levels than wild-type controls (Junghans and Anderson, 1996, 
Ghetie et al., 1996, Spriggs et al., 1992). 
β2m is necessary for expression of the HFE protein on the cell surface (Bhatt 
et al., 2007). HFE-deficiency causes hemochromatosis, an iron overload 
disorder associated with mutation in the HFE gene. The HFE gene is related 
to MHC class I family and was originally named HLA-H (Barton et al., 2015, 
Feder et al., 1996). Mice lacking the endogenous β2m were shown to develop 
iron overload confirming that β2m is essential for the function of the 
hemochromatosis protein (Bhatt et al., 2007, Rothenberg and Voland, 1996). 
 
1.7.1.3 β2-microglobulin in biological fluids 
β2m is expressed on the cell surface as a part of complexes with 
immunological functions. When the complexes dissociate, most of β2m is 
shed from the cell surface into circulation. β2m is normally present in low 
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concentrations in all body fluids – serum, urine, cerebro-spinal fluid, saliva 
(Berggard and Bearn, 1968, Evrin et al., 1971). 
The concentrations of β2m in healthy people are 1-3 mg/l in serum, 1.7 mg/l 
in cerebro-spinal fluid and 1.1 mg/l in saliva (Berggard and Bearn, 1968, Evrin 
et al., 1971) and are kept constant by renal catabolism. In all body fluids, β2m 
is present in its free form (Plesner and Bjerrum, 1980). In human serum, 
beside the free form, 2% of the protein was found to be associated with MHC 
class I heavy chains (Plesner and Bjerrum, 1980). 
More than 99.9% of the circulating β2m is cleared through the kidney 
glomeruli into the kidney tubules where it is reabsorbed by the proximal 
tubular cells and degraded, thus only 0.1% of the kidney filtered β2m enters 
urine in normal, healthy individuals (Peterson et al., 1969, Karlsson et al., 
1980). The function, if any, of free β2m in the body fluids is unknown. 
 
 
1.7.1.4 Pathophysiology of β2-microglobulin 
Increased serum β2m is associated with several pathologies. β2m levels rise 
despite normal kidney function when β2m production is elevated, e.g. in 
chronic inflammatory conditions (Yilmaz et al., 2014), in some viral infections 
(Cooper et al., 1984) and in malignancies of the hematopoetic system (Nakao 
et al., 1981). Serum β2m increases in patients with impaired kidney function 
because of inefficient clearance and catabolism of the protein in renal failure, 
even though production of β2m is normal. Increased urine β2m concentration 
indicates renal proximal tubule impairment causing insufficient reabsorption of 
β2m. Concentration of β2m in cerebro-spinal fluid reflects immune activation 
and lymphoid cell turnover in the central nervous system (Hansen et al., 
1992). 
One of the most serious pathophysiological properties of β2m is its ability to 
form amyloid. Aβ2m amyloidosis can be acquired or genetic (Gejyo et al., 
1986b, Valleix et al., 2012). 
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1.7.2 Wild-type β2-microglobulin amyloidosis 
In 1985, Gejyo et al. identified β2-microglobulin as the protein forming amyloid 
fibrils isolated from amyloid-containing tissue in patients undergoing chronic 
dialysis (Gejyo et al., 1985). This finding started a new approach of research 
of β2m as one of the proteins able to form amyloid in vivo.  
The acquired systemic wild-type Aβ2m amyloidosis is also referred to as 
dialysis-related amyloidosis (DRA) because it is a serious complication for 
patients undergoing long-term dialysis. As β2m is cleared and catabolized 
only by the kidney and is poorly cleared by dialysis membranes, its circulating 
concentrations in end-stage renal failure patients rise up to ~50 µg/ml (Floege 
et al., 1991). As a consequence of the β2m elevated levels in the serum, and 
by mechanisms that are currently poorly understood, wild-type β2m forms 
amyloid fibrils that target the cartilage of osteoarticular tissue, initially on the 
surface of the cartilage, subsequently extending to the synovia, joint capsules 
and tendons.  
 
Epidemiology of wild-type Aβ2m amyloidosis 
The incidence and prevalence of Aβ2m amyloidosis in dialysis patients is not 
known. In 1997, post-mortem examination revealed that the prevalence of 
histologically detectable Aβ2m amyloid already reaches 21 % within 2 years 
of the onset of haemodialysis, 50 %  at 4-7 years and rises to >90 % beyond 
7 years of dialysis (Jadoul et al., 1997). In comparison, clinical studies have 
reported 50 % prevalence at 12 years of hemodialysis and almost 100 % at 
20 years (Koch, 1992, Kopec et al., 2011, Jadoul, 1998). Over the last years, 
the incidence of wild-type Aβ2m amyloidosis has decreased by ~50 % due to 
improved dialysis methods (Hoshino et al., 2016, Schiffl, 2014). However, 
wild-type Aβ2m amyloidosis remains a disabling condition in patients who 
undergo long-term dialysis over 10 years, despite the advanced dialysis 
technology (Schiffl, 2014).  
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Clinical manifestations of wild-type Aβ2m amyloidosis 
The clinical manifestations of wild-type Aβ2m amyloidosis are erosive and 
destructive osteoarthropathies, destructive spondyloarthropathy and carpal 
tunnel syndrome. The typical sites of involvement are sternoclavicular joints, 
hips, knees, shoulders, wrists and spine (Bardin et al., 1987, Jadoul et al., 
1997). The pathological features in osteoarthropathies are joint destructions 
and dislocations, bone lesions of amyloid that can lead to pathologic 
fractures, shoulder and wrist tendons thickening and fluid collection in the 
joints (Kiss et al., 2005). In spondyloarthropathy, Aβ2m amyloid deposits are 
found in intervertebral discs and the spinal ligaments causing erosion of the 
vertebral body and severe narrowing of the intervertebral disc space (Marcelli 
et al., 1996). As the disease progresses, the vertebrae collapse and the 
patients may develop severe neurologic complications (Marcelli et al., 1996). 
Carpal tunnel syndrome is induced by the amyloid deposition around 
synovium in the carpal tunnel causing compression of the nerves (Kiss et al., 
2005). 
Rare cases of visceral dialysis-related amyloid have also been reported – 
organs involved include spleen, heart, gastrointestinal tract, blood vessels, 
lung (Gal et al., 1994, Jimenez et al., 1998, Takayama et al., 2001), but 
typically the amyloid deposits are restricted to osteoarticular structures. 
 
Diagnosis and treatment of wild-type Aβ2m amyloidosis 
The diagnosis of DRA involves the use of imaging techniques – radiography, 
sonography and MRI (Kiss et al., 2005). A tissue biopsy for histological 
confirmation is almost always required but not always possible. 
The treatment of DRA focuses mainly on the prevention of Aβ2m fibrils 
deposition and on relief of the symptoms caused by Aβ2m amyloid deposits. 
Improved dialysis methods help to reduce the circulating β2m (Nakai et al., 
2001) and thus delay the onset of the disease (Schiffl, 2014). Suppression of 
inflammation is also beneficial for the prevention of amyloid deposition 
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(Floege et al., 1992). Steroidal or non-steroidal inflammatory drugs are 
prescribed to relieve pain (Yamamoto and Gejyo, 2005). Surgical intervention 
is necessary when the amyloid deposits induce severe osteoarticular 
symptoms (Yamamoto and Gejyo, 2005). Renal transplantation has been 
shown to stop the further progression of the disease (Floege et al., 1992), 
although in many case, a successful renal transplantation failed to achieve 
the regression of bone cysts induced by wild-type Aβ2m amyloidosis (Mourad 
and Argiles, 1996). 
 
1.7.3 Hereditary systemic amyloidosis due to D76N 
variant β2-microglobulin 
In 2012, Valleix et al. described the first naturally occurring amyloidogenic 
variant of β2m. This extremely amyloidogenic β2m variant is responsible for a 
highly penetrant autosomal dominant hereditary systemic amyloidosis in a 
French family (Valleix et al., 2012). All clinically affected members of the 
family were heterozygous for a single nucleotide mutation, c.286GA 
(GAT/AAT) in the B2M gene, encoding a substitution of a negatively charged 
aspartate residue at the position 76 of the mature protein with an uncharged 
asparagine residue (D76N) (Valleix et al., 2012). 
The clinical manifestations of the Aβ2mD76N amyloidosis are progressive 
bowel dysfunction and weight loss, persistent sicca syndrome, sensorimotor 
axonal polyneuropathy and severe orthostatic hypotension. The onset of the 
symptoms in one member of the family was noticed at the age of 48. 
Histological analysis and SAP scintigraphy revealed extensive amyloid 
deposits in spleen, liver, heart, salivary glands, nerves, colon and adrenal 
glands (Valleix et al., 2012). 
In contrast with the DRA, plasma β2m concentration in the Aβ2mD76N 
amyloidosis patients remained in normal range throughout the course of the 
disease (1.5 µg/ml) and renal function was also normal (Valleix et al., 2012). 
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1.7.4 β2-microglobulin amyloid fibrils 
Since it was established that β2m is able to form amyloid in vivo, β2m protein 
structure and its fibrillogenesis have been intensively studied in vitro.  
Soon after the amyloidogenic ability of β2m was described, in vitro 
fibrillogenesis of the wild-type β2m protein was achieved (Connors et al., 
1985). However, the in vitro fibrillogenesis of wild-type β2m is critically 
dependent on low pH (pH < 4) and high ionic strength of the solution to 
enable partial unfolding and subsequent aggregation into fibrils  (McParland 
et al., 2000, Eichner et al., 2011), which are conditions that do not mimic 
physiological environment. 
When amyloid fibrils isolated from tissue of DRA patients were characterised, 
it was shown that the main constituent of the natural amyloid fibrils is the full-
length intact β2m and a minor part of the natural fibrils consists of a β2m 
fragment lacking the first six N-terminal residues (ΔN6β2m) (Linke et al., 
1987, Stoppini et al., 2005). In contrast to the wild-type full length β2m, 
ΔN6β2m is less stable and forms amyloid-like fibrils in physiological 
conditions (Eichner et al., 2011). Moreover, ΔN6β2m catalyzes the 
oligomerization of wild-type β2m in solution under physiological conditions, 
suggesting that this may play an important role in the pathogenesis of the 
disease (Piazza et al., 2006, Eichner et al., 2011). 
When β2mD76N variant was described, in vitro studies identified that the 
full-length β2mD76N protein incubated in physiological solution with mild 
shaking converts into fibrils at the highest rate ever reported for a globular 
amyloidogenic protein under physiological conditions –  β2mD76N formed fibrils 
within a few hours whereas under the same conditions wild-type β2m 
remained natively folded and soluble (Mangione et al., 2013). Although the 
variant can transform wild-type β2m into insoluble fibrils in a mixed solution in 
vitro, and at much higher rate than ΔN6β2m (Mangione et al., 2013), it is 
notable that there was no wild-type β2m protein found in the amyloid fibrils 
44 
 
isolated from a tissue of Aβ2mD76N amyloidosis patient. These purely 
consisted of the full-length β2mD76N variant protein (Valleix et al., 2012). 
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1.8 Transthyretin amyloidosis 
 
1.8.1 Transthyretin 
Transthyretin (TTR) is a protein found in plasma and cerebro-spinal fluid 
(CSF). Discovered in the 1940’s, it was first named pre-albumin due to its 
migration before albumin in electrophoretic experiments on the biological 
fluids. In 1958, pre-albumin was demonstrated to bind thyroid hormone 
thyroxine (Ingbar, 1958) and ten years later, it was shown that pre-albumin 
also binds retinol-binding protein 4 (RBP) in the plasma (Kanai et al., 1968). 
In 1981, in accordance with nomenclature clarification, pre-albumin was 
renamed to transthyretin, a name indicating its function – transport of 
thyroxine and retinol-binding protein (Nomenclature-Committee, 1981). 
TTR is a 55 kDa homotetramer composed of 4 identical subunits of 127 
amino acids each (Blake et al., 1978). TTR is secreted mostly by hepatocytes 
and by the choroid plexus of the brain (Dickson et al., 1985, Holmgren et al., 
1991) and minor synthesis has also been identified in the retinal and ciliary 
pigment epithelia of the eye, visceral yolk sac, placenta and other organs 
(Cavallaro et al., 1990, Soprano et al., 1986, McKinnon et al., 2005, Soprano 
et al., 1985). TTR concentration in human plasma is 170-350 mg/l and about 
10-fold less in CSF (Smith and Goodman, 1971). Most of TTR is degraded by 
the hepatic parenchymal cells and some TTR is also degraded in the muscle, 
skin and other organs (Makover et al., 1988).  
 
1.8.1.1 Functions of transthyretin 
One of the functions of TTR is transport of thyroid hormone thyroxine (T4). 
Thyroid hormones are essential for proper development of the central 
nervous system, metabolism, bone growth and for other regulatory functions 
during development and in adult life. Thyroid hormones exist in two main 
forms – thyroxine (T4) and 3,5,3’-triiodothyronine (T3). T4 and a small amount 
46 
 
of T3 are produced from an enzymatically cleaved thyroglobulin synthesized 
by the follicles of thyroid gland (Tong et al., 1951). The thyroid hormones are 
distributed from the thyroid gland via circulation. After reaching the target 
tissue, T4 requires a conversion by 5’-deiodinases to more biologically active 
form T3 (Braverman et al., 1970, Jennings et al., 1979). T3 binds to nuclear 
thyroid hormone receptor which then binds to thyroid hormone-responsive 
elements located in the promoter regions of thyroid-responsive genes and 
affects gene transcription (Lavin et al., 1988). More than 99 % of T4 circulates 
in the biological fluids bound to thyroid hormone transporting proteins: 
thyroxine-binding globulin (TBG), TTR and albumin (Robbins and Rall, 1955, 
Ingbar, 1958). In humans, about 70 % of plasma T4 is transported by TBG 
and 15 % by TTR (Woeber and Ingbar, 1968). In rodents, TTR is the main 
carrier of plasma T4 (Norlund et al., 1997). In CSF, TTR is the main T4 carrier 
for both, humans and rodents (Larsson et al., 1985, Hagen and Elliott, 1973, 
Davis et al., 1970). However, studies on transgenic mice have revealed that 
thyroid hormone-carrier proteins are not essential for T4 tissue uptake or 
distribution. Mice lacking TTR have decreased amounts of total plasma T4 
and T3 but normal free plasma hormones levels compared to wild-type mice 
and their development is not affected, the mice are healthy and viable and 
thyroid hormones access and are distributed within the mouse brain 
(Episkopou et al., 1993, Palha et al., 2002). Recently, the possibility of T4 
being able to activate thyroid hormones-responsive genes in tadpoles has 
suggested that T4 may also adopt thyroid hormone-signalling activity and act 
directly on tissue (Maher et al., 2016). TTR, together with other plasma carrier 
proteins is responsible for the maintenance of a large pool of the hormones in 
the circulation but its function in the hormones uptake in the tissue is not fully 
understood. 
TTR also functions as a transporter of RBP-retinol complex (Kanai et al., 
1968). Retinol, or vitamin A, is a precursor of visual pigment chromophore in 
photoreceptors of retina mediating transduction, in which the light is 
translated into nervous signal, and thus ensuring optimal vision (Hubbard and 
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Kropf, 1959, Arshavsky et al., 2002). Retinol is also a precursor of retinoic 
acid that binds to transcription factors in various tissues and regulates 
expression of many genes (Piskunov et al., 2014). Transport of retinol from 
the liver to the peripheral tissue takes place in the plasma, where the retinol 
binds to RBP and subsequently retinol-RBP complex binds to TTR in the 
circulation (Kanai et al., 1968). When not bound to TTR, RBP and retinol are 
quickly filtered by the kidney and lost in urine (van Bennekum et al., 2001). In 
the target tissue, retinol-RBP complex binds to an RBP membrane receptor 
called STRA6 which also mediates the cellular uptake of vitamin A 
(Kawaguchi et al., 2007). Although almost 50 % of circulating TTR is used to 
deliver retinol bound to RBP to targeted tissues (Liz et al., 2010), TTR knock-
out mice do not show any symptoms of vitamin A deficiency despite having 
very low circulating levels of vitamin A and RBP (<6 % and 3% of wild-type 
mice levels, respectively) (Episkopou et al., 1993). The TTR knock-out mice 
can therefore utilize stored retinol from the liver despite a defective retinol 
transport (Episkopou et al., 1993). 
Besides the plasma carrier function, TTR has a proteolytic activity. It was 
shown that 1-2 % of TTR circulates in association with high density 
lipoproteins (HDL) through binding to apolipoprotein A-I (ApoAI) (Sousa et al., 
2000). In in vitro experiments, TTR cleaved ApoAI which affected cholesterol 
transport and increased ApoAI amyloidogenicity, features associated with 
atherosclerosis development (Liz et al., 2004, Liz et al., 2007). TTR has also 
been reported to cleave Aβ peptide, an amyloidogenic peptide associated 
with pathobiology of Alzheimer’s disease (AD), be capable of clearing Aβ, 
degrade aggregated forms of Aβ, and thus could have a protective role in AD 
(Costa et al., 2008, Buxbaum et al., 2008).  It was also suggested that the 
proteolytic activity of TTR plays a role in nerve regeneration (Liz et al., 2009). 
TTR is a negative acute-phase protein – transcription of TTR is down-
regulated in the liver following inflammation or trauma leading to decreased 
concentration of TTR in the blood. However, the TTR synthesis in liver and 
choroid plexus is regulated independently (Dickson et al., 1986). 
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1.8.2 Types of transthyretin amyloidosis 
Transthyretin amyloidoses include two main types: wild-type ATTR 
amyloidosis (previously referred to as age-related senile systemic 
amyloidosis) with the wild-type TTR as the amyloid fibril precursor 
(Westermark et al., 1990), and hereditary systemic ATTR amyloidosis caused 
by a mutation in the TTR gene. Wild-type ATTR amyloidosis is characterised 
by cardiac involvement. Hereditary systemic ATTR amyloidosis presents with 
familial amyloid polyneuropathy, in which the amyloid fibrils are mainly 
deposited in the peripheral nervous system, or familial amyloid 
cardiomyopathy, in which the major site of amyloid deposits is the heart. 
While most amyloidogenic TTR mutations are associated with familial amyloid 
polyneuropathy, and amyloid in the heart may or may not present, cardiac 
amyloidosis is the predominant clinical feature in wild-type ATTR amyloidosis 
and in patients with V122I mutation in the TTR gene in which the amyloid 
polyneuropathy is rare (Connors et al., 2003, Dungu et al., 2012). 
 
1.8.2.1 Wild-type ATTR amyloidosis 
Non-hereditary wild-type ATTR amyloidosis is referred to as senile systemic 
amyloidosis due to its late age of onset, usually after the seventh decade of 
life. The heart is generally the only organ affected, with carpal tunnel 
syndrome being sometimes the other clinical manifestation of the disease 
(Pitkanen et al., 1984, Sekijima et al., 2011). In wild-type ATTR amyloidosis, 
amyloid deposits are derived from wild-type TTR and no genetic 
predisposition has been identified (Westermark et al., 1990).  
 
Epidemiology of wild-type ATTR amyloidosis 
In non-hereditary wild-type ATTR amyloidosis, the prevalence of the disease 
increases with age. In post-mortem analyses, wild-type TTR cardiac amyloid 
was found in 25 % of individuals over the age of 85, with moderate or severe 
deposits in >5 % (Tanskanen et al., 2008). The incidence of wild-type ATTR 
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amyloidosis is much greater in men than women and the median survival 
from the time of diagnosis is less than 4 years (Connors et al., 2011, Pinney 
et al., 2013b). 
 
Clinical manifestations and diagnosis of wild-type ATTR amyloidosis 
Clinical manifestations of wild-type ATTR amyloidosis are atrial fibrillation and 
breathlessness with echocardiogram and MRI showing increased ventricular 
wall thickness and stiffness (Rapezzi et al., 2009, Pinney et al., 2013b). 
Carpal tunnel syndrome can be an early sign of wild-type ATTR amyloidosis, 
preceding cardiac manifestation by 8 to 10 years, as wild-type TTR amyloid 
deposits are found in almost 30 % of elderly people undergoing carpal tunnel 
decompression (Sekijima et al., 2011). Diagnosis of wild-type ATTR 
amyloidosis is confirmed by histological analysis of cardiac tissue biopsy and 
TTR gene sequencing showing no mutations. If cardiac biopsy is not possible, 
abdominal fat aspirate or rectal biopsy may be helpful. However, amyloid may 
not be found in these tissues (Connors et al., 2011). Recently a new method 
of using 99mTc-DPD scintigraphy for cardiac amyloid detection is being 
evaluated, showing remarkable sensitivity of amyloid localisation in the heart, 
especially in respect with ATTR amyloid (Hutt et al., 2014, Puille et al., 2002).  
 
1.8.2.2 Hereditary systemic ATTR amyloidosis 
Hereditary ATTR amyloidosis is a dominantly inherited systemic amyloid 
disease that results from a mutation in the TTR gene. More than 100 variants 
of TTR gene have been identified to date, with >80 of these variants being 
amyloidogenic (Connors et al., 2003). The TTR variants present a clinical 
heterogeneity but majority of the amyloidogenic variants are associated with 
familial amyloid polyneuropathy, a fatal disease characterized by extracellular 
ATTR amyloid deposits mainly in peripheral nervous system, including the 
autonomic  nerves. Some mutations present with familial amyloid 
polyneuropathy (e.g. TTRV30M) (Saraiva et al., 1984), with a combination of 
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familial amyloid polyneuropathy and familial amyloid cardiomyopathy (e.g. 
TTRR34T) (Patrosso et al., 1998), with cardiomyopathy only (e.g. TTRV122I) 
(Jacobson et al., 1990) and some mutation may also present with vitreous 
TTR deposition (e.g. TTRV30M) (Saraiva et al., 1984) or leptomeningeal 
amyloid deposits (e.g. TTRI84S) (Dwulet and Benson, 1986). 
FAP was first described in 1952 in Portugal (Andrade, 1952), subsequently 
reported in Japan (Araki et al., 1968) and Sweden (Andersson, 1976). It was 
then shown that Portuguese, Japanese and Swedish patients carry the same 
variant TTRV30M (Saraiva et al., 1984). Some TTR variants have been well 
represented by extensive kindreds (TTRV30M, TTRT60A, TTRV122I), whereas 
most of the mutations have been found in one family or a single individual.  
 
Epidemiology of hereditary ATTR amyloidosis 
The prevalence of familial amyloid polyneuropathy is estimated at 100.000 
individuals in Europe (Ando et al., 2013). The most common variant 
presenting with polyneuropathy is TTRV30M, which has  the highest prevalence 
in Sweden, Portugal and Japan reaching 1 in 1000 in endemic areas (Ando et 
al., 2005, Hawkins et al., 2015). However, the penetrance varies between 
populations – for example in the TTRV30M carriers, the penetrance is low in 
Sweden with 11 % of carriers having clinical disease at 50 years of age 
(Hellman et al., 2008) but high in Portugal with 80 % of carriers being 
symptomatic by 50 years of age (Plante-Bordeneuve et al., 2003). The 
progression of the disease can be fast following the onset of symptoms but 
the mean duration of disease from onset to death is approximately 10 years 
and may vary depending on endemic region, symptoms, genotype and other 
factors not yet known (Ando et al., 2013). 
Cardiac involvement is common in FAP, and has been reported in over half of 
the variants (Connors et al., 2003). The two most common encountered 
genetic variants in familial amyloid cardiomyopathy are TTRV122I and TTRT60A. 
TTRV122I is the most common type with 3-4 % of people of Afro-Caribbean 
descent carrying the V122I allele (Buxbaum et al., 2010, Yamashita et al., 
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2005). It is estimated that about 1.5 million African Americans carry the 
TTRV122I mutation and are at risk of development of ATTR cardiac 
amyloidosis, although the penetrance is uncertain (Ruberg et al., 2012). 
TTRT60A is the most common variant in the UK (Dungu et al., 2012). 
 
Clinical manifestation and diagnosis of familial amyloid cardiomyopathy is 
similar to wild-type ATTR amyloidosis as it was described in the previous 
section. 
 
Clinical manifestations of familial amyloid polyneuropathy 
Familial amyloid polyneuropathy is characterized by severe peripheral and 
autonomic neuropathy. The first symptoms can occur in patients in their early 
30s and progress substantially in the next two decades, but late onset of the 
disease is also common. The amyloid neuropathy is usually symmetrical 
ascending length-dependent sensorimotor axonal neuropathy. It usually starts 
with loss of sensations of heat and cold in lower limbs progressing into upper 
limbs (Gertz et al., 2015). Within a few years, the sensory neuropathy is 
followed by motor neuropathy with loss of extensor function of toes and feet 
causing unstable walking and progressing over the next 10-20 years. The 
autonomic neuropathy is manifested by urinary incontinence, sweating 
abnormalities, diarrhoea alternating with constipation, erectile dysfunction and 
orthostatic hypotension (Gertz et al., 2015). Carpal tunnel syndrome is also 
common.  
In peripheral nerve biopsies, amyloid deposits are characteristically found in 
the endoneurium and around nerve blood vessels. As the disease 
progresses, nerve fibre density and viability is reduced and endoneurial blood 
vessels are frequently destroyed by the amyloid (Plante-Bordeneuve and 
Said, 2011). No intracellular ATTR amyloid deposits were detected in the 
axons or neuronal cell bodies (Adams and Said, 1996). ATTR amyloid 
deposits are also found in stomach, gastric and rectal walls but not 
particularly in the enteric nervous system (Anan et al., 2001). 
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Diagnosis of familial amyloid polyneuropathy 
Familial amyloid polyneuropathy is diagnosed histologically on tissue biopsy. 
Nerve, skin, fat, salivary gland or rectal biopsies may be used (Foli et al., 
2011, Gertz et al., 2015) but negative result for the presence of amyloid does 
not exclude ATTR amyloidosis. Immunohistochemistry and mass 
spectrometry of laser-captured amyloid are used to confirm the amyloid 
protein and TTR gene sequencing is used to screen for TTR mutation. 
Scintigraphy with radiolabelled SAP reveals the amyloid burden of affected 
tissues.  
 
1.8.2.3 Treatment of ATTR amyloidosis 
The first-line treatment of hereditary systemic amyloidosis includes 
transplantation of failing amyloidotic organ or liver transplantation as the 
major site of TTR synthesis to replace the mutant amyloidogenic protein with 
normal non-mutated TTR (Ando et al., 2013). The concentration of variant 
TTR has been decreased by 98 % in patients following liver transplantation 
(Adams et al., 2000) and this procedure has been shown to increase patient 
survival significantly (Yamashita et al., 2012). However the presence of 
cardiac amyloid deposits is a limiting factor in liver transplantation as 
wild-type TTR can still be deposited as amyloid on the pre-existing amyloid 
template in the heart (Barreiros et al., 2010). Cardiac transplantations in 
TTRV122I patients with cardiomyopathy seem to have promising long-term 
outcomes (Dubrey et al., 2004, Thenappan et al., 2014). 
New therapies are under development for ATTR amyloidosis. One strategy 
for treatment of ATTR amyloidosis focuses on developing molecules that bind 
to the plasma TTR tetramer to stabilize the native tetrameric structure of TTR 
molecule. By stabilizing the tetramer, TTR does not dissociate into monomers 
and misfolding and deposition of TTR monomers is inhibited. In 2006, 
Diflunisal, a non-steroidal inflammatory was reported to stabilise TTR 
tetramers against dissociation into monomers (Sekijima et al., 2006, Miller et 
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al., 2004, Berk et al., 2013). Tafamidis, a novel TTR stabilizer, has been 
developed and tested in medical trials resulting in a slower progression of the 
disease and has received a marketing approval by the European Medicine 
Agency (Johnson et al., 2012, Coelho et al., 2012). However, it was reported 
in a post-approval trial by the French Network for familial amyloid 
polyneuropathy that neurological impairment worsened in 55 % of patients 
with advanced ATTRV30M amyloidosis after one year of Tafamidis treatment, 
showing that Tafamidis was not able to stop progression of the disease in 
these patients (Lozeron et al., 2013). 
Another strategy of treating ATTR amyloidosis uses TTR RNA-inhibiting 
approaches – small interfering RNA (siRNA) therapy and anti-sense 
oligonucleotide (ASO) therapy (Kurosawa et al., 2005, Benson et al., 2006) 
which are now in clinical development. Preliminary data from clinical trials 
using TTR-targeting siRNA showed >80 % reduction in TTR levels without 
major toxic effects (Coelho et al., 2013). ASOs are short synthetic 
oligonucleotides that bind directly to TTR mRNA, leading to its degradation by 
RNase H (Benson et al., 2006). Studies using this interfering approach have 
shown rapid reductions in plasma TTR in transgenic mice expressing human 
TTR (Benson et al., 2006) and in non-human primate model (Ackermann et 
al., 2012). Clinical trials in healthy volunteers and in ATTR amyloidosis 
patients are ongoing (Hawkins et al., 2015). 
 
1.8.3 Transthyretin amyloid fibrils 
Familial amyloid polyneuropathy was first described in 1952 in Portuguese 
patients and in 1978, evidence was presented that the amyloid deposits in 
Portuguese patients with familial amyloid polyneuropathy have TTR (then pre-
albumin) as a major constituent (Costa et al., 1978). In 1981, it was shown 
that Swedish and Japanese familial amyloid polyneuropathy are also caused 
by amyloid deposits consisting of TTR (Benson, 1981, Tawara et al., 1981). In 
1983, studies on the primary structure of purified amyloid fibril protein of 
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Portuguese familial amyloid polyneuropathy patients revealed that there is a 
methionine for valine substitution at the position 30 of mature protein in 
comparison with normal plasma TTR and the variant TTR was also detected 
in the plasma of familial amyloid polyneuropathy patients together with normal 
wild-type TTR (Saraiva et al., 1984). The V30M substitution was then 
confirmed in Swedish and Japanese familial amyloid polyneuropathy patients 
(Dwulet and Benson, 1984, Tawara et al., 1983). In the next few years, other 
mutations in the TTR sequence were described and the exchange of a single 
amino acid residue in the TTR protein was thought to be making the TTR 
protein prone to amyloidogenesis (Pras et al., 1983, Nakazato et al., 1984, 
Wallace et al., 1986, Dwulet and Benson, 1986). In 1988, amyloid fibrils 
isolated from heart of wild-type ATTR amyloidosis patients were identified as 
TTR with normal amino acid sequences showing that wild-type TTR is also 
amyloidogenic (Cornwell et al., 1988). To date, more than 100 mutations in 
the TTR gene have been identified, most of which are associated with 
amyloid formation (http://amyloidosismutations.com/ attr.html). 
Since the TTR and its involvement in amyloidosis have been discovered, the 
amyloidogenicity of the protein has been intensively studied in vitro. Native 
TTR is a tetramer. The amyloid aggregation of TTR requires dissociation of 
the tetramer into monomers and partial unfolding and refolding of such 
monomers into amyloidogenic intermediates with self-association into soluble 
oligomers and subsequently into insoluble amyloid fibrils (Lai et al., 1996). 
The native tetramers of TTR variants that are associated with amyloidosis are 
less stable in vitro than the wild-type TTR and it has been accepted that 
tetramer dissociation and partial denaturation of the released monomers is a 
crucial step for the formation of amyloid fibrils (Colon et al., 1996). On the 
other hand, TTRT119M mutation, a common non-pathogenic variant in the 
Portuguese population, is more stable and when combined with an 
amyloidogenic TTR variant, inhibits fibrils formation both in vitro and in vivo in 
the carriers (McCutchen et al., 1995, Alves et al., 1997). However, it is not 
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known what triggers TTR tetramer dissociation and monomer misfolding in 
vivo.  
TTR is normally a very stable protein that does not thermally denature at 
temperatures <80 oC, and its dissociation into monomers in vitro requires low 
pH or high concentration of denaturants (Lashuel et al., 1998). However, it 
has been shown in vitro that monomeric subunits in the TTR tetramers 
exchange under native conditions showing that the TTR dissociates releasing 
a monomer and re-associates into a native tetramer again (Schneider et al., 
2001). 
Amyloid fibrils isolated from hereditary ATTR amyloidosis patients 
heterozygous for a TTR mutation showed that the deposits consist of mutated 
as well as wild-type TTR and the mutated protein makes up for about two 
thirds of the ATTR amyloid deposits (Dwulet and Benson, 1986, Thylen et al., 
1993). Moreover, a major component of ex vivo ATTR amyloid fibrils is a 49-
127 C-terminal fragment of the TTR monomer, regardless of the presence or 
position of any amyloidogenic mutation (Thylen et al., 1993, Bergstrom et al., 
2005). These findings and follow up in vitro experiments suggested that a 
proteolytic cleavage may have an important role in destabilizing the tetramers 
and releasing truncated monomers that are highly amyloidogenic (Marcoux et 
al., 2015). 
S52P variant TTR is the least stable variant and causes the most aggressive 
known phenotype of ATTR amyloidosis (Mangione et al., 2014). In vitro, full-
length hTTRS52P did not form amyloid fibrils under stirring in physiological 
conditions, same as wild-type human TTR and other TTR variants. However, 
amyloid fibrils were rapidly formed when trypsin was added into the hTTRS52P 
protein solution. The main component of the fibrillar material was identified as 
49-127 fragment of hTTRS52P, the same fragment as seen in ex vivo isolated 
ATTR amyloid fibrils (Mangione et al., 2014). Also the S52P variant was 
shown to be much more susceptible to proteolytic cleavage compared to wild-
type TTR and other TTR variants. Further experiments suggested that TTR 
composed of wild-type TTR and TTRS52P monomers may circulate as a 
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tetramer even if one subunit is cleaved. The 49-127 fragment is released from 
the tetramer under certain conditions leading to its rapid incorporation into 
amyloid fibrils (Marcoux et al., 2015). 
The effect of amyloid deposition on biochemical function of affected tissue 
has never been clearly confirmed and toxicity of non-fibrillar TTR aggregates 
has been studied. In asymptomatic carriers of V30M variant TTR, TTR was 
already aggregated in non-fibrillar form, negative for Congo red staining 
(Sousa et al., 2001). Non-fibrillar TTR was also present in later stages of 
ATTR amyloidosis together with ATTR amyloid fibrils in the affected tissue. It 
was reported that the fibrillar ATTR deposits do not cause cellular damage 
but the non-fibrillar aggregates may be toxic to the cells inducing oxidative 
and inflammatory stress and cell apoptosis (Sousa et al., 2001, Andersson et 
al., 2002). 
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1.9 Aims of this thesis 
Amyloid formation of various precursor proteins has been extensively studied 
in vitro shedding light on the attributes of protein folding and misfolding and 
on the conditions of accelerating or inhibiting fibril formation. However, 
amyloid accumulation in vivo is a much more complicated process involving 
multiple components which may play more or less important roles in 
amyloidogenesis.  
Animal models have been very useful in elucidating mechanisms of diseases 
and in translational research. Transgenic mouse models for some types of 
amyloid have been successfully generated – e.g. pancreatic amyloid 
deposition of IAPP (Janson et al., 1996), Aβ peptide deposition in the brain 
(Hsiao et al., 1996, Sturchler-Pierrat et al., 1997, Rockenstein et al., 2001). 
The only mouse models of systemic amyloidosis closely mimicking the human 
disease have been generated for systemic AA amyloidosis – mice with AA 
amyloid deposits have been produced by inducing inflammation, thus 
increasing the concentrations of circulating SAA  (McAdam and Sipe, 1976, 
Skinner et al., 1977) or by transgenic overexpression of the plasma SAA 
(Simons et al., 2013). These mice have been very informative in 
understanding the mechanisms of the disease. 
Moreover, modelling AA amyloidosis in mice has enabled the discovery of 
principles and further development of the non-invasive SAP scintigraphy 
diagnostic method which has now been used in the clinic for diagnosing and 
imaging amyloidosis in patients (Pepys et al., 1979, Baltz et al., 1986b, 
Hawkins et al., 1990a, Hawkins et al., 1990b, Hawkins et al., 1993). As 
introduced in the previous section, a novel immunotherapy directly targeting 
amyloid deposits has been developed and tested using AA amyloidosis 
mouse models (Bodin et al., 2010, Simons et al., 2013). This immunotherapy 
is in clinical trials now showing very promising results (Richards et al., 2015). 
Although the animal models of systemic AA amyloidosis have been well 
established, different types of amyloidoses have different characteristic 
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patterns of amyloid deposition and different mechanisms preceding the 
precursor protein misfolding. Notably, there is no good animal model of 
cardiac amyloidosis. The prevalence of AA amyloidosis has been decreasing 
over the last decade (Wechalekar et al., 2016) which most likely reflects 
better management of underlying inflammatory disorders in AA amyloidosis 
patients. On the other hand, the number of patients diagnosed with cardiac 
ATTR amyloidosis has increased over the last decade (Wechalekar et al., 
2016) and Aβ2m amyloidosis remains a disabling condition in many patients 
undergoing long-term dialysis (Schiffl, 2014). Despite many attempts to model 
Aβ2m amyloidosis and ATTR amyloidosis in mice, none have been 
successful to date.  
Against this background, the aims in this thesis were to generate mouse 
models of Aβ2m amyloidosis and of cardiac ATTR amyloidosis by transgenic 
expression of highly amyloidogenic variants of these proteins. 
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2 Materials and methods 
 
2.1 Materials 
2.1.1 Standard buffers, solutions and media 
Buffers and solutions routinely prepared in the laboratory are listed below. 
 
0.07 M Barbitone – Calcium (BC) buffer 
Na-Barbitone 60.3 mM 
Barbitone 9.7 mM 
NaN3 0.1 % 
Ca-Lactate (4H2O) 0.58 g/l 
 
0.1 M Carbonate – Bicarbonate buffer 
Na2CO3 0.02 M 
NaHCO3 0.07 M 
pH 9.0 
 
2 x Freezing medium 
Glycerol 30  % 
in LB broth 
 
Homogenisation buffer 
NaCl 140 mM 
Tris 10 mM 
EDTA 10 mM  
NaN3 0.1 % 
PMSF 1.5 mM 
1 tablet of Complete Mini Protease Inhibitor (Roche) 
pH 8.0 
 
MES-SDS buffer 
MES 50 mM 
Tris 50 mM 
EDTA 1 mM 
SDS 0.1 % 
pH 7.3 
 
10% Neutral buffered formalin (NBF) 
Formaldehyde (37-40%) 100ml 
NaH2PO4 4 g 
Na2HPO4 (anhydrous) 6.5 g 
dH2O 900 ml 
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4 % Paraformaldehyde (PFA) 
PFA 4 % 
in PBS 
 
PBS 
NaCl 140  mM 
KCl 2.7  mM 
Na2HPO4 8.1  mM 
KH2PO4 1.5  mM 
pH 7.4 
 
PBST 
Tween 20 0.1  % 
in PBS 
(unless otherwise stated) 
 
Saturated alcoholic Congo red solution 
NaCl 0.35 M 
Congo Red 2 g/l 
in 80 % ethanol 
 
Saturated alcoholic NaCl solution 
NaCl 0.35 M 
in 80 % ethanol 
 
TAE buffer 
Tris base 40  mM 
EDTA 1  mM 
Glacial acetic acid 0.114  % 
 
Tail digest buffer 
Sodium acetate 0.3 M 
Tris-EDTA 10 mM 
SDS 1 % 
Proteinase K 0.2 mg/ml 
 
TE buffer 
Tris-HCl 10 mM 
EDTA 0.1 mM 
pH 7.5 
 
  
61 
 
2.1.2 Primers 
Oligonucleotide primers were designed using NCBI/Primer-BLAST online 
software (http://www.ncbi.nlm.nih.gov/tools/primer-blast). Primers were 
synthesized by Sigma-Aldrich (UK), provided lyophilized. 100 µM stock 
solutions were made by adding appropriate amounts of sterile nucleases-free 
dH2O and stored at -20 °C. Stock solutions of oligonucleotides were further 
diluted in dH2O to 10 µM working solution. All primers used are listed in 
Tables 2.1 and 2.2. Annealing temperatures of primers were calculated using 
the online ThermoScientific Tm calculator tool: 
(http://www.finnzymes.fi/tm_determination.html). 
 
 
Use of primer pairs  Name Sequence 
hβ2m amplification hβ2m4-For 5’ - TTGCACTACTGGGAGATAAAGC 
 
hβ2m4-Rev 5’ - TCAGAGTATCATCCCCCAATTT 
hβ2m mutagenesis B2m-mut-A 5’- CACTGAAAAAAATGAGTATGCCTGCCGTGTGAACC 
 
B2m-mut-B 5'- CGGCAGGCATACTCATTTTTTTCAGTGGGGGTGAATTCAG 
hβ2m transgenics screening hβ2m-F1 5’ - ACTGAATTCACCCCCACTGA 
 
hβ2m-R2 5’ - ATGGGATGGGACTCATTCAG 
  hβ2m Ligation sites sequencing T7F primer 5’ - GTAATACGACTCACTATAGGGC 
 
T3 primer 5’ - CCCTTTAGTGAGGGTTAATT 
hβ2m Exon1 sequencing B2m-seq1  5' - GTGGGAGGCTCTCTCTTGTG 
 
B2m-seq2 5’ - CTTGGAGAAGGGAAGTCACG 
hβ2m Exon2+3 sequencing B2m-seq3 5’ - CGCAATCTCCAGTGACAGAA 
 
B2m-seq4 5’ - CAGTTCCTTTGCCCTCTCTG 
hβ2m Exon4 sequencing B2m-seq5 5’ - GGAATTGATTTGGGAGAGCA 
 
B2m-seq6 5’ - AAGGGGTCCTGAAACCAATC 
hβ2m RT-PCR hβ2m RT-PCR 5’ 5’ - CGAGACATGTAAGCAGCATCA 
 hβ2m RT-PCR 3’ 5’ - GAGCTACCTGTGGAGCAACC 
    
 
Table 2.1: List of hβ2m primers 
Oligonucleotide primes used for cloning, mutagenesis, Gibson assembly, 
sequencing and RT-PCR of DNA sequences of the human B2M gene. 
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Use of primer pairs  Name Sequence 
hTTR-NS amplification hTTR-NS-4-For 5’ - TGTTTCCTGTTGACTGGGCATA 
(Exon 1 fragment) hTTR-NS-4-Rev 5’ -  AGAGGACACTTGGATTCACCG 
hTTR-MS amplification hTTR-SM-10-For 5’ - AGCAACTGTTCTCAGGGGAC 
(Exon 2+3+4 fragment) hTTR-SM-10-Rev 5’ - TCCTGGAGAATCCTGGTTGGA 
hTTR Exon1 sequencing hTTR-NS-seq1F 5’ - TTGGTTGTTTTGTTTTGGTGA 
 hTTR-NS-seq1R 5’ - CTGGGTACCCTTGCCCTAGT 
hTTR Exon2 sequencing hTTR-SM-seq2F 5’ - TCGCTCCAGATTTCTAATACCA 
 hTTR-SM-seq2R 5’ - TGATGTGAGCCTCTCTCTACCA 
hTTR Exon3 sequencing hTTR-SM-seq3F 5’ - GTGTTAGTTGGTGGGGGTGT 
 hTTR-SM-seq3R 5’ - TGAGTAAAACTGTGCATTTCCTG 
hTTR Exon4 sequencing hTTR-SM-seq4F 5’ - GCTTGCCAGCATATTTGAGC 
 hTTR-SM-seq4R 5’ - GTAAAGAAGTGGGCCCTTGG 
hTTR mutagenesis TTR_S52P_mut_For 5’ - AGTGAGCCTGGAGAGCTGCATGGGCTC 
 TTR_S52P_mut_Rev 5’ - GCAGCTCTCCAGGCTCACTGGTTTTCCTATAAGGTG 
Gibson assembly: 
  Alb e-p For TTRass6 5’ - GCGCGCTTGGCGTAATCA 
Alb e-p Rev TTRass1 5’ - GGGGTTGATAGGAAAGGTG 
Exon 1 For TTRass2 5’ - ctttcctatcaaccccCAGAAGTCCACTCATTCTTG 
Exon 1 Rev TTRass3 5’ - aacgtaagtGTCGACAATTAATGAGCTTC 
Exon 2-4 For TTRass4 5’ - ttgtcgacACTTACGTTCCTGATAATGGG 
Exon 2-4 Rev TTRass5 5’ - ttacgccaagcgcgcACGCGTGGCAGATAAAAC 
hTTR transgenics screening hTTRg-3U 5’ - ACCCAAGGCTTTTGCCTAAT 
 hTTRg-3D 5’ - ATTGCTTCCCATTTGACTGC 
hTTR RT-PCR hTTR RT-PCR 5’ 5’ - GCTCTGGGAAAACCAGTGAG 
 hTTR RT-PCR 3’ 5’ - GCCGTGGTCGAATAGGAGTA 
GAPDH RT-PCR msGAPDHf 5’ - CATTTCCTGGTATGACAATGAATACG 
 msGAPDHr 5’ - GGATAGGGCCTCTCTTGCTC 
 
 
 
Table 2.2: List of hTTR primers  
Oligonucleotide primes used for cloning, mutagenesis, Gibson assembly, 
sequencing and RT-PCR of DNA sequences of the human TTR gene. 
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2.1.4 Antibodies 
Primary Ab Host Reactivity Conjug. Manufacturer Use 
β2-microgobulin 14H3 Mouse Human  
University of Pavia 
(Stoppini et al., 1997) 
WB, ELISA 
β2-microgobulin Rabbit Human  Dako (A0072) WB, ELISA, IHC 
β2-microgobulin B2M-01 Mouse Human FITC 
Bioscience (ABX172) 
(Hilgert et al., 1984) 
WB, FC, IF 
CD45 Rat Mouse APC Biolegend FC 
CD16/CD32 (Fc-block) Rat Mouse  BD Bioscience (553142) FC 
ApoAII Rabbit Mouse  Provided by Dr.Higuchi (*) IHC 
mSAA1 Goat Mouse  R&D (AF2948) IHC 
α2-macrogobulin Rabbit Human  Dako (Q0102) WB, IP 
TTR (Prealbumin) Rabbit Human  Dako (A0002) WB, IH, RIE 
TTR Sheep Human  Binding site WB 
SAA  Mouse  Binding site (a-SAA1-95) ELISA 
 
Secondary Ab Host Reactivity Conjug. Manufacturer Use 
IgG Goat Rabbit HRP Dako (P0048) WB, ELISA 
IgG Rabbit Sheep HRP Dako (P0163) WB 
IgG Horse Rabbit HRP Vector Lab. (MP7401) IHC 
IgG Horse Goat HRP Vector Lab. (MP7405) IHC 
Clean-Blot IP Detection   HRP ThermoScientific (21230) WB 
SAA  Mouse Biotin Binding site (aSAA1-96) ELISA 
Streptavidin  Biotin HRP Sigma (S5512) ELISA 
 
Other Ab and stains Host Reactivity Conjug. Manufacturer Use 
Hoechst 33342     Sigma (B2261) IF 
Rabbit IgG    Sigma (15006) IP 
 
Table 2.3: List of antibodies 
Antibodies used for Western blot (WB), ELISA, immunohistochemistry (IHC), flow 
cytometry (FC), immunofluorescence (IF), immunoprecipitation (IP) and rocket 
immunoelectrophoresis (RIE). 
(*) Antibody kindly provided by Dr. Keiichi Higuchi, Institute of Pathogenesis and 
Disease Prevention Shinshu University Graduate School of Medicine, Japan 
64 
 
2.2 Molecular cloning methods 
2.2.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) is an in vitro DNA cloning method 
which allows selective amplification of a desired DNA sequence. PCR 
requires heat-stable DNA polymerase, DNA template, DNA precursors 
(deoxynucleoside triphosphates – dATP, dTTP, dCTP, cGTP) and two 
oligonucleotide primers. The reaction consists of a series of cycles of three 
steps: 
 Denaturation – melts the double helix DNA into single strands 
 Annealing – enables the primers to bind to the complementary DNA 
sequence 
 Extension – allows DNA polymerase synthesis of a new 
complementary DNA strand by adding dNTP to the primer. 
PCR was used to amplify the wild-type human β2-microglobulin (hβ2M) and 
human TTR (hTTR) genes and/or fragments of these genes, to insert specific 
mutation into a gene by site-directed mutagenesis, to prepare DNA fragments 
for Gibson assembly, to genotype animals and to identify mRNA expression 
of genes of interest by RT-PCR. 
Wild-type hβ2M and hTTR genes were both amplified from human genomic 
DNA using Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo 
Scientific).  hβ2M gene was amplified with hβ2M4-For and hβ2M4-Rev pair of 
primers (Tm = 65.5 
oC). hTTR sequence was split into 2 fragments, hTTR-NS 
and hTTR-MS. These two fragments were amplified separately using hTTR-
NS-4-For and hTTR-NS-4-Rev pair of primers (Tm = 60.0 
oC) and hTTR-SM-
10-For and hTTR-SM-10-Rev pair of primers (Tm = 60.0 
oC), respectively. The 
PCR protocol followed the Thermo Scientific guidelines using 2 µl of template 
genomic DNA (50-250 ng), 200 µM dNTPs (each), 0.5 µM 
oligodeoxynucleotide primers and 1U of Phusion Hot Start II DNA polymerase 
in Phusion HF buffer to make up 50 µl reaction mix (Table 2.4). 25-cycle or 
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35-cycle PCR was run with the cycling conditions listed in Table 2.5. 
Amplifications were performed on a Techne TC-5000 gradient thermal cycler. 
After amplifications the PCR products were analysed by electrophoresis on 
an agarose gel. The conditions of PCR used as a part of other methods are 
specified in the sections describing such methods. 
 
Component Volume per 50 µl reaction [µl] Final concentration 
dH2O 31.5   
5x Phusion HF Buffer 10 1x 
10mM dNTPs 1 200 µM each 
 10M Primer For 2.5 0.5 µM 
10M Primer Rev 2.5 0.5 µM 
Phusion DNA polymerase 0.5 1 U 
Template DNA 2 (50-250 ng/50 µl reaction) 
Table 2.4: Components of a PCR reaction mix 
 
 
Cycle step Temperature Time Cycles 
Initial denaturation 98 °C 30s 1 
    
Denaturation 98 °C 10s 
35 Annealing  [Tm] °C 20s 
Extension 72°C 15-30s/1kb of amplicon 
    
Final extension 72°C 7.5min 1 
  4°C hold   - 
Table 2.5: PCR cycling conditions 
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2.2.3 Agarose gel electrophoresis 
Agarose electrophoresis is a standard method for separating DNA fragments. 
According to the fragment size, 0.5 %, 0.8 % and 1 % agarose gels were 
used to separate fragments (generally larger than 1 kb). Powdered agarose 
(Sigma Aldrich, UK) was dissolved in TAE buffer (40 mM TRIS base, 1 mM 
EDTA, 0.114 % glacial acetic acid) by boiling in a microwave oven. When 
cooled down to 65 oC, 20 ml of agarose was mixed with 1 µl of 10 mg/ml 
ethidium bromide and poured into a gel casting tray. Once the gel was set, 
100 ml of TAE mixed with 5 µl of 10 mg/ml ethidium bromide was added into 
an electrophoresis gel tank to submerge the gel. Ethidium bromide is a 
fluorescent dye that binds to DNA by intercalating between the bases. It 
enables visualization of DNA fragments under UV light by absorbing this UV 
light and transmitting the energy as visible orange light. 
5 µl of PCR product or restriction digest was mixed with 1 µl of 6x loading dye 
(Fermentas) and loaded into wells. 1 kb DNA ladder (Gibco BRL) or λ x 
HindIII were used as markers and run alongside the samples. 0.5 % agarose 
gel was run at 50 V for 90min. 1 % agarose gel was run at 65 V for 60-90min. 
 
2.2.4 Restriction analysis 
Restriction enzymes (RE) are bacterial enzymes capable of cleaving DNA in 
a specific DNA sequence. Restriction enzyme digests were used to: 
1. Perform restriction mapping of PCR-amplified clones and potential 
recombinant plasmids. 
2. Prepare DNA vectors. 
3. Digest methylated parental DNA templates after a PCR mutagenesis. 
All restriction enzymes were supplied by New England Biolabs (UK) unless 
otherwise stated. DNA was digested under conditions recommended by the 
manufacturer. Generally, 1 µl of DNA or PCR product was mixed with 9 µl of 
RE reaction mix (1-10 U of RE and 100 µg/ml BSA in recommended RE 
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buffer) and incubated at 37 oC for 1 hour. The presence of restriction 
fragments was confirmed by electrophoresis using 0.8 % agarose gel for 
sufficient fragment separation. For digestion of methylated parental DNA 
templates after a PCR mutagenesis, 20 U of DpnI enzyme was added to 25 µl 
of PCR product and incubated at 37 oC for 2 hours. 
 
2.2.5 Vectors 
pBluescript II SK (-) is a 3.0 kb plasmid with ampicillin resistant gene and a 
multiple cloning site (MCS) with 21 restriction enzyme recognition sites. This 
polylinker interrupts a coding sequence for β-galactosidase. The vector was 
linearised with EcoRV (pBSIISK(-)xEcoRV), gel purified and stored at -20 oC. 
pLitmus38i is a 2.8 kb plasmid with ampicillin selectable marker. NheI, SalI 
and MluI sites in the polylinker were used to cut the vector to prepare sticky 
ends for inserting hTTR fragments into the vector. The cut vector was treated 
with calf intestine phosphatase (CIP) to dephosphorylate the 5’ and 3’ ends to 
prevent re-ligation of the linearised plasmid. After treatment with CIP, both 
vectors pLitmus38ixNheIxSalI and pLitmus38ixSalIxMluI were gel purified and 
stored at -20 oC. 
 
2.2.6 Gel purification 
Gel purification is used to isolate and purify desired DNA fragments based on 
their size. QIAquick Gel Extraction Kit and protocol were used for DNA 
purification: 
DNA was run on a 0.8 % agarose at 50 V for 1 hour in the dark. Following 
electrophoresis, DNA band was viewed under long-wavelength UV and 
excised from the agarose gel with a sterile scalpel blade. Care was taken to 
minimise exposure of DNA to light to avoid DNA damage. The excised gel 
containing the DNA fragment was mixed with QG buffer (5.5 M guanidine 
thiocyanate, 20 mM Tris-HCl, pH 6.6) in a 1 : 3 volume ratio (100 mg ~ 100 
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µl), and incubated at 50 oC for 10 min or until the gel was dissolved. 1 volume 
of isopropanol was added into the dissolved mixture if the DNA fragment was 
< 500 bp or > 4 kb. The sample was then applied to a QIAquick column, 
centrifuged for 1 min. The QIAquick columns have a silica membrane that 
binds DNA in the presence of high ionic-salt buffers. These buffers drive 
hydrogen bond formation between silica gel and DNA as the DNA passes 
through the column. After the centrifugation, the flow through was discarded 
and 500 μl of QG buffer was applied to the column and spun for 1 min. Two 
washes in 750 μl and 500 μl of PE buffer followed (10 mM Tris-HCl pH 7.5, 80 
% ethanol). The alcohol based washes remove contaminants in the sample 
such as nucleotides, proteins, salts and other impurities. After the last wash, 
the column was transferred into a clean tube, centrifuged for 1 min to dry and 
transferred into a clean tube again. DNA is released from the silica membrane 
by eluting with a low-ionic solution. Such solution disrupts the hydrogen 
bonds that bind DNA to the silica. DNA was eluted in 50 µl of EB buffer (10 
mM Tris-HCl, pH 8.5) and stored at -20 oC. 
 
2.2.7 Vector and insert ligation 
Vector and insert ligation was performed using Quick Ligation Kit (New 
England Biolabs, UK) and the manufacturer’s guidelines were followed: 12 ng 
of vector was combined with 3-fold or 10-fold molar excess of insert (3 : 1 and 
10 : 1 of insert to vector ratio) and the volume was adjusted to 5 µl with dH2O. 
5 µl of 2x Quick Ligation Buffer (66 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, 1 
mM ATP, 7.5 % polyethylene glycol, pH 7.6)   was mixed in before adding 1 µl 
(2000 U) of Quick T4 DNA Ligase. The reaction mix was mixed thoroughly, 
centrifuged briefly, incubated at room temperature for 5 minutes, chilled on 
ice and transformed. 
Gel purified 10.1 kb hβ2M PCR product was inserted by blunt-end ligation into 
an pBSIISK(-)xEcoRV vector to form a hβ2M/pBSIISK(-) recombinant 
plasmid. The ligation was carried out at 3 : 1 and 10 : 1 insert to vector molar 
69 
 
ratio as described above and the plasmids were transformed into competent 
cells. 
Gel purified 7 kb NheI-SalI fragment of hTTR-NS PCR product was ligated 
with gel purified pLitmus38ixNheIxSalI vector at 3 : 1 insert to vector molar 
ratio to form hTTR-NS/pLitmus38i recombinant plasmid. Gel purified 7.7 kb 
SalI-MluI fragment of hTTR-MS PCR product was ligated with 
pLitmus38ixSalIxMluI to form hTTR-SM/pLitmus38i recombinant plasmid. 
Ligated plasmids were then transformed into competent cells. 
 
2.2.8 Transformation 
NEB 5-alpha chemically competent E.coli high efficiency cells (NEB, UK) 
were used to transform the recombinant plasmids. Tubes with 50 µl of cells 
were thawed out on ice for 10 minutes. 2 µl containing 10-100 ng of 
recombinant plasmid DNA was added to the cells. Each tube was mixed with 
gentle flicking 3 times. The cell mixture was incubated on ice for 30 minutes, 
then exposed to a heat shock at exactly 42 oC in a water bath for exactly 30 
seconds and immediately placed back on ice for 5 minutes. 950 µl of SOC 
medium was added under aseptic conditions to the cell mixture and incubated 
at 37 oC for 60 minutes in a shaking incubator for cell recovery and 
expression of antibiotic resistance. 50 µl and 200 µl of transformation mix 
were plated out onto warm and dry LB agar plates containing 100 µg/ml of 
ampicillin. Plates were incubated overnight at 37 oC. When required, some 
plates were treated with 40 µl of 25 mg/ml X-gal and dried prior to cell plating. 
Cells with hTTR-NS recombinant plasmids were incubated at 30 oC with 25-
50 µg/ml of ampicillin. 
 
2.2.9 Screening of transformed cells 
To identify which cells contain the recombinant plasmid, two marker gene 
systems were used: 
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1. Antibiotic resistance gene: a host cell strain that is sensitive to ampicillin 
and a vector that carries a resistance gene to ampicillin were chosen. 
2. β-galactosidase gene complementation: the host cell contains a fragment 
of the β-galactosidase gene, the vector carries a different fragment of β-
galactosidase gene with a  MCS polylinker in it and only after 
transformation the active β-galactosidase enzyme is produced and able to 
convert colorless substrate X-gal (5-bromo, 4-chloro, 3-indolyl β-D-
galactopyranoside) to a blue product.  When an insert is successfully 
cloned into the MCS of a vector, the β-galactosidase gene is inactivated. 
Thus in the presence of X-gal, cells transformed with a vector carrying the 
insert are colourless, while cells containing non-recombinant plasmid are 
blue. 
 
2.2.10 Growth of bacterial cultures 
Bacterial cultures for plasmid preparation were grown from a single colony. A 
single colony was inoculated into ~4 ml of LB broth (10 mg/ml Trypton, 5 
mg/ml yeast extract, 10 mg/ml NaCl) containing 100 µg/ml ampicillin and 
grown overnight at 37 oC in a shaking incubator. Cells with hTTR-NS 
recombinant plasmids were incubated at 30 oC with 25-50 µg/ml of ampicillin. 
 
2.2.11  DNA purification and quantification 
To remove contaminants like enzymes, salts, unincorporated nucleotides or 
oil, QIAquick systems were used to clean DNA.  
For DNA clean-up after PCR reaction, QIAquick Gel Extraction Kit Protocol 
was followed as described above. DNA was eluted in 50 µl of EB buffer 
(10mM Tris-HCl, pH 8.5) and stored at -20 oC. 
Plasmid DNA from bacterial cultures was harvested using QIAprep Spin 
Miniprep Kit: ~2 ml of culture were pelleted, supernatant was removed and 
the pellet was rinsed with 200 µl of 10 mM Tris-HCl (pH 8.0) and thoroughly 
resuspended in 250 µl of P1 buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 
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100 µg/ml RNase). 250 µl of buffer P2 (200 mM NaOH, 1 % SDS) was added 
and mixed gently to lyse the cells, followed by adding 350 ul of neutralising 
N3 buffer (4.2 M Guanidin-HCl, 0.9 M potassium acetate, pH 4.8). The high 
salt concentration causes denatured proteins, chromosomal DNA, cell debris 
and SDS to precipitate. Precipitated protein was removed by centrifugation for 
10 min at 13000 RPM. The supernatant containing the plasmid DNA was 
applied to a QIAprep spin columns and centrifuged for 1 min at the top speed. 
The flow-through was discarded, the column was washed by adding 500 µl of 
buffer PB (5 M Guanidin-HCl, 30% isopropanol) and spun for 1 min. Two 
washes in 750 µl and 500 µl of PE buffer (10 mM Tris-HCl pH 7.5, 80 % 
ethanol) followed when the column was spun for 1 min after each wash. After 
the last wash, the column was transferred into a clean tube, centrifuged for 1 
min to dry and transferred into a clean tube again. DNA was eluted in 50 µl or 
30 µl of EB buffer (10 mM Tris-HCl, pH 8.5) and stored at -20 oC. 
After purification, DNA was quantified by running on an agarose gel alongside 
standards of known DNA concentrations. Different dilutions of DNA samples 
were visually compared to standards. 
 
2.2.12  Storage of transformed cells 
Long-term storage of desired bacterial colonies is possible in a freezing 
medium containing glycerol. 600 µl of bacterial culture grown in LB was mixed 
with 600 µl of 2 x freezing medium (sterile 30 % glycerol in LB broth) under 
aseptic conditions, mixed gently but thoroughly and stored at -80 oC. 
 
2.2.13 Site-directed mutagenesis 
In vitro site-directed mutagenesis is a method of creating specific changes in 
a known DNA sequence. The specific mutation is introduced by designing a 
pair of primers, each of which carries the mutation, and uses PCR with a high 
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fidelity DNA polymerase. During PCR, the mutation is incorporated into the 
amplicon replacing the original sequence.  
In hβ2mD76N variant, a single base substitution c.286GA in the hβ2M gene 
encodes replacement of aspartate residue at position 76 of the mature protein 
with asparagine residue (D76N). This mutation was introduced into the wild-
type hβ2m sequence with primers B2m-mut-A and B2m-mut-B (Figure 2.1) 
using hβ2M/pBSIISK(-) recombinant plasmid as a DNA template and Phusion 
Hot Start II DNA polymerase in a 50 µl PCR reaction. PCR with the 
overlapping primers results in a product that re-circularizes to form a doubly-
nicked plasmid. After a 20-cycle PCR, 25 µl of the PCR product was mixed 
with 1 µl of DpnI restriction enzyme to remove the methylated parental non-
mutated plasmid. 3 µl of digested product was transformed into NEB 5-alpha 
chemically competent E.coli high efficiency cells which are able to perform 
nick repairs in the mutated hβ2M/pBSIISK(-) recombinant plasmids. 3 µl of 
the undigested PCR product was also transformed as a control for colony-
growing density. 50 µl and 200 µl of the cell mixtures were plated out on LB 
agar plates and grown overnight as described above. The obtained 
transformants were tested for carrying the correct inserts by subjecting the 
purified mutated plasmid DNA to restriction digest with HindIII in a 10 µl 
reaction mix in 37 oC for 60 min. 5 µl of the digest was analysed on 0.8 % 
agarose gel. Potentially mutated recombinant plasmids from single colonies 
were sequenced. The verified mutated hβ2M/pBSIISK(-) recombinant plasmid 
was named hβ2MD76N/pBSIISK(-). 
In hTTRS52P variant, a single base substitution c.214TC in the hTTR gene 
encodes replacement of serine residue at position 52 of the mature protein 
with proline residue (S52P). This mutation was incorporated into the wild type 
hTTR sequence with TTR_S52P_mut_For and TTR_S52P_mut_Rev primers 
(Figure 2.1). 20-cycle PCR was run as described above using hTTR-
SM/pLitmus38i recombinant plasmid as a template DNA, Phusion Hot Start II 
DNA polymerase and 5 % DMSO in 50 µl reaction. The PCR product was 
treated with DpnI enzyme and transformed into NEB 5-alpha chemically 
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competent E.coli high efficiency cells as above. Purified mutated recombinant 
plasmid DNA of the transformants was digested with HindIII to test the correct 
restriction pattern of the mutated hTTR-SM/pLitmus38i recombinant plasmid 
before sequencing. The verified mutated hTTR-SM/pLitmus38i recombinant 
plasmid was named hTTR-SMS52P/pLitmus38i. 
 
 
hβ2M mutagenesis primers: 
 
             5’-CACTGAAAAAAATGAGTATGCCTGCCGTGTGAACC-3’   Tm = 78.78 
                |||||||||||||||||||||||||||            Tmoverlap = 72.2 
3’-GACTTAAGTGGGGGTGACTTTTTTTACTCATACGGACGGC-5’           Tm = 78.96 
 
 
 
hTTR mutagenesis primers: 
 
                 5’-AGTGAGCCTGGAGAGCTGCATGGGCTC-3’       Tm = 78.9 
                    |||||||||||||||||||              Tmoverlap = 65.4 
3’-GTGGAATATCCTTTTGGTCACTCGGACCTCTCGACG-5’               Tm = 78.0 
 
 
Figure 2.1: Primer design for site-directed mutagenesis 
Primers for site-directed mutagenesis were designed using NCBI/Primer Blast online 
software. The single base substitution c.286GA in the hβ2M gene, encoding 
replacement of aspartate residue at position 76 of the mature protein with 
asparagine residue (D76N), and the substitution c.214TC in the hTTR gene, 
encoding replacement of serine residue at position 52 of the mature protein with 
proline residue (S52P), were introduced by designing a pair of primers, each carrying 
the desired mutation. When designing the primers, the guidelines were: the 
annealing temperature Tm of such primers should be just over 78⁰ C, the mutation is 
at least 4 bases form the 5’end and 8 bases from the 3’end and 3’end of each primer 
has at least 8 non-overlapping bases. At least one G or C should be at the end of 
each primer (modified from OpenWetWare Site-directed mutagenesis protocol). 
 
 
B2m-mut-A 
B2m-mut-B 
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2.2.14 Gibson Assembly 
Gibson Assembly allows in a single reaction insertion of one or more DNA 
fragments into virtually any position of a linearized vector and does not rely on 
the presence of restriction sites within a particular sequence to be 
synthesized or cloned (Gibson et al., 2009). This method requires DNA 
fragments with 15-25 nucleotides overlaps with adjacent DNA fragment. To 
achieve this, DNA fragments and a vector to be assembled are PCR amplified 
using specifically designed primers with appropriate nucleotide overlaps. DpnI 
digested and gel purified PCR amplified fragments are then assembled 
together following the guidelines of Gibson assembly cloning kit (NEB, UK) 
protocol: 0.02 – 0.5 pmol of DNA fragments (2-10 µl), containing 25-100 ng of 
vector and 3-fold excess of inserts, were mixed with 10 µl of Gibson 
Assembly Master Mix (2x) and appropriate amount of dH2O to make up 20 µl 
reaction mix. The reaction mix was then incubated at 50 oC for 15 min. After 
the incubation, 2 µl of the reaction mix was transformed into NEB 5-alpha 
competent E.coli following the transformation protocol. Cells were then plated 
out on agar plates with 25 µg/ml ampicillin and grown overnight at 30 oC. 
Gibson assembly was used to assemble hTTR gene sequence under the 
control of mouse albumin enhancer and promoter in pBSIISK(-) plasmid. First, 
the enhancer/promoter of mouse albumin inserted into pBSIISK(-) vector 
(Albe-p/pBSIISK(-) (Gorski et al., 1986, Pinkert et al., 1987) was PCR 
amplified with TTRass6 and TTRass1 primers (Tm = 60.7 
oC), 75ng of hTTR-
NS/pLitmus38ixNheI was amplified with TTRass2 and TTRass3 primers (Tm = 
56.3 oC) and  hTTR-SMS52P/pLitmus38ixEcoRV was amplified with TTRass4 
and TTRass5 primers (Tm = 59.3 
oC) with addition of  5 % DMSO (Table 2.2). 
20 or 35 cycle PCR was run with high-fidelity DNA polymerase as described 
in section 2.2.1. The PCR products were then digested with DpnI enzyme, 
concentrated on a microcon column and gel purified. Such prepared 3 PCR 
fragments were assembled together following the Gibson assembly protocol 
as described above with 0.012 pmol of Albe-p/pBSIISK(-) (40 ng) and 3-fold 
75 
 
molar excess of hTTR fragments. Assembled recombinant plasmid was 
transferred into NEB 5-alpha competent E.coli and grown at 30 oC for 36 h on 
agar plates with 25 µg/ml of ampicillin, subcloned and purified. After a HindIII 
digest to verify the correct assembly, the assembled sequence was verified 
by sequencing. The verified assembled plasmid was named Alb-
hTTRS52P/pBSIISK(-). 
 
 
2.3 Generation of transgenic mice 
 
2.3.1 Gene construct preparation 
Prepared gene constructs were excised from recombinant plasmids with 
restriction enzymes, gel purified and quantified. The transgenes were then 
diluted to optimal concentration for microinjections 2 ng/µl in TE buffer. 
10.1 kb hβ2MD76N gene construct was excised from hβ2MD76N/pBSIISK(-) 
recombinant plasmid with BamHI and XhoI. 
10.9 kb Alb-hTTRS52P gene construct was excised from Alb-
hTTRS52P/pBSIISK(-) recombinant plasmid with BssHII and NotI. 
 
2.3.2 Microinjections 
Microinjections and embryo transfers were performed by Dr Paul Simons and 
Dr Raya Al-Shawi. Briefly, young C57Bl/6J female mice (3 – 6 weeks old) 
were superovulated to increase the number of fertilized eggs used for 
microinjection. To induce superovulation, 5 IU of PMS (pregnant mare’s 
serum) was intraperitoneally injected to induce ovarian follicular development 
and oocyte maturation. After 47 hours, injections of 5 IU of hCG (human 
chorionic gonadotropin) followed to induce ovulation and the females were 
then mated with C57Bl/6J stud males. Next morning, the females were 
checked for vaginal plugs before harvesting fertilized eggs. Microinjected 
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embryos were implanted by Dr Raya Al-Shawi into pseudopregnant CBA X 
C57BL/6 F1 recipient females. 
 
2.3.3 Transgenic founders identification 
DNA for genotyping of 6 weeks old mice was obtained from a tail tip. The 
tissue was digested in 300 µl of tail buffer (0.3 M sodium acetate, 10 mM Tris-
EDTA, 1 % SDS, 0.2 mg/ml Proteinase K) at 43 oC overnight. Tail lysates 
were vortexed, incubated on ice for 20 min and spun at 9000 g (IEC 
Micromax RF Centrifuge, Thermo Electron Corporation, USA) at 4 oC for 10 
min to remove tissue debris and precipitated SDS. 100 µl of supernatant was 
transferred into a clean tube, incubated on ice for another 10 min and 
centrifuged at 9000 g at 4 oC for 10 min. 1 µl of supernatant was transferred 
into a PCR tube and covered with 30 µl of mineral oil. The PCR sample was 
spun for 15 s and subjected to a denaturation step at 98 oC for 10 min. 49 µl 
of PCR mix (0.2 mM dNTPs, 0.3 µM oligonucleotide primers, 1.5 mM MgCl2, 
1.25 U Taq polymerase in NH4 buffer, all from Bioline) was added to the 
sample immediately after the denaturation to make up 50 µl PCR reaction 
volume. Cycling conditions were: initial denaturation at 94 oC for 5 min 
followed by 35 cycles of denaturation at 94 oC for 30 s, annealing at 55 oC for 
30 s and extension at 72 oC for 1 min. Final extension at 72 oC lasted 5 min 
and samples were then held at 10 oC. 
hβ2MD76N transgenic animals were identified using hβ2m-F1 and hβ2m-R2 
primers (Table 2.1) distinguishing positive and negative animals by amplifying 
a 662 bp fragment of the transgene. 
hTTRS52P transgenic animals were identified using hTTRg-3U and hTTRg-3D 
(Table 2.2) distinguishing positive and negative animals by amplifying a 689 
bp fragment of the transgene. 
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2.3.4 Establishment of transgenic lines 
Mice positive for the transgene of interest born to the microinjected females 
were bred with C57Bl/6J mice to identify germ line transmitters. The animals 
that proved to transmit the transgene into the first generation were named the 
transgenic founders (G0) of separate lines. Transgenic offspring of the G0 for 
each line were bred further into subsequent generations to ensure the 
transgene did not segregate out. After a successful transgene transmission 
and a secure establishment of the lines, expression levels of transgenic mice 
were examined. 
 
 
2.4 Biochemistry 
 
2.4.1 Protein sample preparation 
Serum was used to analyse the levels of expression of a protein of interest. 
Tissue homogenate was used to investigate the presence of soluble and 
insoluble proteins in the tissue. 
 
2.4.1.1 Tissue homogenization 
After collection, mouse tissue samples were snap-frozen in liquid nitrogen 
and kept at -70 oC until needed. The tissue was then placed on ice and 
processed as quickly as possible to avoid protein degradation. 10 µl of 
homogenization buffer was added per 1 mg of tissue and the sample was 
homogenized by 3 x 3 sec blasts with a shaft of a homogenizer (Ultra Turrax 
T25, J&K IKA-Labortechnik, Germany) while cooling the sample tube on ice. 
The sample was allowed to settle for 30 min on ice. An aliquot of the 
homogenate (~10%) containing the total protein composition (H) was 
removed and snap-frozen in liquid nitrogen. The rest of the sample was 
centrifuged at 13500 g at 4 oC for 30 min. The supernatant (S1) was collected 
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and kept on ice. The same starting volume of homogenization buffer was 
added into the pellet, homogenized by 3 x 3 blasts while cooling the tube on 
ice and spun again at 13500 g at 4 oC for 30 min. The supernatant after this 
second homogenization (S2) was collected and kept on ice. This 
homogenization step was repeated 2 more times, when supernatants S3 and 
S4 were collected. After the aspiration of S4, the pellet (P) was resuspended 
again in the same volume of homogenization buffer by a quick blast, aliquoted 
out and snap-frozen in liquid nitrogen. 
 
2.4.1.2 Sample preparation for denaturing protein gel 
electrophoresis 
Mouse serum was mixed with 10x reducing agent (0.5 M DTT,Sigma) and 4x 
NuPAGE LDS sample buffer (Life Technologies, UK) to make up 10 µl or 20 
µl loading sample. 
For hβ2mD76N transgenic mice and their controls, 1 µl of serum in 10 µl total 
sample volume was prepared, denatured at 80 oC for 10 min, chilled on ice 
for few minutes, span briefly and loaded onto a gel. For hTTRS52P transgenic 
mice and their controls, 0.2 µl of serum in 20 µl total sample volume was 
prepared, denatured in 95 oC for 20 min, chilled on ice for few minutes, span 
and loaded onto a gel. 
1 µl of tissue homogenate/tissue homogenate supernatants/tissue pellet were 
mixed with 5 µl of 4x NuPAGE LDS sample buffer, 0.8 µl of β-
mercaptoethanol and 13.2 µl of  dH2O to make up a 20 µl sample volume. 
The samples were then denatured at 95 oC for 20 min, span briefly and 
loaded onto a gel. 
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2.4.1.3 Sample preparation for native protein gel 
electrophoresis 
hβ2mD76N transgenic mouse serum for native gel electrophoresis was 
prepared by mixing 1 µl of serum with 2 µl of bromophenol blue loading dye 
and loaded in a well of 1 % agarose gel. 
Native hβ2mD76N transgenic mouse serum was compared to denatured 
hβ2mD76N transgenic mouse serum on a native 1% agarose gel. The 
denatured serum was prepared by mixing 1 µl of serum with 2 µl of 9 M urea 
in 0.07 M Barbitone – Calcium buffer (60.3 mM Na-barbitone, 9.7 M 
Barbitone, 0.1 % NaN3, 0.58 g/l Ca-lactate x 4H2O) and loaded onto a gel. 
 
2.4.1.4 Protein deglycosylation 
Peptide N-glycosidase F (PNGase F) is an enzyme that cleaves glycans from 
asparagine residue of glycoproteins. To test whether the hTTR in hTTRS52P 
transgenic mice is glycosylated, a deglycosylation of the protein was 
performed. 
The manufacturer protocol was followed. Generally, 0.4 µl of serum of 
hTTRS52P transgenic mouse (~20 µg of total protein) was used for 20 µl 
reaction. Firstly, mouse serum was denatured in Glycoprotein Denaturing 
Buffer in 10 µl reaction mix at 100 oC for 10 min. The test tubes were then 
quenched on ice, span briefly and a total reaction volume of 20 µl was made 
up by adding 2 µl of 10 x G7 reaction buffer, 2 µl of 10 % NP40, 4 µl of dH2O 
and 1 µl of PNGase F enzyme. The mixture was incubated at 37 oC for 1 h 
and 24 h. A sample prepared without the addition of 1 µl of PNGase F 
enzyme was included as a control of the reaction conditions. 10 µl of the 
deglycosylated samples were then loaded onto an SDS-PAGE gel and 
electrophoresed or stored at -20 oC.  
80 
 
2.4.2 Protein gel electrophoresis 
SDS-PAGE electrophoresis 
Separation of proteins under denaturing conditions was performed using 
SDS-PAGE electrophoresis. SDS present in the running buffer denatures the 
proteins into their linear structure and coats the proteins alongside the whole 
molecule with a uniform negative charge. The charge of the proteins is now 
dependent of their molecular weights and the proteins are separated 
accordingly as they run through the matrix of the gel in an electrical field. 
NuPAGE Novex 4-12 % Bis-Tris gels or 12 % Bis-Tris gels of 1 mm thickness 
were used. Protein samples were run alongside a pre-stained protein 
standard (SeeBlue Plus2, Life Technologies, UK) at 100 V for minimum of 90 
min in ice-cold MES-SDS buffer (50 mM MES, 50 mM Tris base, 0.1 % SDS, 
1 mM EDTA, pH 7.3).  
 
Native gel electrophoresis 
In native gel electrophoresis, non-denatured proteins run according to their 
charge in an electrical field. The proteins were separated in 1 % agarose gel 
prepared in 0.07 M BC buffer using medium electroendosmosis agarose 
(Pronadisa, Spain). After boiling, agarose was poured into a 1 mm thick 
warmed gel cast with Gel-bond hydrophilic polyester film (Amersham?). The 
gel was left to set overnight at 4 oC in a humid chamber. 3 µl samples were 
loaded into a well template aligned ~ 2 cm from the edge of the gel. Once all 
the samples soaked into the gel, the well template was carefully removed and 
the gel was placed on a continuous cooling plate and run at 180 V for 4 
hours. 
 
Rocket immunoelectrophoresis 
Rocket immunoelecrophoresis is used to determine concentration of a 
specific protein in a protein mixture. The samples to be compared are loaded 
and electrophoresed into an agarose gel containing a specific antibody for 
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protein of interest detection. In the presence of an excess antigen, soluble 
antigen-antibody complexes are formed. As the antigen moves further into the 
gel, more complexes are formed until a point of equivalence between the 
antigen and antibody concentration is reached. At this point, the complexes 
are insoluble and a precipitate in a shape of a rocket is formed. The 
quantitation is based on measuring the height of the precipitate peak. 
Rocket immunoelectrophoresis was used to determine the concentration of 
human TTR in the serum of hTTRS52P transgenic mice. A 1% agarose was 
prepared in 0.07 M BC buffer using medium electroendosmosis agarose 
(Pronadisa, Spain). After boiling, agarose was held at 56 oC water bath. 200 
l  polyclonal rabbit anti-human prealbumin antibody (Dako, 3.9 g/l) was 
added into 20 ml of the agarose, mixed well and poured into a 1 mm thick 
warmed gel cast with Gel-bond hydrophilic polyester film (Amersham). The 
set gel was left overnight at 4 oC in a humid chamber. 2 mm wells were 
punched out and the wells were then loaded with 2 l sample and/or 
standard. Standards were prepared from recombinant human TTRS52P protein 
diluted in PBS and spiked with mouse TTR-KO serum to avoid the serum 
matrix interference in result quantitation. Serum samples were loaded either 
undiluted or diluted in PBS. Electrophoresis was carried out at 180 V for 6 h 
with continuous base-plate cooling in BC buffer. After electrophoresis, the gel 
was rinsed and washed overnight in 5 % NaCl containing 0.02 % NaN3 at 37 
oC. After washing, the gel was rinsed with dH2O and pressed under wet filter 
paper for 15 min, dried and stained in Coomassie blue staining solution (0.1 
% Coomassie brilliant blue R350, 20 % methanol, 10 % acetic acid). After 
rinsing in dH2O, the gel was destained in destaining solution (30% methanol, 
10 % acetic acid) until satisfying background to rocket ratio was achieved. 
The gel was then dried, scanned and rocket heights were measured using 
Photoshop software (Adobe). The rocket heights were plotted against TTR 
concentration of the standards. 
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2.4.3 Western blot 
After SDS-PAGE electrophoresis, the gel was transferred to polyvinylidene 
difluoride (PVDF) membrane using iBlotTM Gel Transfer Stacks Mini (Thermo 
Fisher Scientific, UK) and iBlotTM Dry Blotting System at 20 V for 7 min 
according to manufacturer instructions. After native gel electrophoresis, a 
PVDF membrane was cut to the size of the gel, soaked in 100 % methanol for 
1 min and rinsed and washed in PBS for 10 min. The gel was places onto a 
glass plate and placed in a tray with a small amount of dH20. The rehydrated 
membrane was then placed on the gel followed by several layers of 3MM 
paper (Whatmann) wetted in dH2O and a glass plate with weights was placed 
on the top. The proteins were allowed to transfer from the gel to the 
membrane by capillary force overnight. 
After blotting, the membrane was rinsed twice and washed twice for 10 min in 
PBST (0.1% Tween 20 in PBS) and incubated in Protein Free T20 (Pierce, 
UK) blocking buffer for 90 min to block non-specific antibody binding sites and 
minimise background. After the washes, the membrane was incubated with 
primary antibody diluted in blocking buffer either for 2 h at room temperature 
or overnight at 4 oC, on an orbital shaker (antibodies used for Western blot 
are in Table 2.3). After the incubation, the membrane was rinsed 3 times and 
washed 3 times for 10 min in PBST and then incubated with horse radish 
peroxidase (HRP) conjugated secondary antibody diluted in blocking buffer 
for 60 min at room temperature on an orbital shaker. Antibodies used for 
western blot analysis are listed in table 2.3). After the secondary antibody 
incubation, the membrane was rinsed 3 times and washed 3 times for 10 min 
in PBST. The protein detection was achieved using ECL system (Amersham 
Biosciences, UK). When autoradiography was performed, the film (Amersham 
Hyperfilm, GE Healthcare, UK) was pre-sensitised by a flash to raise its 
absorbance and to increase the linear range of signal detection by the film, 
then the film was placed on the top of the membrane, exposed at different 
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time points and developed using an automatic X-ray film processor (Compact 
X4, Xograph). 
 
2.4.4 ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a quantitative method used 
to determine concentrations of a particular protein in a sample. Sandwich 
ELISA is a format in which the target antigen is detected using two layers of 
antibodies: a capture antibody that is bound to a microtiter plate to create a 
solid phase, and a detection antibody that binds to a different epitope of the 
captured antigen of interest. Optimised in-house protocols or commercial kits 
were used to measure concentrations of several proteins. 
 
2.4.4.1 Human β2m ELISA optimisation 
96-well microtiter plate with a high protein-binding capacity (CL S3590-
100EA, Corning) was coated with 100 µl capture mouse monoclonal 14H3 
anti-hβ2m antibody (University of Pavia, Italy, (Stoppini et al., 1997)) diluted in 
0.1 M Carbonate-Bicarbonate buffer (pH 9.0). The tested concentrations were 
1 / 2 / 4 / 10 / 20 / 40 / 100 µg/ml. The antibody coated plate was incubated 
covered at room temperature for 8 hours. The coating solution was removed 
and wells were washed 3 times with 250 µl of PBST to remove any unbound 
material.  
The remaining protein-binding sites in the coated wells were blocked with 250 
µl of blocking buffer. Different blocking buffers were tested to determine which 
buffer gives the lowest background, does not interfere with other assay 
components and does not possess any enzymatic activity that would lead to 
false positive results. The blocking buffers tested were: 1% bovine serum 
albumin (BSA) in PBS, 10% horse serum (HS) in PBS, 10% goat serum (GS) 
in PBS, Pierce Protein-free buffer (Thermo Fisher Scientific, UK) and 1% fetal 
calf serum (FCS) in PBS. Covered plate was incubated overnight at 4 oC and 
washed 3 times with washing buffer.  
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To determine the most dynamic detection range of antibody binding, 0 – 20 
µg/ml of recombinant hβ2m diluted in appropriate blocking buffer was used to 
obtain a suitable standard curve. To avoid inaccuracy due to serum matrix 
interference, addition of serum of mice expressing endogenous β2m (WT) or 
of β2m knock-out mice (KO) into standards was also analysed. 100 µl of 
standard diluted in appropriate blocking buffer was added into wells in 
duplicates for accurate quantitation and incubated at room temperature for 2 
hours. Wells were then washed 3 times with washing buffer to remove any 
unbound protein. 
Polyclonal rabbit anti-hβ2m antibody (Dako, A0072) was used as a detection 
antibody and the concentrations tested were: 0.05 / 0.1 / 0.2 / 0.4 / 1 / 10 
µg/ml diluted in appropriate blocking buffer. 100 µl was added into each well 
and incubated at room temperature for 1 hour (an example of an ELISA plate 
testing different concentrations of antibodies is in Figure 2.2). After washing, 
100 µl of HRP conjugated secondary goat anti-rabbit antibody (Dako, P0448) 
at the concentration 0.25 µg/ml diluted in blocking buffer was added and 
incubated for 1 hour at room temperature. Horse radish peroxidase (HRP) is 
an enzyme that catalyzes the reduction of H2O2 to H2O. In the presence of a 
chromogenic substrate which acts as a hydrogen donor for this reduction, the 
solution changes colour and the optical density of the solution can be 
measured using a spectrophotometer. After washing off the secondary 
antibody 3 times with washing buffer, 100 µl of tetramethylbenzidine (TMB) 
substrate (0.2 mg/ml of TMB with 0.01 % H2O2; Pierce 34021) was added into 
each well and incubated in the dark until sufficient colour developed (7-15 
min). A blue product is generated in direct proportion to the amount of hβ2m 
present in the sample tested or the calibrator. The enzymatic reaction was 
stopped by adding 100 µl of 1 M HCl causing a colour change from blue to 
yellow. The sample absorbance in each well was measured at 450 nm using 
FLUOstar Omega plate reader (BMG Labtech, GmBH Germany). The 
unknown sample protein concentration was interpolated from the obtained 
standard curve and multiplied by the dilution factor. 
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1 2 3 4 5 6 7 8 9 10 11 12 
 
0.05 µg/ml detection Ab 0.1 µg/ml detection Ab 
Capture 
Ab µg/ml 
1 1 10 10 100 100 1 1 10 10 100 100 
A   0 0 0 0 0 0 0 0 0 0 0 0 
B   0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
C   1 1 1 1 1 1 1 1 1 1 1 1 
D   5 5 5 5 5 5 5 5 5 5 5 5 
E   0 0 0 0 0 0 0 0 0 0 0 0 
F   0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
G   1 1 1 1 1 1 1 1 1 1 1 1 
H   5 5 5 5 5 5 5 5 5 5 5 5 
 
0.2 µg/ml detection Ab 0.4 µg/ml detection Ab 
 
 
Figure 2.2: Grid experiment for ELISA capture and detection antibody 
optimization 
The 96-well plate was divided into 4 quadrants. The 6 columns in each quadrant 
represent capture antibody concentrations, the 4 rows in each quadrant represent 
standard curve points, each of the 4 quadrants represents a different detection 
antibody concentration. Each quadrant contains all the possible combinations of 
capture antibody at 1, 10 and 100 µg/ml and standard curve points of 0, 0.2, 1 and 5 
µg/ml of recombinant hβ2m diluted in a blocking buffer, at a detection antibody 
concentration of 0.05, 0.1, 0.2 and 0.4 µg/ml. The capture antibody used is mouse 
monoclonal 14H3 anti-hβ2m. The detection antibody used is polyclonal rabbit anti-
hβ2m. 
 
 
2.4.4.2 Human β2m ELISA 
To determine the concentration of hβ2m in the serum of transgenic mice, the 
optimised protocol was as follows:  
The microtiter plate wells were coated with 100 µl of 10 µg/ml mouse 
monoclonal 14H3 anti-hβ2m capture antibody diluted in 0.1 M Carbonate-
Bicarbonate buffer for 8 h at room temperature, washed 3 times with PBST 
and blocked with 250 µl of Pierce protein-free blocking buffer overnight at 4 
oC. To obtain a standard curve, 100 µl of recombinant hβ2mD76N protein 
diluted in blocking buffer at concentrations: 0 / 0.31 / 0.625 / 1.25 / 2.5 / 5 / 10 
86 
 
µg/ml and spiked with 5 µl of WT or β2m-KO serum, according to the 
background of the mice analysed, was added into wells in duplicates. Mouse 
serum was diluted 1/20 in blocking buffer and 100 µl per well (in duplicates) 
was incubated at room temperature for 2 h. After 3 washes in PBST, 100 µl of 
polyclonal rabbit anti-hβ2m detection antibody diluted in blocking buffer was 
used at concentration 4.8 µg/ml and incubated for 1 h at room temperature. 
Any unbound material was washed off and wells were incubated for 1 h with 
HRP conjugated goat anti-rabbit antibody diluted in blocking buffer at 
concentration 0.25 µg/ml. After 3 washes, 100 µl of TMB was added into each 
well and incubated in the dark for 7-10 min. The reaction was stopped by 
adding 100 µl of 1M HCl and the plate was read at 450 nm within 15 min. The 
standard curve was obtained using Prism software and the unknown sample 
protein concentrations were interpolated and multiplied by the dilution factor. 
 
2.4.4.3 Mouse SAA ELISA 
96-well microtiter plate with a high protein-binding capacity (CL S3590-
100EA, Corning) was coated with 100 µl of 1 µg/ml capture anti-mouse SAA 
antibody aSAA1-95 (Binding site, UK) diluted in 0.1 M Carbonate-Bicarbonate 
buffer and incubated covered at 4 oC overnight. Next day, the plate was 
washed 3 times with PBST, blocked with 250 µl of 2 % BSA in PBST blocking 
buffer for 2 h at room temperature and washed. To obtain a standard curve, 
50 µl of mouse SAA protein diluted in blocking buffer at concentrations: 0 / 
0.156 / 0.078 / 0.31 / 0.625 / 1.25 / 2.5 / 5 µg/ml was added into wells in 
duplicates. Mouse serum was diluted 1/100 in blocking buffer (when normal 
levels of SAA were expected) and 50 µl per well in duplicates was incubated 
for 1 h at room temperature. After 3 washes with PBST, 100 µl of biotinylated 
detection anti-mouse SAA antibody aSAA1-96 (Binding site, UK) diluted at 2 
µg/ml in blocking buffer was added into the wells and incubated for 1 h at 
room temperature. The detection antibody was washed off 3 times with PBST 
and 100 µl of HRP conjugated streptavidin (Sigma S5512) diluted 1/3000 in 
blocking buffer was added into wells and incubated for 1 h at room 
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temperature. After 3 washes in PBST, 100 µl of TMB substrate was added in 
the wells and incubated in the dark for 10 min. The reaction was stopped by 1 
M HCl and absorbance was read at 450 nm using FLUOstar Omega plate 
reader (BMG Labtech, GmBH Germany). The unknown protein 
concentrations were interpolated from the standard curve as described 
above. 
 
Biotinylation of aSAA1-96 antibody 
The anti-mouse SAA antibody aSAA1-96 (Binding site, UK) was biotinylated 
using NHS-D-Biotin (Sigma H1759). The biotin was dissolved in DMSO 
immediately prior to use at concentration 5 mg/ml. 50 µl of such prepared 
biotin was mixed with 500 µl of antibody at concentration 2 mg/ml in 0.1 M 
Carbonate-Bicarbonate buffer and incubated for 30 min to 2 h at room 
temperature. After the incubation, 50 µl of 1 M glycine was added into the 
mixture to stop the reaction. The biotinylated IgG was eluted in 3.5 ml PBS 
and the absorbance at 280 nm was measured on a luminescence 
spectrophotometer (LS55, PerkinElmer Inc., MA). 
 
2.4.4.4 Mouse cystatin C ELISA  
Cystatin C levels in the serum of transgenic mice and their littermate controls 
were measured using Cystatin C ELISA kit (Biovendor, R&D, Czech 
Republic). Manufacturer’s instructions of the sandwich ELISA assay were 
followed and the unknown were interpolated from the standard curve as 
described above. 
 
2.4.4.5 Total thyroxine ELISA 
To quantify the total thyroxine (T4) in mouse serum, a Thyroxine (T4) ELISA 
kit was used (Calbiotech, USA). The kit was a solid phase competitive ELISA 
when the T4 in the mouse serum competes with HRP-conjugated T4 for 
binding sites as they are added into streptavidin-coated wells at the same 
time together with anti-T4-biotin labelled antibody. Upon the addition of the 
88 
 
substrate, the intensity of the developed colour is inversely proportional to the 
concentration of T4 in the serum sample. A standard curve and the unknown 
were interpolated as described above. 
 
2.4.5 Immunofluorescence 
Immunofluorescence is a technique using fluorescent-labelled antibodies to 
detect specific target antigen. Direct immunofluorescence was performed on 
blood films. 
Blood films were prepared manually on slides by spreading a drop of blood to 
obtain appropriate film thickness and length, air-dried at room temperature 
and processed within 24 hours. The films were fixed for 10 min either in 4 % 
PFA in PBS at room temperature or in 100 % methanol at -20 oC. After 
fixation, samples were rinsed and washed 3 times in PBS and blocked for 30 
min in 2 % BSA in PBS. After blocking, the slides were assembled into a 
sequenza rack and incubated for 1 hour with 100 µl of FITC-conjugated 
mouse monoclonal anti-human β2m antibody B2M-01 (ABX172, Source 
BioScience, UK) (Hilgert et al., 1984) diluted 1/200 in blocking buffer. The 
fluorescein isothiocyanate (FITC) is a fluorochrome prone to photobleaching, 
therefore incubation and subsequent steps were performed in the dark when 
possible. After rinsing in PBS, the samples were counterstained with Hoechst 
33342 (B2261 Sigma-Aldrich, UK) diluted 1/10000 in PBS for 10 min. After 3 
washes in PBS, slides were mounted in Citifluor (Citifluor Ltd., UK), overlaid 
with a coverslip, kept in the dark and analysed under UV microscope (Nikon 
TE300) within 24 hours.  
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2.4.6 Flow cytometry 
Fluorescence-based flow cytometry enables sorting heterogeneous mixture of 
cells based upon the light scattering and fluorescence characteristics of each 
cell. Flow cytometry was used to analyse expression of hβ2m on cell surface 
of leucocytes of hβ2mD76N transgenic mice. 
25 µl of whole blood was mixed with 25 µl of 0.1 % EDTA to prevent clotting 
and the sample was kept on ice. Erythrocytes were lysed by adding 1 ml of 
erythrocyte lysing buffer (150 mM ammonium chloride, 10 mM sodium 
bicarbonate, 1 mM disodium EDTA) into each sample and gentle mixing for 
20 min. Leucocytes were collected by spinning at 200 g for 10 min at 4 oC. 
Cells were then fixed with 1 % PFA in PBS for 5 min and washed 3 times with 
FACS wash buffer (1 % FBS, 0.1% NaN3 in PBS). After the last wash, cells 
were resuspended in 50 µl of FACS wash buffer and incubated with Fc-block 
(rat anti-mouse CD16/CD32, BD Bioscience, UK) to reduce non-specific Fc 
receptor-mediated binding by antibodies of interest. Cells were then stained 
with APC-conjugated anti-mouse CD45 antibody (Biolegend, CA) and FITC-
conjugated anti-human β2m B2M-01 antibody (Source Bioscience, UK) for 1h 
in the dark on ice. After staining, cells were washed twice with 1.5 ml of FACS 
wash buffer, resuspended in 500 µl FACS wash buffer and analysed on 
FACSCalibur (BD Bioscience, CA) using the CellQuest software. 
 
 
2.5 Reverse Transcription PCR 
Reverse transcription PCR (RT-PCR) is a technique for detection of mRNA 
transcription. After RNA isolation from tissue, a single-stranded 
complimentary DNA (cDNA) is synthesized from single-stranded RNA 
template using a reverse transcriptase enzyme. The reverse transcription 
reaction product is then used as a template for PCR. 
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2.5.1 RNA purification 
Total RNA was extracted from liver, kidney, spleen, heart, tongue, skeletal 
muscle and brain of transgenic animals and non-transgenic controls using 
RNeasy Plus Universal Mini Kit. After collection, 30 – 50 mg of mouse tissue 
was snap-frozen in liquid nitrogen and kept at -70 oC until needed. The tissue 
was homogenized in 900 µl QIAzol lysis reagent using a stainless steel bead 
and TissueLyser (Qiagen) for 2 x 2 min at 20 Hz. The homogenate was 
collected and left for 5 min to promote dissociation of nucleoprotein 
complexes. 100 µl of gDNA Eliminator solution was added into each sample, 
shook vigorously for 15 s, followed by 180 µl of chloroform, shook again and 
left for 3 min before centrifugation at 12000 g for 15 min at 4 oC. The upper, 
aqueous phase was collected and mixed with 1 volume of 70 % ethanol. This 
mixture was then applied to an RNeasy mini spin column and centrifuged at 
8000 g for 15 s at room temperature. The membrane of the column was then 
washed by 700 µl of buffer RWT and span for 15 s at 8000 g at room 
temperature and then washed twice by 500 µl of buffer RPE and span for 15 s 
at 8000 g each time. The column was then dried by spinning for 1 min at 8000 
g. The RNA was eluted from the membrane in 50 µl of RNase-free water. The 
amount of RNA in each sample was measured using 8 sample 
spectrophotometer Nanodrop ND-8000 (Labtech International). 
 
2.5.2 Reverse transcription 
QuantiTect Reverse Transcription kit from QIAgen was used and 
manufacturer’s guidelines were followed. Firstly, genomic DNA (gDNA) 
contamination in the RNA samples was removed by incubating 500 ng 
purified RNA with 2 µl of gDNA wipeout buffer in 14 µl reaction volume for 2 
min at 42 oC. After this step, first strand cDNA synthesis was achieved by 
mixing the 14 µl reaction from gDNA elimination step with 4 µl of Quantiscript 
RT buffer, 1 µl of RT primer mix and 1 µl of reverse transcriptase on ice and 
incubating for 30 min at 42 oC followed by 3 min incubation at 95 oC to 
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inactivate the enzyme. The RT primer mix enables cDNA synthesis from all 
regions of RNA transcripts. Reverse transcriptase is an RNA-dependent DNA 
polymerase enabling transcription of cDNA from an RNA template with a 
hybrid-dependent exoribonuclease activity degrading an RNA strand in 
RNA-DNA hybrids. A reaction without the reverse transcription enzyme was 
prepared simultaneously for each sample as a negative control. cDNA 
prepared in the reverse transcription step was then used immediately in a 
PCR reaction as a template or stored at -20 oC. The 20 µl PCR reaction mix 
consisted of 1 µl of cDNA, 0.2 mM dNTPs, 0.3 µM oligonucleotide primers, 
1.5 mM MgCl2 and 1.25 U Taq polymerase in NH4 buffer. The PCR reaction 
mix was covered with 30 µl of mineral oil, denatured at 94 oC for 5 min and 
followed by 25 cycles of denaturation at 94 oC for 30 s, annealing at 55 oC for 
30 s and extension at 72 oC for 1 min. Final extension at 72 oC lasted 5 min 
and samples were then held at 10 oC. 
The primers used in the PCR reaction to obtain hβ2m mRNA were hβ2m RT-
PCR 5’ primer and hβ2m RT-PCR 3’ primer amplifying a 240 bp PCR product 
(Table 2.1), PCR primers used for the identification of hTTR mRNA were 
hTTR RT-PCR 5’ primer and hTTR RT-PCR 3’ primer amplifying a 226 bp 
PCR product (Table 2.2). A control RT-PCR reaction was performed on 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a house-keeping 
gene expressed in all tissues with primers msGAPDHf and msGAPDHr 
(Table 2.2) amplifying a 133 bp PCR fragment. 
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2.6 Histochemistry 
 
2.6.1 Tissue sample preparation 
The organs of euthanized mice were dissected out and fixed in 10 % NBF 
overnight at room temperature. The tissue was then dehydrated through a 
series of graded ethanol incubations to displace the water within the tissue 
and infiltrated with paraffin wax. The infiltrated tissue was then embedded into 
wax blocks.  
Paraffin embedded blocks were sectioned on a microtome (Leica RM2135, 
Germany) using disposable microtome blades (Feather S35, Japan). Cut 
sections were placed on a surface of a 45 oC paraffin section mounting bath 
(Barnstead, Electrothermal, UK), collected onto a Superfrost Plus microscope 
slide (Thermo Scientific) and dried at 37 oC overnight. 3 µm sections were cut 
for immunohistochemistry and H&E staining, 6 µm for Congo red staining. 
 
2.6.2 Histological staining 
Sections were dewaxed through 2 baths of xylene (5 min each) and hydrated 
through baths of graded ethanol (3 x 100%, 1 x 90%, 1 x 75%, 1 x 50%, 2 min 
each) followed by 5 min bath in tap water.  
For Congo red staining, sections were then immersed for 5 min in Mayer’s 
haematoxylin (Pioneer Research Chemicals, UK) for nuclear counterstaining 
and then placed in tap water for 5 min. Following a rinse in dH2O, the sections 
were incubated  for 20 min in filtered saturated alcoholic NaCl solution (0.35 
M NaCl in 80 % ethanol) with 0.01 % NaOH and then 20 min in filtered 
alcoholic Congo red solution (0.35 M NaCl, 2 g/l Congo red (Raymond Lamb, 
UK) in 80 % ethanol) with 0.01 % NaOH. Immediately after the staining, the 
sections were rinsed in 100 % ethanol and immersed into 2 baths of 100 % 
ethanol (2 min each) and cleared in 2 baths of xylene (5 min each) before 
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mounting with DPX (BDF, UK) or ClearVue mountant XYL (4212, Thermo 
Scientific) and covered with a coverslip. 
For Heamotoxylene and Eosin (H&E) staining, rehydrated sections were 
immersed in Coles Haematoxylene (Pioneer Research Chemicals, UK) for 10 
min, rinsed in tap water for 5 min and destained in 1 % acid alcohol (Pioneer 
Research Chemicals, UK). After rinsing in tap water for 5 min, section were 
stained in 1 % aqueous eosin (Pioneer Research Chemicals, UK) for 2 min, 
rinsed in tap water and immersed in 100 % ethanol, cleared in xylene (2 x 5 
min), mounted with DPX or ClearVue mountant and covered with a coverslip. 
 
2.6.3 Immunostaining 
The localisation of specific proteins within a tissue was assessed by 
immunohistochemistry. All steps were performed at room temperature unless 
otherwise stated. The sections were rehydrated as described above and 
incubated in 0.6 % H2O2 (Sigma, UK) for 15 min to block the tissue 
endogenous peroxidase. After a rinse in PBS, the slides were assembled into 
a sequenza rack and washed with PBST. Any non-specific binding sites were 
blocked with 30 min incubation in 2.5 % normal horse serum (Vector 
Laboratories). The slides were then incubated with 100 µl of primary antibody 
diluted in Dako antibody diluent for 1 hour at room temperature or at 4 oC 
overnight. Antibodies used for immunohistochemistry are listed in Table 2.3. 
Non-primary antibody controls were incubated with the antibody diluent only. 
The antibody was washed away by two washes in PBST followed by 30 min 
incubation with 100 µl of secondary antibody conjugated with HRP 
micropolymers (Vector Laboratories). Any excess stain was washed off by 
PBST. The slides were then rinsed in PBS and stained with DAB (Metal 
Concentrate, Thermo Scientific UK) diluted 1:10 in Stable peroxide solution 
(Thermo Scientific, UK). The DAB is bound by the substrate and oxidised by 
the peroxidase producing a brown alcohol-insoluble precipitate at the site of 
enzymatic activity. After sufficient brown colour was developed (incubation 
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time no more than 10 min), the reaction was stopped by PBST. The slides 
were then rinsed in tap water, counterstained with Mayer’s haematoxylene 
(Pioneer Research Chemicals) for 30 s, destained in tap water for 5 min and 
dehydrated through 2 min baths of graded ethanol (1 x 50 %, 1 x 75 %, 1 x 90 
%, 3 x 100%). The sections were then cleared in two 5 min immersions in 
xylene and mounted with DPX or ClearVue mountant. 
Immunostaining for TTR protein required antigen retrieval. In this case, the 
slides were rehydrated and the endogenous peroxidase was blocked as 
described above, rinsed in dH2O, incubated in 1 % sodium metaperiodate 
(Fisher Scientific, UK) for 10 min and rinsed and washed twice in dH2O for 5 
min. Then the slides were incubated in 0.1 % sodium borohydrate (Fisher 
Scientific, UK) for 10 min and again washed twice in dH2O for 5 min for each 
wash. The slides were then rinsed in 0.9 % NaCl, placed into a moisture 
chamber and incubated covered with 6 M guanidine hydrochloride in 0.9 % 
NaCl for 4 h. After rinsing in 0.9 % NaCl, the slides were then assembled into 
a sequenza rack, washed in PBST and stained with antibodies as described 
above. 
 
2.6.4 Microscopy 
Histological examination of stained sections was performed using a light 
microscope (Leica, Germany) and photographs were taken using Leica IM50 
software. Congo red stained sections were analysed with and without 
polarizer and under UV light. 
Immunofluorescence was performed within 24 hours using Nikon TE300 light 
microscope with UV filters. 
 
 
2.7 Whole body 
125
I-human SAP retention 
SAP is universally present in all amyloid deposits and persists there for a 
prolonged period of time. Whole body 125I-hSAP retention method is based on 
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the ability of human SAP avidly bind to amyloid and is used as a specific and 
quantitative in vivo tracing tool for systemic amyloid deposition in mice and 
humans (Hawkins et al., 1988). 
125I-radiolabelled human SAP was prepared in the National Amyloidosis 
Centre (UK) as described in (Hawkins et al., 1988). The mice were injected 
intravenously with 106 c.p.m. of high specific activity 125I-hSAP and counted  
24h and 48h after the label administration in a gamma counter to obtain the 
retention of the tracer. The 125I-hSAP injections and the whole body counts 
were performed by Dr S. Ellmerich from the Centre for amyloidosis and acute 
phase proteins, UCL. To protect the animals from uptake of radiolabelled 
iodine by thyroid gland, the mice were given 0.006 % KI in drinking water at 
least 24 h prior to injections and were kept on the KI treated water for a week 
after the injections. In the absence of amyloid, there is a rapid whole body 
clearance of the radiolabelled SAP and by 48 h, less than 10 % of the tracer 
is detectable. 
 
 
2.8 Preparation of AEF for seeding experiments 
Amyloidosis can be accelerated in experimental animals by administration of 
amyloid-enhancing factor (AEF). To prime amyloidosis in hβ2mD76N and 
hTTRS52P transgenic mice, in vitro-prepared and/or ex vivo-isolated amyloid 
fibrils and/or extract of amyloidotic tissue were used in a number of 
experiments. Spontaneous and amyloid-seeded amyloid deposition in 
transgenic and control mice was investigated. 
 
Aβ2mD76N fibrils preparation 
In vitro-prepared human Aβ2mD76N fibrils were obtained from Dr P. Mangione 
(Centre for amyloidosis and acute phase proteins, UCL). The fibrils were 
resuspended in sterile endotoxin-free PBS at a concentration 1 mg/ml and 
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stored at -80 oC. When needed, the fibril suspension was further diluted in 
PBS prior to a 100 µl intravenous (i.v.) injection. 
Human ex-vivo Aβ2mD76N fibrils were isolated by Dr P. Mangione from a 
spleen of Aβ2mD76N amyloidosis patient with severe Aβ2m amyloid 
deposition. Isolated amyloid fibrils were resuspended in sterile endotoxin-free 
PBS at a concentration 100 µg/ml and stored at -80 oC. Each mouse received 
a 100 µl injection equal to 10 µg of fibrils intravenously. 
 
ATTRS52P fibrils preparation 
Human ex-vivo ATTRS52P fibrils were isolated by Dr P. Mangione from a 
spleen of ATTRS52P amyloidosis patient with severe ATTR amyloid deposition. 
Isolated amyloid fibrils were resuspended in sterile endotoxin-free PBS at a 
concentration 100 µg/ml and stored at -80 oC. Each mouse was injected with 
10 µg of fibrils, i.e. 100 µl of the fibril suspension intravenously. 
 
Preparation of ATTRS52P AEF from a tissue extract 
Unfixed spleen from ATTRS52P amyloidosis patience with abundant infiltration 
of amyloid was provided by Dr G. Tennent (Centre for amyloidosis and acute 
phase proteins, UCL) from Amyloid Research Tissue bank. The spleen was 
thawed out from -80 oC and briefly rinsed in ice-cold 10 mM Tris-HCl, 0.138 
mM NaCl, 0.1 %NaN3, pH 8.0. 300 mg of tissue was teased, mixed with 15 
ml of sterile PBS and shook vigorously for 10 min. The suspension was then 
centrifuged and the supernatant was used to inject experimental mice with 
200 µl intravenously.  
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3 Generation and establishment of 
hβ2mD76N transgenic mouse lines 
 
3.1 Introduction 
Human β2-microglobulin (hβ2m) is a protein expressed by all nucleated cells. 
The human B2M gene consists of 4 exons and 3 introns and the promoter of 
the β2M gene has been identified within a hundred base pairs upstream 
(Gussow et al., 1987). β2m is a part of major histocompatibility complex 
(MHC) class I molecules on the cell surface presenting antigens to CD8+ 
cytotoxic T-lymphocytes. The association of the MHC class I heavy chain and 
β2m is a prerequisite for cell-surface expression of the complex. β2m 
deficiency is rare and results in complex immunodeficiency.  
One of the most serious pathophysiological properties of the β2m protein in 
humans is its ability to form amyloid, which can be acquired, or genetic. In 
healthy people, the range of serum β2m concentration is 0.7 – 2.7 µg/ml 
(Berggard and Bearn, 1968, Greipp et al., 1988, Floege et al., 1991). β2m is 
catabolised by the kidneys and patients with impaired kidney function have 
increased β2m concentrations due to its insufficient clearance. Because of its 
size, β2m is not cleared by dialysis membranes and its plasma concentrations 
remain elevated. Majority of end stage renal failure patients on long term 
dialysis develop acquired Aβ2m amyloidosis (dialysis-related amyloidosis) 
(Gejyo et al., 1986b). Hereditary systemic Aβ2m amyloidosis caused by a 
mutation in the β2m gene has also been described (Valleix et al., 2012). 
Mice transgenic for human β2m were successfully generated in the past to 
study expression of the human MHC class I complex on the cell surface 
(Krimpenfort et al., 1987, Chamberlain et al., 1988). The β2M transgene used 
to produce transgenic mice for the MHC class I experiments contained the full 
length human β2m gene with 2.9 kb 5’ flanking sequence and 1.5 kb of 3’ 
flanking sequence and 120 bp of pEMBL9 bacterial vector DNA at the 3’ end. 
These mice produced hybrid MHC class I antigens on the cell surface 
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consisting of murine MHC class I heavy chains in association with the human 
β2m. The tissue expression of the transgene in these mice was very similar to 
the tissue expression of the endogenous mouse β2m. The concentration of 
free circulating human β2m in the transgenic mice was not reported.  
In 2010, hβ2m transgenic mice generated specifically to study Aβ2m 
amyloidosis were reported. The human β2m construct consisted of a 360 bp 
human β2m gene cDNA expressed under the control of cytomegalovirus 
immediate early gene enhancer (CMV-IE)/chicken β-actin promoter and rabbit 
β-globin poly(A) signal (Zhang et al., 2010, Niwa et al., 1991). The wide-
spread expression of the transgene driven by the house-keeping β-actin 
promoter was confirmed in those mice. Despite the reported high 
concentration of circulating human β2m, the transgenic mice did not develop 
Aβ2m amyloidosis (Zhang et al., 2010). 
In 2012, a single nucleotide mutation in B2M gene was discovered in one 
family which causes hereditary systemic Aβ2m amyloidosis (Valleix et al., 
2012). The highly amyloidogenic c.286GA (GAT/AAT) mutation in the B2M 
gene encodes a substitution of aspartate at the position 76 of the mature 
protein with asparagine (D76N). Unlike in dialysis-related amyloidosis caused 
by sustained elevated concentrations of serum wild-type β2m, the patients 
carrying the D76N mutation develop Aβ2m amyloidosis despite normal serum 
levels of β2m variant (< 3 µg/ml) and normal renal function (Valleix et al., 
2012).  
Therefore the hypothesis was that expression of this first naturally occurring 
highly amyloidogenic human β2mD76N (hβ2mD76N) variant in mice will lead to 
an animal model of Aβ2m amyloidosis.  
The aim to support the hypothesis was to generate hβ2mD76N transgenic mice 
by cloning the human B2M gene from human genomic DNA and introducing 
the D76N mutation by site-directed mutagenesis. The transgenic mice were 
characterised with respect to the hβ2mD76N transgene expression, the 
hβ2mD76N protein concentration in the circulation and cell surface expression 
of the D76N variant for both, hβ2mD76N transgenic mice expressing the 
99 
 
endogenous mouse β2m and hβ2mD76N transgenic mice in which the 
endogenous β2m was knocked-out.  
100 
 
3.2 Results 
Transgenic mice carrying a highly amyloidogenic variant D76N of human 
β2-microglobulin (hβ2m) were generated to study the mechanisms of Aβ2m 
amyloidosis. The transgene was prepared by cloning a full length wild-type 
hβ2m gene from human genomic DNA, in which the single base substitution 
c.286GA (GAT/AAT) was introduced, encoding replacement of aspartate 
residue at the position 76 of the mature protein with asparagine residue 
(D76N). The advantage of using human genomic sequence, including exons 
and introns, over cDNA-based constructs is that the levels of expression of 
cDNA constructs can be much lower than the expression levels obtained by 
genomic DNA sequence. It was shown that introns enhance the efficiency of 
gene expression and thus play a role in facilitating transcription of 
microinjected genes (Brinster et al., 1988, Whitelaw et al., 1991). The human 
β2m gene own promoter and regulatory sequences within the 5’ and 3’ ends 
were used to drive the expression of the transgene to maintain the tissue-
specific expression of the transgene (Chada et al., 1985, Hammer et al., 
1987). 
 
3.2.1 Cloning of human β2-microglobulin 
The hβ2m gene was PCR-amplified from genomic DNA with hβ2m4-For and 
hβ2m4-Rev primers (Table 2.1) using Phusion Hot Start II High-Fidelity DNA 
Polymerase. This polymerase was chosen to minimise PCR-introduced errors 
into the cloned sequence. The amplified 10.1 kb fragment contained the 7.4 
kb sequence of hβ2m gene with 2.1 kb 5’ flanking sequence and 630 bp 3’ 
flanking sequence to maintain the gene regulatory elements (Figure 3.1). The 
10.1 kb fragment was then cloned into an EcoRV site of a 3 kb pBSIISK(-) 
vector by blunt-end ligation. 
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Figure 3.1: Amplification of human β2-microglobulin gene 
10.1 kb hβ2m fragment containing the 7.4 kb sequence of hβ2m gene with its 4 
exons and 3 introns, 2.1 kb 5’ flanking sequence and 630 bp 3’ flanking sequence, 
was PCR-amplified from human genomic DNA using hβ2m4-For and hβ2m4-Rev 
primers and ligated with pBSIISK(-)xEcoRV vector. 
 
 
After the hβ2m/pBSIISK(-) ligation product was transformed, plasmid DNA of 
12 clones was purified by alkaline lysis and run on an agarose gel to assess 
the DNA size for each clone. The expected size of a correctly assembled 
recombinant plasmid was 13.1 kb and 9 of the 12 plasmids were recombinant 
(not shown). These recombinant plasmids were mapped by restriction 
analysis to verify the identity. BamHI and XhoI restriction sites are present in 
the multiple cloning site of the pBSIISK(-) vector but are missing in the 
sequence of the hβ2m gene (Figure 3.2). Restriction digest with these two 
enzymes results in cutting the insert out of the vector, producing two 
fragments of 10.1 kb (insert) and 3 kb (vector). In 8 plasmids, a 10.1 kb insert 
was cut out of the vector as shown in Figure 3.3 A. To further verify the 
identity of the cloned DNA, I used HindIII to map the clones as this enzyme 
has two recognition sites within the β2m gene. Because the β2m gene can be 
inserted in two different orientation into the plasmid, which contains a single 
HindIII site, two different restriction patterns of 3 fragments can be generated: 
4.2 kb, 4.4 kb and 4.6 kb (Figure 3.2 B) or 7.2 kb, 4.4 kb and 1.6 kb (Figure 
3.2 A). The restriction mapping suggested that 7 out of the 12 clones 
analysed (clones 1, 4, 5, 6, 10, 11, 12) carry one hβ2m gene insert(Figure 3.3 
B). 
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Figure 3.2: hβ2m/pBSIISK(-) recombinant plasmid 
Map of a 10.1 kb hβ2m fragment ligated into an EcoRV site of a 3 kb pBSIISK(-) 
vector. BamHI, XhoI and HindIII restriction enzymes were used for mapping of the 
sequence structure of recombinant plasmids. hβ2m insert can be bluntly cloned into 
the EcoRV linearised pBSIISK(-) vector in two directions. While cutting the insert out 
of the vector with BamHI and XhoI is not affected by the direction of insertion, HindIII 
digest distinguishes these two insertion possibilities by giving two different restriction 
patterns of 3 fragments: 7.2 kb (3 kb vector + 4.2 kb fragment a), 4.4 kb (fragment b), 
1.6 kb (fragment c) with insertion 5’  3’ (Figure A) or 4.2 kb (fragment a), 4.4 kb 
(fragment b), 4.6 kb (3 kb vector + fragment c) with insertion 3’  5’ (Figure B). 
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Figure 3.3: hβ2m/pBSIISK(-) restriction analysis 
A – 9 clones were digested with BamHI and XhoI, enzymes that have their restriction 
sites in the polylinker of the vector but not in the genomic sequence of hβ2m, cutting 
the hβ2m insert (10.1 kb) out of the pBSIISK(-) vector (3 kb). 8 plasmids (1, 4, 5, 6, 
8, 10, 11, 12) showed this restriction pattern. Uncut 3 kb vector (UV), linearised 3 kb 
vector (LV), 10.1 kb insert alone (In) and 1 kb marker (M) were run alongside the 
recombinant plasmids on an agarose gel. 
B – hβ2m/pBSIISK(-) recombinant plasmids 1, 3, 4, 5, 6, 8, 10, 11, 12 were analysed 
with HindIII enzyme. The hβ2m fragment can be bluntly inserted into the vector in 
two orientations. HindIII restriction digest distinguishes between the two orientations 
by producing two sets of restriction pattern: 7.2 kb, 4.4 kb and 1.6 kb fragments as 
seen in clones 4, 6, 11, 12 (lanes marked with Y) and 4.3 kb, 4.4 kb and 4.6 kb 
fragments seen in clones 1, 5 and 10 (lanes marked with X). Clones number 3 and 8 
appeared to have the hβ2m insert but were not of the predicted size and were 
discarded. Uncut 3 kb vector (UV), linearized 3 kb vector (LV), 10.1 kb hβ2m insert 
cut with HindIII (In x HindIII; producing 3 fragments of 4.4 kb, 4.2 kb and 1.6 kb) and 
a 1 kb marker were run as controls alongside the samples. 
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One hβ2m/pBSIISK(-) recombinant plasmid (clone 11) was sequenced by 
Source BioScience (UK) to exclude sequence alterations due to PCR-
introduced errors. All 4 exons, exon-intron boundaries, 5’ and 3’ ends and 
ligation sites were sequenced to ensure that correct transcription and splicing 
of the transgene would be maintained as well as no alterations in the amino 
acid coding sequence were present. Primers for sequencing were designed 
using NCBI/Primer-BLAST online software and are listed in Table 2.1. The 
coding and regulatory sequences of the recombinant hβ2m/pBSIISK(-) clone 
(number 11) were identical to the reference sequence and this clone was 
used as a template for site-directed mutagenesis. 
 
3.2.2 Mutagenesis of human β2-microglobulin 
The D76N mutation in the wild-type hβ2m gene was introduced by double 
primer site-directed mutagenesis. This method involves designing a pair of 
primers which are partly complimentary to one another and also to the DNA to 
be mutated except that they contain the desired mutation. B2m-mut-A and 
B2m-mut-B primers (Table 2.1) were designed so that the c.286GA 
(GATAAT) substitution was present in the short oligonucleotide sequences 
priming a PCR amplification of the hβ2m/pBSIISK(-) recombinant plasmid 
(Figure 3.4). Recombinant plasmid number 11 as a DNA template and 
Phusion Hot Start II High-Fidelity DNA Polymerase were used in a 20-cycle 
PCR. The use of a high-fidelity polymerase is crucial to minimise the chances 
of unwanted mutations during the PCR and the hot-start formulation of the 
enzyme ensures that the primers are not degraded by the enzyme’s 
exonuclease activity during the reaction set-up. 
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                    5’-CACTGAAAAAAATGAGTATGCCTGCCGTGTGAACC-3’  
                       |||||||||||||||||||||||||||                
       3’-GACTTAAGTGGGGGTGACTTTTTTTACTCATACGGACGGC-5’ 
 
 
Figure 3.4: hβ2mD76N site-directed mutagenesis 
B2m-mut-A and B2m-mut-B primers were designed which are partly complimentary 
to each other and to the targeted hβ2m gene, but containing CA mutation causing 
the D76N substitution. In the first round of PCR reaction, the double stranded 
template hβ2m/pBSIISK(-) DNA denatures, the primers anneal to the template and 
new DNA strands are extended, resulting in plasmids with a single mismatch in the 
mutation site. Subsequent PCR cycles predominantly lead to double-stranded 
plasmids carrying the desired mutation on both strands. 
 
In the first round of PCR reaction, plasmids with a single mismatch at the 
mutation site in one strand are produced. As there is no DNA ligase in the 
mix, the new DNA strand is not covalently joined to the primer and there is a 
nick on the strand where the phosphodiester backbone of the DNA is not 
sealed. After several cycles of the PCR reaction, there will be a mixture of the 
original parental non-mutated plasmids and newly synthesized nicked 
plasmids which carry the mutation on both strands. To remove the parental 
non-mutated plasmids from the entire PCR product, the difference between 
DNA isolated from dam+ bacterial cells which is methylated and the newly 
B2m-mut-B 
B2m-mut-A 
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synthesized DNA from a PCR reaction which is not methylated was used. 
After the site-directed mutagenesis PCR reaction, DpnI enzyme which 
cleaves DNA only when its recognition site (GATC) is dam methylated, was 
used to cut the parental DNA, leaving only the non-methylated mutated 
plasmids in the PCR product to be transformed into competent cells. E.coli 
can repair nicked DNA, as long as the nick is opposite an intact strand of 
DNA, so when the nicked mutated plasmids were transformed, they were 
repaired and able to replicate.  
After transformation, plasmid DNA of 12 different clones was purified and 
mapped with HindIII restriction digest to establish which clones carry the 
hβ2m/pBSIISK(-) recombinant plasmid DNA and that the sequence of these 
plasmids has not been altered by major deletions or insertions. The mutation 
itself does not interfere with the restriction sites for HindIII and so the same 
pattern of 3 restriction fragments of 7.2 kb, 4.4 kb and 1.6 kb as in the 
template hβ2m/pBSIISK(-) clone number 11 was expected (Figure 3.2 A). The 
7.2 kb, 4.4 kb and 1.6 kb bands were produced in 11 out of the 12 clones 
analysed (Figure 3.5).  
These 11 clones were sequenced by Source BioScience (UK) using the 
hβ2m-seq3 primer (Table 2.1) to determine which clones carry the D76N 
mutation in the hβ2m sequence (hβ2mD76N). The mutation was confirmed in 
all 11 clones (Figure 3.6). One hβ2mD76N/pBSIISK(-) clone (plasmid number 
4) was then sequenced further to exclude sequence alterations due to PCR-
introduced errors. All 4 exons, exon-intron boundaries, 5’ and 3’ ends and 
ligation sites were verified to ensure that correct transcription and splicing of 
the transgene mRNA would be maintained and that no alterations in the 
amino acid coding sequence (except for the D76N substitution) were present. 
The same primers as for non-mutated hβ2m/pBSIISK(-) sequencing were 
used. No sequence alterations were detected in the coding and regulatory 
regions of the hβ2mD76N/pBSIISK(-) clone number 4 and the hβ2mD76N 
transgene from  this clone was prepared for microinjection. 
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Figure 3.5: Mutated hβ2m/pBSIISK(-) x HindIII 
Because the desired D76N mutation in the hβ2m sequence does not change the 
HindIII restriction pattern of the hβ2m/pBSIISK(-) recombinant plasmids, the non-
mutated template plasmid DNA (T) and the mutated hβ2m/pBSIISK(-) recombinant 
plasmids (m1 – m12) produce the same restriction fragments of 7.2 kb, 4.4 kb and 
1.6 kb. 11 out of 12 clones analysed showed the predicted pattern of fragments 
indicating no gross alteration of the DNA structure. 
 
 
 
Figure 3.6: Partial-sequence chromatograms of the B2M gene 
Left – wild-type human β2m coding sequence; Right – amyloidogenic variant of 
human β2m. c.286GA (GAT/AAT) single base substitution (arrows) encodes 
replacement of the negatively charged aspartate residue at the position 76 of the 
mature protein with an uncharged asparagine residue (D76N). The D76N mutation, 
introduced into the wild-type human β2m coding sequence by site-directed 
mutagenesis was confirmed in 11 out of 12 clones analysed. 
 
108 
 
3.2.3 Generation of hβ2mD76N transgenic mice 
The hβ2mD76N/pBSIISK(-) was digested with BamHI and XhoI, cutting out a 
10.1 kb hβ2mD76N fragment. The fragment was gel purified, quantified and 
used for pronuclear injection. The microinjections into C57Bl/6J embryos and 
embryo transfers into pseudo-pregnant recipient female mice were performed 
by Dr Raya Al-Shawi and Dr Paul Simons. 
38 mice were born from the pronuclear microinjections. Ear and tail biopsies 
were collected and used for genotyping. Transgenic mice were identified by 
PCR using primers hβ2m-sc-F1 and hβ2m-sc-R2 (Table 2.1) that amplify a 
662 bp fragment of the transgene. Five mice showed integration of the 
hβ2mD76N transgene - three males (mouse numbers 2, 4, 6) and two females 
(numbers 11 and 22), and the PCR clearly distinguished the transgenic mice 
from wild-type mice (Figure 3.7). All five transgenic mice were bred with 
C57Bl/6J mice to identify germline transmitters. Four mice proved to transmit 
the transgene to the first generation, establishing lines 2, 4, 6 and 11. Mouse 
number 22 died before producing any offspring.  
 
 
 
 
Figure 3.7: Identification of hβ2m D76N transgenic mice by PCR 
hβ2mD76N transgenic mice were identified by PCR using hβ2m-sc-F1 and hβ2m-sc-
R2 primers. Mice positive for hβ2mD76N transgene (2, 4, 6) are distinguishable from 
their negative littermates (1, 3, 5, 7, 8) and a wild-type C57Bl/6J mouse (WT) by 
amplifying a 662 bp fragment. Human genomic DNA (H) used as a positive control 
and 100 bp marker (M) were run alongside the samples. 
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Lines 2, 6 and 11 transmitted the transgene in a Mendelian fashion with 
approximately 50 % frequency of the transgene inheritance. In the first 
generation of line 4, 15/18 offspring were transgenic suggesting that the 
transgene in the genome of line 4 founder had more than one independently 
segregating integration site. All mice of all four lines were viable and fertile. 
hβ2mD76N transgenic mice on C57Bl/6J background express the endogenous 
mouse β2m. Although the β2m sequence is 70 % identical between the 
human and mouse β2m, it was reported that mouse β2m is not 
amyloidogenic, unlike its human equivalent (Ivanova et al., 2004, Eichner et 
al., 2011). Importantly, it has been reported that while ΔN6β2m, a truncated 
hβ2m found in amyloid deposits of dialysis-related amyloidosis patients, can 
aggregate in vitro into fibrillar material at physiological conditions (pH 7.2, 37 
oC while shaking at 200 RPM), addition of mouse β2m into the ΔN6β2m 
protein mixture abolishes the aggregation potential of the ΔN6β2m (Eichner et 
al., 2011). For these reasons, the hβ2mD76N transgenic mice were also 
crossed with mouse β2m knock out (β2m-KO) mice (B6.129P2-B2mtm1Unc/J, 
The Jackson Laboratory) to produce hβ2mD76N transgenic mice lacking the 
endogenous mouse β2m and to compare the effects of the murine β2m in the 
transgenic mice. All mice developed without any pathological abnormalities. 
 
3.2.4 Expression of hβ2m mRNA in tissue of hβ2mD76N 
transgenic mice 
β2m is a protein ubiquitously expressed by all nucleated cells. In the 
hβ2mD76N transgenic mice, the hβ2m transgene was expressed under the 
control of the gene’s own promoter and own regulatory sequences. 2.9 kb 
and 1.2 kb of 5’ and 3’ flanking sequences of B2M gene were previously 
shown to regulate a pattern of hβ2m transgene expression in transgenic mice 
with a tissue-specific pattern very similar to that of endogenous mouse β2m 
(Chamberlain et al., 1988). Liver, spleen, heart, kidney, tongue, skeletal 
muscle and brain of line 2 hβ2mD76N transgenic mice lacking the endogenous 
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mouse β2m were analysed for the transgenic hβ2m mRNA expression by 
reverse transcription PCR (RT-PCR). 
RNA was isolated from mouse tissue and the samples were treated with 
DNase (gDNA wipe-out buffer, QIAGEN) to eliminate any contaminating 
genomic DNA. The obtained cDNA from the line 2 hβ2mD76N transgenic tissue 
was then PCR amplified using human β2m specific primers hβ2m RT-PCR 5’ 
and hβ2m RT-PCR 3’ primers (Table 2.1) which amplify a 240 bp PCR 
product. The primers were designed so that each primer is complementary to 
a short sequence on different exons. This enables to distinguish between 
PCR amplification of RNA and amplification of contaminating DNA which 
would contain the intron sequence. hβ2m mRNA was detected in all analysed 
tissue in the transgenic mice (Figure 3.8). The specificity of the human β2m 
primers was confirmed by RT-PCR of mRNA obtained from tissue of control 
β2m-KO mice, in which no amplification with  hβ2m RT-PCR 5’ and hβ2m RT-
PCR 3’ primers was produced (Figure 3.9). 
As a positive control, RT-PCR of the ubiquitously present mouse house-
keeping gene GAPDH was simultaneously performed. Using msGAPDHf and 
msGAPDHr primers (Table 2.2), a 133 bp PCR product was amplified from 
obtained cDNA in all analysed tissues of hβ2mD76N transgenic mice as well as 
of β2m-KO mice (Figure 3.8 and 3.9). This result confirmed that the extracted 
RNA is of a good quality and that no amplification of cDNA in the tissue with 
hTTR primers in the RT-PCR reactions is due to the fact that the gene of 
interest is not expressed and not due to lack of total RNA itself in the 
analysed samples or failure of cDNA synthesis. 
To exclude the possibility of false positive signal by genomic DNA 
contamination, a control reaction prepared without the addition of reverse 
transcriptase enzyme into the RNA isolated from tissues of hβ2mD76N 
transgenic mice and β2m-KO mice was also performed. Using primers 
amplifying hβ2m cDNA and GAPDH cDNA (not shown), the PCR did not 
show any amplification of hβ2m and mouse GAPDH fragments, confirming 
111 
 
that the amplification of hβ2m and mouse GAPDH was specific to the 
extracted RNA from the mouse tissue (Figure 3.8).  
 
 
 
 
Figure 3.8: Expression of transgene-encoded hβ2m mRNA 
hβ2m transgene mRNA expression in tissue of hβ2mD76N transgenic mice on β2m-
KO background was analysed by RT-PCR. RNA isolated from liver, kidney, spleen, 
heart, tongue, skeletal muscle and brain was used for cDNA synthesis using reverse 
transcriptase (RT) and a mixture of random primers and oligo-dT primers to ensure 
cDNA synthesis from all regions of RNA transcripts. The synthesized cDNA was then 
amplified by 25 cycle PCR using Taq polymerase. Primers specific for human β2m 
amplified a 240 bp fragment in all tissue analysed. Successful RNA extraction was 
confirmed by control RT-PCR reactions using primers specific for mouse GAPDH, an 
ubiquitously expressed gene, amplifying a 133 bp fragment in all tissue analysed. 
When no RT was added into the tissue RNA, PCR with hβ2m primers was not able 
to amplify a DNA fragment confirming that the signal was specific for the cDNA25 bp 
DNA ladder (M) was run alongside the samples. 
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Figure 3.9: Negative control RT-PCR of hβ2m transgene encoded mRNA 
RNA isolated from liver, kidney, spleen, heart, tongue, skeletal muscle and brain of 
non-transgenic control mice lacking the endogenous mouse β2m (mβ2m-KO) was 
used for cDNA synthesis using reverse transcriptase and subjected to PCR 
amplification with mouse GAPDH primers detecting a ubiquitously expressed 
GAPDH house-keeping gene, and  hβ2m primers. While the GAPDH primers 
amplified a 133 bp fragment, confirming successful extraction of RNA from the tissue 
as well as cDNA synthesis by reverse transcriptase, no amplification of hβ2m was 
detected confirming the specificity of hβ2m the primers to hβ2m transgene only. 
  
113 
 
3.2.5 hβ2m in the serum of hβ2mD76N transgenic mice 
Presence of hβ2m in the serum of the founders of hβ2mD76N transgenic lines 
2, 4, 6 and 11 was evaluated by Western blot analysis. Recombinant purified 
hβ2m protein of known concentrations was used as a positive control of the 
protein migration and for estimation of the serum hβ2m concentration in the 
transgenic mice.  
Three different anti-hβ2m antibodies were tested: Dako rabbit polyclonal anti-
hβ2m antibody, Source Bioscience B2M-01 mouse monoclonal anti-hβ2m 
antibody and 14H3 mouse monoclonal anti-hβ2m antibody from University of 
Pavia (Table 2.3). 12 kDa band of the hβ2m protein was clearly detected in 
the serum of transgenic mice of lines 2, 4 and 11 but no hβ2m was detected 
in the serum of the founder of line 6. As expected, no such hβ2m signal was 
detected in the serum of C57Bl/6J mice and β2m-KO mice. When the 
intensity of hβ2m signal in the serum of transgenic mice was compared with 
the intensity of equivalent volume of human serum run together with the 
transgenic samples, the hβ2m concentration in all three lines appeared 
higher. From the signal intensity given by the known concentrations of the 
recombinant hβ2m protein, the estimated serum hβ2m concentration in line 
11 was ~10 ng/µl and between 10 – 100 ng/µl in lines 2 and 4. 
The Dako polyclonal antibody also strongly cross-reacted with denatured 
mouse β2m but both, the human and mouse proteins were distinguishable on 
an SDS-PAGE gel with mouse β2m migrating slightly slower (~13 kDa) than 
the 12 kDa human β2m protein. Both monoclonal B2M-01 and 14H3 
antibodies were human β2m specific recognising the human β2m protein 
only. Because the monoclonal antibodies were both raised in mouse and anti-
mouse secondary antibodies used for detection were strongly reacting with 
denatured IgG present in the mouse serum analysed, HRP-conjugated Clean-
Blot IP Detection Reagent (Table 2.3) was used for detection of these 
antibodies as the Clean-Blot specifically binds to functional primary antibodies 
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(whole IgG) without binding to denatured IgG fragments. Western blots for all 
three tested antibodies are shown in Figure 3.10. 
 
 
 
 
 
Figure 3.10: hβ2m in serum of hβ2mD76N transgenic mice 
Presence of hβ2m in serum of hβ2mD76N transgenic mice was analysed by Western 
blot. hβ2m was detected in serum of the transgenic founders of line 2, line 4 and line 
11 and co-migrated with β2m protein in human serum (Hum). No hβ2m was detected 
in the serum of line 6 mouse. Three different antibodies were tested: Dako rabbit 
polyclonal anti-hβ2m, Source Bioscience B2M-01 mouse monoclonal anti-hβ2m and 
14H3 mouse monoclonal anti-hβ2m. Both monoclonal antibodies were human β2m 
specific and no signal was detected in serum of C57Bl/6J (WT) and β2m-KO mice 
(KO). The Dako polyclonal antibody showed cross-reactivity with mouse β2m 
(mβ2m) but the mβ2m protein migrated slightly slower (~13 kDa) on an SDS-PAGE 
gel than the hβ2m (12 kDa). Recombinant purified human β2mD76N protein 
(rhβ2mD76N) of known concentration was used for comparison. 1 µl of serum was 
loaded for each sample. 
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3.2.6 Quantitation of hβ2m in serum of hβ2mD76N 
transgenic mice 
Although commercial kits for measuring human β2m in serum are available, 
they are not suitable for detection of hβ2m in mouse serum due to cross-
reactivity with mouse β2m. Further, the amounts of serum required are not 
possible to obtain by routine single blood sampling in mice. Therefore, to 
quantify the concentration of hβ2m in the serum of hβ2mD76N transgenic mice, 
a new sandwich enzyme-linked immunosorbent assay (ELISA) protocol for 
detection of hβ2m was developed and optimized. 
 
3.2.6.1 hB2m ELISA optimization 
An ELISA protocol was developed to enable a specific detection and 
quantitation of hβ2m antigen in a mixture of mouse serum proteins including 
mouse β2m. In sandwich ELISA, the antigen is detected using two layers of 
antibodies: a capture antibody that is bound to a microtiter plate, and a 
detection antibody that binds to a different epitope of the captured antigen. 
HRP-linked secondary antibody is then applied to bind to the Fc-region of the 
detection antibody. In the last step, a chemical substrate is added, which is 
converted by the enzyme into a coloured product and its absorbance is 
measured. Test samples are then plotted against a standard curve obtained 
from absorbance measurement of standards. 
 
Capture and detection antibody optimization 
Monoclonal anti-hβ2m antibody 14H3 (Table 2.3) was used to coat the 
microtiter plate wells. The tested range of the antibody concentration was 1 - 
100 µg/ml. Although 1 µg/ml of the anti-hβ2m capture antibody showed 
sufficient coating of the protein-binding site in the wells, 10 µg/ml was used 
for further optimisation and experiments to ensure that maximal coating was 
reached. 
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For detection of the h2m antigen captured by the monoclonal antibody in the 
wells, Dako rabbit polyclonal anti-hβ2m antibody (Table 2.3) was used as it 
can recognise different epitopes of the captured antigen. When the 
concentration of the detection antibody was lower than 1 µg/ml, not enough 
antibody was provided to bind to the captured antigen and no or very weak 
colour of the final product developed in each well regardless of the amount of 
antigen available, reading no or very low absorbance. The signal was 
improved with antibody concentration of 1 µg/ml and higher. The optimal 
signal to noise ratio was reached with 10 µg/ml of the detection antibody and 
was used in further steps of optimisation and experiments (Figure 3.11). 
 
 
 
Figure 3.11: Optimisation of capture and detection antibodies in hβ2m ELISA 
To detect hβ2m antigen in mouse serum, different concentrations of capture and 
detection antibodies were compared by analysing the signal reached to obtain a 
standard curve. For antigen capture, monoclonal anti-hβ2m antibody 14H3 was used 
to coat the wells of a microtiter plate. To obtain a standard curve, 0.5, 5 and 20 µg/ml 
of recombinant hβ2m protein mixed with β2m-KO serum and β2m-KO serum alone 
as a blank were used. The antigen was then detected by Dako rabbit polyclonal anti-
hβ2m antibody. The capture antibody (C) at concentrations 1 µg/ml and 10 µg/ml 
and detection antibody (D) at concentrations 1 µg/ml and 10 µg/ml were combined 
and obtained standard curves were compared. The best signal to noise ratio was 
reached when 10 µg/ml of capture antibody and 10 µg/ml of detection antibody were 
applied. 1% BSA was used as a blocking buffer. 
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Blocking buffer optimisation 
To improve the sensitivity of the assay by reducing non-specific binding and 
increasing the signal to noise ratio, 6 different blocking buffers were tested: 
PBST, 1 % bovine serum albumin in PBS, 10 % horse serum in PBS, 10 % 
goat serum in PBS, 1 % foetal calf serum in PBS and Pierce Protein-free T-20 
buffer (Thermofisher Scientific). The optimised 10 µg/ml of capture antibody 
and 10 µg/ml of detection antibody were applied and recombinant hβ2m 
protein diluted in an appropriate blocking buffer was used to obtain standard 
curves. Insufficient blocking activity was observed for 1 % BSA, 10 % goat 
serum and 10 % horse serum. In contrast, PBST, Pierce Protein-Free buffer 
and 1 % foetal calf serum showed high sensitivity with low background 
(Figure 3.12) and these buffers were investigated further. 
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Figure 3.12: Optimisation of blocking buffer in hβ2m ELISA 
PBST, Pierce protein-free T-20 blocking buffer (Pierce), 1 % bovine serum albumin 
(BSA) in PBS, 10 % horse serum (HS) in PBS and 10 % goat serum (GS) in PBS 
and 1 % fetal calf serum (FCS) in PBS were tested to improve the hβ2m ELISA 
assay sensitivity. 0 µg/ml, 1 µg/ml and 10 µg/ml of recombinant hβ2m protein diluted 
in appropriate blocking buffer were used to compare the signal reached in the assay. 
Insufficient blocking was observed with 1 % BSA, 10 % HS and 10 % GS due to low 
sensitivity or high background. PBST, Pierce and 1 % FCS showed satisfactory 
blocking activity for their low background signal and high signal to noise ratio. 
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Serum matrix interference 
Naturally occurring proteins, heterophilic antibodies or other endogenous 
components of the serum can affect assay sensitivity and lead to inaccurate 
results. Interfering effect of the serum matrix on the measurement of hβ2m in 
the serum of transgenic mice was tested by spiking recombinant hβ2m 
protein used as a standard with different amounts of mouse serum. The effect 
of endogenous mouse β2m present in the wild-type serum was also 
compared to serum lacking the mouse β2m protein. 
Addition of mouse serum decreased the signal obtained for each point of the 
standard curve. The more serum was added to the recombinant hβ2m 
protein, the more interference was observed and the lower optical density of 
the final product was measured (Figure 3.13). To ensure accurate 
measurements of hβ2m serum concentrations in the transgenic mice, each 
concentration of recombinant hβ2m protein used as a standard was mixed 
with control serum in a volume equivalent to the amount of analysed serum 
applied into wells. 
 
 
 
Figure 3.13: The effect of serum matrix on hβ2m ELISA 
The interfering effect of serum components on the measurement of serum levels of 
hβ2m in transgenic mice by ELISA was tested by spiking recombinant hβ2m protein 
of known concentration with 1 µl, 2 µl and 5 µl of mouse serum. The more serum 
was added to the recombinant hβ2m protein, the lower signal was detected. The 
same effect of serum matrix was observed for both, WT and β2m-KO serum. 
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When the effect of endogenous mouse β2m present in the wild-type serum 
was compared to serum lacking the mouse β2m protein, only a minimal 
difference was observed confirming high specificity of the assay (Figure 3.14). 
 
 
 
Figure 3.14: The effect of endogenous mouse β2m in ELISA assay 
The effect of endogenous mouse β2m present in the wild-type serum (WT) was 
compared to serum lacking the mouse β2m protein (KO). Only a minimal increase in 
signal was observed in serum containing the endogenous mouse β2m confirming 
assay specificity for human β2m protein in mouse serum matrix.  
 
 
The serum matrix interference in relation to different blocking buffers was also 
analysed. PBST, Pierce Protein-Free buffer and 1 % fetal calf serum were 
compared when the purified recombinant hβ2m protein was mixed with 5 µl of 
wild-type serum and 5 µl of β2m-KO serum. Pierce and PBST showed high 
sensitivity with low background for both, the β2m-KO as well as the wild-type 
serum matrix. The sensitivity of the assay decreased slightly with 1 % foetal 
calf serum used for blocking  (Figure 3.15) and for this reason this blocking 
buffer was not used in further experiments. 
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Figure 3.15: Optimisation of blocking buffer for serum matrix interference  
The effect of serum matrix interference and different blocking buffers on sensitivity of 
the ELISA assay was analysed by comparing the signal obtained when 5 µl of wild-
type serum was mixed with recombinant hβ2m protein. While lower sensitivity was 
observed when 1 % fetal calf serum (FCS) in PBS was used for blocking, PBST and 
Pierce Protein-Free buffers showed good sensitivity and low signal to noise ratio. 
 
hβ2m ELISA optimisation summary 
After several optimisation steps, the hβ2m ELISA assay protocol to quantify 
the concentration of hβ2m in the serum of hβ2mD76N transgenic mice was as 
follows: 
10 µg/ml of monoclonal anti-hβ2m antibody 14H3 was used to coat the wells 
of a microtiter plate to capture the hβ2m antigen in a mixture of serum 
proteins including endogenous mouse β2m. The remaining protein-binding 
sites in the wells were blocked with Peirce Protein-Free T20 buffer. 5 µl of 
mouse serum diluted in Peirce Protein-Free T20 blocking buffer was added to 
the wells and the captured antigen was detected by adding 10 µg/ml of rabbit 
polyclonal anti-hβ2m antibody (Dako). Known concentrations of recombinant 
hβ2m protein mixed with 5 µl of wild-type or β2m-KO mouse serum, 
depending on the genetic background of mice analysed, were used to obtain 
a standard curve for each plate assayed. 
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3.2.6.2 Concentrations of hβ2m in serum of hβ2mD76N 
transgenic mice 
Three independent lines – line 2, line 4 and line 11 of transgenic mice that 
express the hβ2mD76N transgene have been established. The mice were 
generated on C57Bl/6J wild-type background (WT) in which the endogenous 
mouse β2m is also expressed. The three lines were also crossed on β2m 
knock-out background (β2m-KO) in which the mice lack expression of the 
endogenous mouse β2m.  
The concentrations of hβ2m in the serum of hβ2mD76N transgenic mice on the 
WT background and on the β2m-KO background were quantified for each line 
by the optimised hβ2m ELISA assay. The values are shown as mean ± 
standard deviation (SD) for number of mice (n) analysed. 
In healthy humans, plasma β2m concentration is 0.7 – 2.7 µg/ml (Berggard 
and Bearn, 1968, Greipp et al., 1988, Floege et al., 1991). The highest serum 
concentration hβ2m was measured in line 2. In this line, the serum hβ2m in 
the transgenic mice on WT background (T/WT) was 18.82 ± 4.05 µg/ml 
(n=14), whereas in the transgenic mice on β2m-KO background (T/KO) the 
concentration was 35.33 ± 6.43 µg/ml (n=15). In line 11, the hβ2m 
concentration in T/WT mice was 6.31 ± 1.02 µg/ml (n=7) and in T/KO mice 
3.70 ± 1.87 µg/ml (n=20). In line 4, hβ2m serum levels of T/WT mice were 
analysed but as the founder of this line had more than one integration site of 
the transgene, the hβ2m concentration varied among the offspring. A higher-
expressing line 4 mouse of the first generation was crossed on β2m-KO 
background and its offspring were then analysed. In this line, the hβ2m 
concentration in T/KO mice was 9.46 ± 2.08 (n=11). The results are shown in 
Figure 3.16. 
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Figure 3.16: Quantitation of serum hβ2m in hβ2mD76N transgenic mice 
Concentrations of circulating hβ2m in the three established lines of hβ2mD76N 
transgenic mice on wild-type genetic background (top) and on mouse β2m-KO 
background (bottom) was quantified by ELISA. 
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In all three lines, hβ2mD76N transgenic females on β2m-KO background had 
higher concentrations of serum hβ2m than transgenic males (Table 3.1). The 
sex difference was statistically significant in line 2 and line 11. Because the 
transgene in the line 4 was integrated into the genome of the founder in more 
than one site, smaller number of animals of one lineage was available to be 
grouped and analysed. 
 
 
 
 
Table 3.1: Serum hβ2m concentration in transgenic males and females 
Plasma hβ2m concentrations in three lines of hβ2mD76N transgenic males and 
females mice. Values represent mean ± SD for number (n) of mice analysed. Mann-
Whitney two-tailed test was used for statistical analysis. 
 
 
In humans and mice, endogenous β2m increases in blood with age (Norlund 
et al., 1997, Smith et al., 2015). When young and 12-15 months old 
transgenic mice of line 2 on β2m-KO background were compared, increase in 
serum hβ2m was not observed, with concentrations 39.13 ± 5.33 µg/ml (n=8) 
for 3-6 months old transgenic mice and 35.62 ± 5.39 µg/ml (n=10) for 12-15 
months old transgenic mice (Figure 3.17). The increase of plasma β2m in 
Males Females Males Females
Line 2 18.3 ± 4.70 19.52 ± 3.59 32.20 ± 4.93 41.6 ± 4.05
(n) (5) (6) (10) (5)
P value
Line 4 N/A N/A 8.8 ± 1.4 9.7 ± 2.3
(n) (3) (8)
P value
Line 11 6.55 ± 0.50 6.22 ± 1.21 2.84 ± 1.68 4.99 ± 1.38
(n) (2) (5) (12) (8)
P value
ns
ns p = 0.012
[hβm] µg/ml
T/WT T/KO
ns p = 0.012
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humans is evident in from the sixth decade and in mice older than 18 months 
(Norlund et al., 1997, Smith et al., 2015), and the hβ2mD76N transgenic mice 
may have been too young to notice a difference in the plasma concentrations 
of hβ2m. 
 
 
 
 
 
Figure 3.17: Serum hβ2m in hβ2mD76N transgenic females in relation to age 
Serum concentration of hβ2m in line 2 transgenic females on β2m-KO background 
was analysed in relation to age. The concentration in mice between 3 months and 15 
months of age only slightly decreased with age (Pearson r = -0.1324) 
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3.2.7 Cell surface expression of hβ2m in hβ2mD76N 
transgenic mice 
The hβ2mD76N transgenic mice do not express human heavy chain of MHC 
class I complex, but it has been previously shown in human β2m transgenic 
mice that murine class I heavy chains associate with human β2m and such 
hybrid complexes are efficiently expressed at the cell surface (Chamberlain et 
al., 1988). To determine whether the D76N variant hβ2m forms cell surface 
complexes with the mouse MHC I, leukocyte in blood films of transgenic and 
non-transgenic mice were stained with FITC-labelled anti-human β2m 
monoclonal antibody B2M-01. Specific staining was detected in the 
transgenic mice, except line 6 transgenics in which no immunofluorescence 
was observed confirming no transgene expression. No signal was detected in 
leukocytes of non-transgenic controls and β2m-KO mice (Figure 3.18). 
To show that the immunofluorescent signal detected in the blood films of 
transgenic mice did not come from within the cells due to cell 
permeabilization, FACS analysis on living blood cells was performed to 
confirm the cell surface localization of the variant β2m. The cells were 
labelled with APC-conjugated anti-CD45, the leukocyte common antigen, and 
human β2m signal was analysed using FITC-labelled anti-human β2m 
monoclonal antibody B2M-01. The leukocytes of non-transgenic mice and 
β2m-KO mice gave indistinguishable pattern of background fluorescence 
whereas leukocytes of hβ2mD76N transgenic mice showed significantly higher 
signal confirming localisation of D76N variant β2m on cell surface (Figure 
3.19). 
127 
 
        
 
 
Figure 3.18: hβ2m immunofluorescence of leukocytes of hβ2mD76N transgenic 
mice 
Direct immunofluorescence staining of blood films using FITC-labelled monoclonal 
anti-hβ2m antibody B2M-01. The bright green fluorescence (white arrows) of 
leukocytes of hβ2mD76N transgenic mice confirmed the expression of human β2m in 
lines 2 and 4. No hβ2m immunofluorescence was observed in transgenic mice of line 
6. No signal was detected on leukocytes of C57Bl/6J mice (WT) and β2m-KO (KO) 
mice. Nuclei of leucocytes were stained blue with Hoechst 33342. Erythrocytes 
appear green due to strong autofluorescence. 
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Figure 3.19: hβ2m cell surface expression in hβ2mD76N transgenic mice 
Peripheral blood leukocytes were analysed by FACS analysis to assess whether the 
D76N variant β2m was expressed on the cell surface. 
Top - the signal of FITC-labelled anti-human β2m monoclonal antibody B2M-01 
detected on leukocytes of hβ2mD76N transgenic mice (red) confirmed the localisation 
of the D76N variant hβ2m on the cell surface. Background levels of autofluorescence 
only were detected on the leukocytes of non-transgenic littermates and β2m-KO 
mice (white). 
Bottom – no difference in signal of the cell surface D76N variant β2m was seen 
between line2 hβ2mD76N transgenics lacking the endogenous mouse β2m (green) 
and line 2 hβ2mD76N transgenics carrying mouse β2m allele (pink). 
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3.3 Discussion 
Although attempts have been made to model Aβ2m amyloidosis in mice, 
none have been successful to date. Here, transgenic mice expressing a 
highly amyloidogenic variant β2mD76N have been generated as a potential 
new model of Aβ2m amyloidosis.  
β2m is expressed by all nucleated cells. To maintain the ubiquitous 
expression of the transgene, the hβ2M gene was cloned from genomic DNA 
and the gene’s own promoter and regulatory sequences within the 2.1 kb of 5’ 
flanking sequence and 630 bp 3’ flanking sequence were used to drive the 
expression of the transgene. The advantage of using genomic sequence, 
including exons and introns, over cDNA-based construct is that the levels of 
expression of cDNA constructs can be much lower than the expression levels 
obtained by genomic DNA sequence because introns enhance the efficiency 
of gene expression and thus play a role in facilitating transcription of 
microinjected genes (Brinster et al., 1988, Whitelaw et al., 1991). 
Furthermore, it was shown that own enhancer and promoter of a gene of 
interest maintains a tissue-specific expression of the transgene (Chada et al., 
1985, Hammer et al., 1987). Although the promoter of the B2M gene was 
identified (Gussow et al., 1987), the regulatory sequences enhancing the B2M 
gene expression were not. Chamberlain et al. (1988) generated transgenic 
mice expressing hβ2m in which 2.9 kb and 1.2 kb of 5’ and 3’ flanking 
sequences, respectively, of the hB2M genomic sequence showed to regulate 
the hβ2m transgene expression with a tissue-specific pattern very similar to 
that of endogenous mouse β2m. Indeed, in the hβ2mD76N transgenic mice 
presented here, the hβ2m mRNA expression was confirmed in all tissues 
analysed. Moreover, the concentrations of the plasma human β2m in the 
three independent lines of the hβ2mD76N transgenic mice were similar or much 
higher than in healthy humans. 
In healthy people, the range of serum β2m concentration is 0.7 – 2.7 µg/ml 
(Berggard and Bearn, 1968, Greipp et al., 1988, Floege et al., 1991) and 
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similar levels were measured in the line 11 of the hβ2mD76N transgenic mice. 
Aβ2m amyloidosis is a complication of patients with end stage renal failure 
whose circulating β2m levels rise up to 50-70 µg/ml and remain elevated for a 
long period of time (Floege et al., 1991). In chronic kidney disease, serum 
β2m concentration increases up to ~20 µg/ml but Aβ2m amyloidosis is not 
present in the patients (Sedighi et al., 2015).  However, a patient with chronic 
kidney disease not on dialysis who developed Aβ2m amyloidosis was 
reported. In this patient the serum β2m concentration reached 32 µg/ml, 
which is higher than normally seen in chronic kidney disease patients 
(Zingraff et al., 1990). Line 2 of the hβ2mD76N transgenic mice had measured 
plasma concentrations of the human β2m reaching to 40 µg/ml, which are 
concentrations at which Aβ2m amyloidosis may develop in people. On the 
other hand, patients carrying the highly amyloidogenic D76N variant β2m, 
causing hereditary systemic Aβ2m amyloidosis, had normal concentrations of 
serum β2m (1-3 µg/ml). Therefore, the concentrations of the highly 
amyloidogenic D76N variant β2m in the transgenic mice presented here 
should be sufficient for amyloid deposition. 
In context with the plasma concentration of human β2m in transgenic mice, 
Zhang et al. (2010) generated a mouse model expressing wild-type human 
β2m and reported that the plasma concentrations of human β2m in those 
mice were ~190 µg/ml. To quantitate the human β2m plasma concentrations, 
they used semi-quantitative measurement by Western blot using Dako anti-
hβ2m antibody, the same antibody used for detection of hβ2m in the 
hβ2mD76N transgenic mice presented here, and used plasma of wild-type mice 
expressing endogenous mouse β2m for comparison. However, there is a 
discrepancy in the literature about plasma concentration of the mouse β2m in 
mice. Zhang et al. (2010) reported that levels of plasma mouse β2m in 
C57Bl/6J mice are 113 µg/ml, similarly to Ivanova et al. (2004) who reported 
levels around 200 µg/ml. However, the data are either not shown by the 
authors or show a presence of the mouse β2m in mouse plasma without a 
comparable concentration estimate control (Zhang et al., 2010, Ivanova et al., 
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2004). On the other hand, Smith et al. (2015) reported and showed that levels 
of plasma mouse β2m in C57Bl/6J mice are <10 µg/ml (Smith et al., 2015). 
Consistently with this, the data presented here show that the concentration of 
plasma mouse β2m in C57Bl/6J mice is higher than plasma β2m 
concentration in humans but not higher than 10 µg/ml. In the hβ2m transgenic 
mouse model generated by Zhang et al. (2010), the signal intensity of mβ2m 
in wild-type mice on an immunoblot used for quantitation of the β2m 
concentration was similar with hβ2m signal in the transgenic mice. Based on 
the observations described here, the levels of hβ2m in their transgenic mice 
are probably similar to levels seen in healthy humans, which are much lower 
than the concentrations reported. 
β2m is essential for a correct assembly of MHC class I molecules in the ER 
and transport of the complex to the plasma membrane. It has been shown 
that β2m deficient mice lack MHC class I proteins and CD8+ T cells (Zijlstra 
et al., 1990, Koller et al., 1990). On the other hand, in mice lacking 
endogenous β2m but expressing human β2m, murine class I heavy chains 
associate with human β2m and form functional hybrid complexes that are 
efficiently expressed at the cell surface (Chamberlain et al., 1988). In 
hβ2mD76N transgenic mice presented here, the D76N variant human β2m 
protein was detected on cell surface of leukocytes in all three transgenic lines 
confirming the ability of the human variant to form functional MHC class I 
heterodimers with murine MHC class I heavy chains and present them on the 
cell surface. Interestingly, there was no difference observed in the signal of 
hβ2mD76N on the cell surface between hβ2mD76N transgenic mice expressing 
the endogenous mouse β2m and hβ2mD76N transgenic mice lacking the 
endogenous β2m protein. In cells cultured in vitro, cell surface murine MHC 
class I molecules exchange endogenous mouse β2m subunits with 
exogenous free human β2m or free bovine β2m molecules present in the 
culture medium (Bernabeu et al., 1984). Both bovine and human β2m are 
equivalent in stabilizing the mouse MHC class I heavy chains and the 
heterodimers are able to present antigenic peptides. The affinity of murine 
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β2m for murine MHC class I heavy chain is much lower and the murine 
subunit exchange activity is much weaker compared to human β2m (Shields 
et al., 1998, Pedersen et al., 1995). It is therefore possible that mouse/human 
MHC class I heterodimers are preferably formed in the hβ2mD76N transgenic 
mice or that β2m subunit exchange of assembled MHC class I on the cell 
surface favours the exchange of mouse β2m for the human β2m protein. The 
ratio of MHC class I with mouse β2m subunit and MHC class I with human 
β2m subunit on the cell surface of hβ2m transgenic mice is not known, nor is 
it known whether the presence of the hβ2m in transgenic mice has an effect 
on the total number of MHC class I formed and expressed on the cell surface. 
 
In summary, three lines of transgenic mice expressing a highly amyloidogenic 
human β2mD76N variant have been successfully generated. In these mice, the 
plasma levels of the human β2m are similar or much higher than in Aβ2mD76N 
amyloidosis patients. Because the concentration of an amyloidogenic protein 
is an important prerequisite for priming formation of amyloid fibrils in vivo, the 
hβ2mD76N transgenic mice may have a high potential for developing Aβ2m 
amyloidosis.  
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4 Characterization of hβ2mD76N transgenic 
mice as a potential model of 
β2-microglobulin amyloidosis 
 
4.1 Introduction 
The previous chapter described generation and establishment of transgenic 
mice carrying the highly amyloidogenic D76N variant of β2m. The need for a 
transgenic model of Aβ2m amyloidosis arises from the fact, that although 
Aβ2m amyloidosis, a serious complication of the majority of patients 
undergoing long-term dialysis, has been known for over 30 years, the 
mechanisms of the disease are poorly understood. Although attempts have 
been made to model Aβ2m amyloidosis in mice, none has been successful to 
date. 
Amyloid deposits in the dialysis-related Aβ2m amyloidosis are specific for the 
tissue of musculo-skeletal system despite the fact that the β2m protein is 
ubiquitously released from all nucleated cells of the body. The specificity of 
the deposition in joints, ligaments, cartilage and bones causes erosive and 
destructive osteoarthropathies, carpal tunnel syndrome, bone cysts and 
pathological fractures. Although in recent years the onset of this disease in 
patients undergoing dialysis has been significantly delayed due to advanced 
dialysis technology, dialysis-related amyloidosis remains a disabling 
complication in patients on long-term dialysis, with 50 % of patients after 13 
years on dialysis still developing clinically severe manifestation of the disease 
(Kopec et al., 2011, Hoshino et al., 2016). 
Biochemical analyses showed that amyloid deposits present in Aβ2m 
amyloidosis patients consist of  full-length non-mutated β2m and a truncated 
species of β2m missing the first six N-terminal residues (ΔN6β2m) (Gorevic et 
al., 1986, Stoppini et al., 2005) and fibrillogenesis of β2m in vitro has been 
extensively studied. It has been reported that while the truncated ΔN6β2m 
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can aggregate in vitro into fibrillar material at physiological conditions (pH 7.2, 
37 oC while shaking at 200 RPM), in fact the ΔN6β2m was able to convert 
full-length human β2m into amyloid-like aggregates under the physiological 
conditions under which full-length human β2m alone does not aggregate, 
addition of mouse β2m into the ΔN6β2m protein mixture completely abolished 
the aggregation potential of the ΔN6β2m (Eichner et al., 2011). Furthermore, 
mouse β2m is not amyloidogenic in vitro, even in acidic conditions (pH 2.0) in 
which human β2m aggregates into fibrillar material (Ivanova et al., 2004, 
Eichner et al., 2011). However, it is not known whether mouse β2m affects 
fibrillogenesis of human β2m in vivo. 
In 2010, Zhang et al. generated transgenic mice expressing wild-type human 
β2m as a model of Aβ2m amyloidosis. Although the authors have reported 
that the mice have high plasma concentrations of the human β2m (~190 
µg/ml), the actual plasma concentration may be much lower as it was 
discussed before. Nevertheless, the mice did not develop spontaneous Aβ2m 
amyloidosis up to 24 months of age, despite the fact that expression of the 
endogenous murine β2m was silenced in the transgenic mice (Zhang et al., 
2010). Priming of Aβ2m amyloid deposition with exogenous seeds of Aβ2m 
amyloid fibrils also failed and the transgenic mice lacking the mouse β2m did 
not develop Aβ2m amyloidosis (Zhang et al., 2010). 
In the previous chapter, generation and establishment of transgenic mice 
expressing the highly amyloidogenic β2mD76N variant were presented. The 
recently described first naturally occurring β2mD76N variant causes highly 
penetrant hereditary systemic Aβ2m amyloidosis in one French family with a 
severe phenotype of extensive visceral amyloid deposits with the onset in the 
fourth decade (Valleix et al., 2012). The most disabling condition in the 
patients carrying this mutation is progressive bowel dysfunction caused by 
severe autonomic neuropathy (Valleix et al., 2012). Amyloid deposits were 
also found in spleen, liver, heart, salivary glands, adrenal gland and colon but 
surprisingly no amyloid was found in bones, joins and ligaments typical for 
dialysis-related Aβ2m amyloidosis. Moreover, in contrast with dialysis-related 
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Aβ2m amyloidosis in which elevated β2m concentrations are one of the pre-
requisites of developing Aβ2m amyloid deposits, the β2mD76N patients had 
normal levels of circulating β2m (Valleix et al., 2012).  
In vitro studies showed that the β2mD76N protein incubated in physiological 
solution at pH 7.4 with mild shaking rapidly converted into fibrils within a few 
hours, in contrast to wild-type β2m which remained natively folded and 
soluble under the same conditions (Mangione et al., 2013). Moreover, the 
β2mD76N variant can transform wild-type β2m into insoluble fibrils in a mixed 
solution in vitro at much higher rate than ΔN6β2m (Mangione et al., 2013). 
Interestingly, there was no wild-type β2m protein found in the amyloid fibrils 
isolated from a tissue of Aβ2mD76N amyloidosis patient, which purely 
consisted of the full length variant (Valleix et al., 2012, Mangione et al., 2013). 
 
In this project, transgenic mice carrying the recently discovered highly 
amyloidogenic D76N variant of β2m were generated. 3 independent 
transgenic lines were established which present with similar or higher 
concentrations of circulating hβ2mD76N than concentrations seen in β2mD76N 
amyloidosis patients. Given the aggressive amyloidogenicity of the β2mD76N 
variant, the hypothesis was that these mice will develop Aβ2m amyloidosis. 
The aims to support this hypothesis were to assess amyloid deposition in the 
transgenic mice in various tissues in which Aβ2m amyloid may occur, by 
histological analysis with Congo red staining and immunohistochemistry. 
hβ2mD76N transgenic mice on both, wild-type mouse β2m and β2m-KO 
backgrounds were analysed to evaluate the effect of the mouse β2m on 
human β2m deposition and amyloid formation in the mice. The possibility of 
accelerating Aβ2m deposition by seeding the transgenic mice with pre-formed 
Aβ2m amyloid fibrils, a method commonly used in priming amyloid deposition 
in mouse models of AA amyloidosis (Willerson et al., 1969, Simons et al., 
2013) and ApoAII amyloidosis (Higuchi et al., 1998) was also investigated. 
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4.2 Results 
 
4.2.1 Assessment of spontaneous amyloid deposition 
in hβ2mD76N transgenic mice 
The D76N variant β2m has been shown to be highly amyloidogenic and 
patients heterozygous for this mutation suffer from systemic amyloid deposits. 
The patients are clinically affected as early as in their fourth decade with 
heavy amyloid deposits in the viscera, involving especially spleen and adrenal 
glands. In a post-mortem examination of a 70 year old patient carrying the 
D76N mutation in the β2M gene, amyloid deposits were found in spleen, liver, 
heart, salivary glands, colon and nerves (Valleix et al., 2012). In 
dialysis-related amyloidosis patients, persistent elevated levels of wild-type 
β2m are responsible for amyloid deposits in joints and bones.  
In the hβ2mD76N transgenic mice, spontaneous amyloid deposition was 
assessed by Congo red staining of sections of wax embedded tissue and light 
microscopy with polarized light. Because of the wide-spread amyloid 
depositions in the Aβ2mD76N patients, the assessment involved a wide variety 
of tissues. The examined tissues included liver, kidney, spleen, heart, lung, 
stomach, gut, adrenal, sciatic nerve, salivary gland, tongue, skin, fat, eye and 
sternum cartilage in all three lines of the hβ2mD76N transgenics on both, wild-
type and β2m-KO background. Because of the age-dependence in amyloid 
deposition typical for amyloidosis, the analysis was performed on mice 6 
months old up to 24 months old. Age-matched non-transgenic wild-type and 
β2m-KO mice were also analysed as negative controls.  
Despite the aggressively amyloidogenic character of the D76N variant of β2m 
and despite a thorough search of extensive tissue samples, no spontaneous 
deposition of Aβ2m amyloid was found in the transgenic mice. The number of 
animals analysed for each line and the outcome of the analysis is 
summarised in Tables 4.1 – 4.3. 
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Congo red positive staining exhibiting green birefringence under the polarised 
light typical for amyloid was detected in two 22 months old non-transgenic 
C57Bl/6J mice. In mice, two types of systemic amyloidoses associated with 
aging can naturally occur: AApoAII amyloidosis in which the amyloidogenic 
precursor is apolipoprotein A-II (ApoAII), an abundant protein in serum high-
density lipoprotein (Takeda et al., 1994, Higuchi et al., 1997), and AA 
amyloidosis associated with chronic inflammation in which serum amyloid A 
(SAA), an acute phase apolipoprotein, is the amyloidogenic precursor 
(McAdam and Sipe, 1976, Eriksen et al., 1976, Higuchi et al., 1991b). 
Immunohistochemistry with antibodies against hβ2m, mouse ApoAII and 
mouse SAA confirmed that ApoAII was the amyloid protein in the tissue of the 
two 22 months old non-transgenic mice. No immunoreactivity was detected 
with anti-mouse SAA and anti-hβ2m antibodies in the Congo-red positive 
tissues (Figure 4.1).  
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Line 2 Spontaneous amyloid deposition 
 6-12 months 12-18 months 18-24 months 
 T/WT T/KO T/WT T/KO T/WT T/KO 
Liver 0/3 0/1 - 0/3 0/8 0/3 
Kidney 0/3 0/1 - 0/3 0/8 0/3 
Spleen 0/3 0/1 - 0/3 0/8 0/3 
Heart 0/3 0/1 - 0/3 0/8 0/3 
Lung 0/3 0/1 - 0/3 0/8 0/3 
Tongue 0/3 0/1 - 0/3 0/8 0/3 
Salivary gland 0/3 0/1 - 0/3 0/8 0/3 
Adrenal 0/3 0/1 - 0/3 0/8 0/3 
Sciatic nerve 0/3 0/1 - 0/3 0/8 0/3 
Gut 0/3 0/1 - 0/3 0/8 0/3 
Stomach 0/3 0/1 - 0/3 0/8 0/3 
Muscle 0/3 0/1 - 0/3 0/8 0/3 
Fat 0/3 0/1 - 0/3 0/8 0/3 
Skin 0/3 0/1 - 0/3 0/8 0/3 
Eye - - - - 0/7 - 
Optic nerve - - - - 0/5 - 
Lacrymal gland - - - - 0/5 - 
Cartilage - - - 0/1 - 0/3 
 
 
Table 4.1: Analysis of spontaneous amyloid deposition in hβ2mD76N transgenic 
mice 
Summary of tissue analysed by Congo red in line 2 hβ2mD76N transgenic mice on 
wild-type background (T/WT) and on β2m-KO background (T/KO) at age groups 6-
12, 12-18 and 18-24 months old. The samples are scored as number of mice with 
amyloid / number of mice analysed for each tissue. 
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Line 4 Spontaneous amyloid deposition 
 6-12 months 12-18 months 18-24 months 
 T/WT T/KO T/WT T/KO T/WT T/KO 
Liver 0/2 0/3 - 0/3 0/4 - 
Kidney 0/2 0/3 - 0/3 0/4 - 
Spleen 0/2 0/3 - 0/3 0/4 - 
Heart 0/2 0/3 - 0/3 0/4 - 
Lung 0/2 0/3 - 0/3 0/4 - 
Tongue 0/2 0/3 - 0/3 0/4 - 
Salivary gland 0/2 0/3 - 0/3 0/4 - 
Adrenal 0/2 0/3 - 0/3 0/4 - 
Sciatic nerve 0/2 0/3 - 0/3 0/4 - 
Gut 0/2 0/3 - 0/3 0/4 - 
Stomach 0/2 0/3 - 0/3 0/4 - 
Muscle 0/2 0/3 - 0/3 0/4 - 
Fat 0/2 0/3 - 0/3 0/4 - 
Skin 0/2 0/3 - 0/3 0/4 - 
Eye - 0/1 - 0/1 0/4 - 
Optic nerve - 0/1 - 0/1 0/4 - 
Lacrymal gland - 0/1 - 0/1 0/4 - 
 
 
Table 4.2: Analysis of spontaneous amyloid deposition in hβ2mD76N transgenic 
mice 
Summary of tissue analysed by Congo red in line 4 hβ2mD76N transgenic mice on 
wild-type background (T/WT) and on β2m-KO background (T/KO) at age groups 6-
12, 12-18 and 18-24 months old. The samples are scored as number of mice with 
amyloid / number of mice analysed for each tissue. 
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Line 11 Spontaneous amyloid deposition 
 6-12 months 12-18 months 18-24 months 
 T/WT T/KO T/WT T/KO T/WT T/KO 
Liver 0/2 0/4 - 0/2 0/3 - 
Kidney 0/2 0/4 - 0/2 0/3 - 
Spleen 0/2 0/4 - 0/2 0/3 - 
Heart 0/2 0/4 - 0/2 0/3 - 
Lung 0/2 0/4 - 0/2 0/3 - 
Tongue 0/2 0/4 - 0/2 0/3 - 
Salivary gland 0/2 0/4 - 0/2 0/3 - 
Adrenal 0/2 0/4 - 0/2 0/3 - 
Sciatic nerve 0/2 0/4 - 0/2 0/3 - 
Gut 0/2 0/4 - 0/2 0/3 - 
Stomach 0/2 0/4 - 0/2 0/3 - 
Muscle 0/2 0/4 - 0/2 0/3 - 
Fat 0/2 0/4 - 0/2 0/3 - 
Skin 0/2 0/4 - 0/2 0/3 - 
Eye - 0/4 - - 0/2 - 
Optic nerve - 0/4 - - 0/2 - 
Lacrymal gland - - - - 0/1 - 
 
 
Table 4.3: Analysis of spontaneous amyloid deposition in hβ2mD76N transgenic 
mice 
Summary of tissue analysed by Congo red in line 11 hβ2mD76N transgenic mice on 
wild-type background (T/WT) and on β2m-KO background (T/KO) at age groups 6-
12, 12-18 and 18-24 months old. The samples are scored as number of mice with 
amyloid / number of mice analysed for each tissue. 
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Figure 4.1: Amyloid deposition in aged non-transgenic mice  
Amyloid deposition in kidney and liver of a 22 months old non-transgenic wild-type 
control mouse was detected in Congo red stained section. Amyloid (black arrows) is 
stained red and exhibits green/orange birefringence under polarised light. The co-
localisation of amyloid with mouse ApoAII protein in the tissue was confirmed by 
immunostatining with anti-mouse ApoAII antibody (1/4000), seen in dark brown. No 
co-localised signal was detected when the amyloidotic tissue was immunostatined 
with anti-mouse SAA antibody (1/100) and Dako anti-human β2m antibody (1/600). 
G – kidney glomerulus, BV – blood vessel in liver tissue. 
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4.2.2 β2m deposition in hβ2mD76N transgenic mice 
Because no amyloid was found in the hβ2mD76N transgenic mice, tissues of 
transgenic animals on both, wild-type and β2m-KO backgrounds were 
examined by immunohistochemistry with anti-human β2m antibody to analyse 
whether any extracellular accumulation of β2m, suggesting β2m deposition 
and aggregation, could be detected. Because β2m is expressed on all 
nucleated cells, indeed, the hβ2m expression in the hβ2mD76N transgenic 
mice was confirmed in all tissue analysed, and because free β2m is 
circulating in the blood, some β2m signal was expected in all transgenic 
tissue. 
Because the Dako anti-human β2m antibody cross-reacted on Western blot 
with denatured mouse β2m, the specificity of Dako polyclonal anti-human 
β2m antibody (Table 2.1) to human β2m in fixed and wax embedded tissue 
was tested. Liver, kidney and spleen of 6-9 months old of 2 transgenic mice 
on wild-type background was immunostained together with tissues of 2 non-
transgenic wild-type mice and 2 non-transgenic β2m-KO mice. 
As expected, hβ2m signal was detected in the tissues of transgenic mice and 
no signal was detected in the tissue of non-transgenic β2m-KO mice. Only 
very weak background staining was detected in the tissues of non-transgenic 
wild-type mice expressing endogenous mouse β2m confirming the specificity 
of the antibody to human β2m (Figure 4.2). 
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Figure 4.2: Specificity of Dako anti-human 2-microglobulin antibody 
Under denaturing conditions of Western blot, Dako polyclonal anti-human β2m 
antibody cross-reacts with mouse β2m. In order to use the antibody in 
immunohistochemistry to evaluate the localisation of the variant human β2m in the 
tissue of hβ2mD76N transgenic mice, sections of fixed and wax embedded samples of 
β2m-KO mice (n=2), C57Bl/6J (WT) mice (n=2) and hβ2mD76N transgenic mice 
expressing also the endogenous mouse β2m (hβ2mD76N-Tg/WT, n=2) were 
compared. The specificity of the antibody under native conditions was confirmed by 
giving a strong signal in the tissue of transgenic mice, whereas only very weak 
background staining was detected in the WT and β2m-KO mice. The figure shows 
representative images. 
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Because amyloid deposition is time dependent, tissues of 4-week old 
hβ2mD76N transgenic mice on β2m-KO background (n=3) were compared to 
18-months old hβ2mD76N transgenic mice on β2m-KO background (n=3). 
Transgenic mice on the β2m-KO background were chosen because of the 
possible inhibitory effect of mouse β2m on aggregation of human β2m 
reported in in vitro experiments (Eichner et al., 2011), as discussed earlier. 
Two β2m-KO mice were used as negative controls. The tissues analysed 
included liver, kidney, spleen, heart, lung, stomach, gut, adrenal, sciatic 
nerve, salivary gland, tongue, skin, fat and sternum cartilage. 
In the young, 4 weeks old mice, some β2m signal was observed in all tissue 
analysed as expected. Large amount of the human β2m protein was detected 
in the liver where the hβ2m appeared to be lining the sinusoids and radiating 
from the hepatic venules. Strong human β2m signal was also detected in the 
spleen, at the top of the villi of the intestine and in epidermis of the skin. 
Considerably more β2m signal was observed in liver, kidney, stomach, 
intestine, skin and tongue of the 18 months old mice when compared to the 
tissue of young mice. Representative images are shown in Figures 4.3 – 4.8. 
The hβ2m in the tissues of the old mice seemed to be accumulated 
extracellularly. With advancing age, the pattern of hβ2m signal became more 
widespread and more prominent suggesting deposition of hβ2m in the tissue, 
an observation consistent with pre-fibrillar aggregation. On the other hand, 
increasing expression of the transgene in older mice cannot be ruled out. 
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Figure 4.3: Comparison of hβ2m localisation between young and old hβ2mD76N 
transgenic mice 
Immunohistochemistry on liver and spleen of 1 month old (n=3) and 18 months old 
(n=3) hβ2mD76N transgenic mice on β2m-KO background (hβ2mD76N-Tg/mβ2m-KO) 
stained with Dako anti-human β2m antibody. Strong β2m signal was observed in 
both, the liver and the spleen. More β2m was detected in the liver tissue of old mice 
than in the young mice. The localisation of β2m seemed extracellular, lining the 
sinusoids and surrounding the blood vessels (BV) suggesting increased β2m 
deposition with advanced age. 
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Figure 4.4: Comparison of hβ2m localisation between young and old hβ2mD76N 
transgenic mice 
Immunohistochemistry on kidney and heart of 1 month old (n=3) and 18 months old 
(n=3) hβ2mD76N transgenic mice on β2m-KO background (hβ2mD76N-Tg/mβ2m-KO) 
stained with Dako anti-human β2m antibody. Very little β2m expression was 
observed in the tissue of the 1 month old mice. In the 18 months old mice, more β2m 
was detected in the kidney compared to 4 weeks old mice. β2m seemed to be 
localised in the sinusoids of the kidney, similarly to the liver, and in the glomeruli (G).  
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Figure 4.5: Comparison of hβ2m localisation between young and old hβ2mD76N 
transgenic mice 
Immunohistochemistry on stomach and gut of 1 month old (n=3) and 18 months old 
(n=3) hβ2mD76N transgenic mice on β2m-KO background (hβ2mD76N-Tg/mβ2m-KO) 
stained with Dako anti-human β2m antibody. Strong β2m signal was detected in the 
villi and mucosa of the intestine, more so in the old mice compare to young 
transgenics. β2m in the stomach of young mice was not detected, whereas strong 
β2m signal was observed in the stomach submucosa of aged mice. β2m-KO mice 
were used as negative controls. 
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Figure 4.6: Comparison of hβ2m localisation between young and old hβ2mD76N 
transgenic mice 
Immunohistochemistry on salivary gland and adrenal of 1 month old (n=3) and 18 
months old (n=3) hβ2mD76N transgenic mice on β2m-KO background 
(hβ2mD76N-Tg/mβ2m-KO) stained with Dako anti-human β2m antibody. β2m was 
detected in both organs but no difference was observed between the young and old 
mice. β2m is also visible in the fat tissue surrounding the adrenal of the old 
transgenic mouse. β2m-KO mice were used as negative controls. 
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Figure 4.7: Comparison of hβ2m localisation between young and old hβ2mD76N 
transgenic mice 
Immunohistochemistry on sciatic nerve and tongue of 1 month old (n=3) and 18 
months old (n=3) hβ2mD76N transgenic mice on β2m-KO background 
(hβ2mD76N-Tg/mβ2m-KO) stained with Dako anti-human β2m antibody. Stronger β2m 
signal was detected in the tongue of old mice compared to young mice, concentrated 
around the blood vessels (BV). β2m in the fat tissue surrounding the sciatic nerve is 
seen in the picture of the old transgenic mouse. 
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Figure 4.8: Comparison of hβ2m localisation between young and old hβ2mD76N 
transgenic mice 
Immunohistochemistry on skin and sternum cartilage of 1 month old (n=3) and 18 
months old (n=3) hβ2mD76N transgenic mice on β2m-KO background 
(hβ2mD76N-Tg/mβ2m-KO) stained with Dako anti-human β2m antibody. Age related 
increase in β2m was observed in the dermis and fat of the skin. β2m signal was 
detected in the fat surrounding the cartilage but the cartilage itself does not contain 
any β2m. 
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4.2.3 Investigation of potential means to increase β2m 
concentration  
Although high concentrations of the β2m variant circulate in the hβ2mD76N 
transgenic mice, especially in line 2, the mice did not develop spontaneous 
amyloid deposits. In dialysis-related amyloidosis, β2m circulating 
concentrations rise from ~1 µg/ml up to ~50 µg/ml due to chronic kidney 
disease and renal failure caused by insufficient clearance of the protein by the 
kidneys (Floege et al., 1991, Sedighi et al., 2015). After ~10 years of dialysis, 
the high concentrations of the plasma β2m result it Aβ2m amyloid fibril 
formation and deposition. I speculated whether inducing renal failure in mice 
would increase the circulating β2m variant and subsequently increase the 
chances of depositing the β2m variant as amyloid fibrils in the hβ2mD76N 
transgenic mice. 
In mice, chronic kidney failure can be induced by administration of folic acid – 
administration of high-dose folic acid (~200 µg/g of body weight) leads to the 
folic acid undergoing glomerular filtration which is followed by widespread 
tubular damage, and reliably induces severe nephrotoxicity within days after 
the folic acid administration (Koziolek et al., 2010, Long et al., 2008, Yuan et 
al., 2003). In patients with chronic kidney disease, serum β2m levels are 
elevated (Liabeuf et al., 2012). However, in this mouse model of chronic 
kidney disease, β2m levels have not been reported. 
Dr Jill Norman (Nephrology, UCL) and Dr James Tomlinson (MRC Clinical 
Sciences Centre, Hammersmith hospital site, Imperial College) kindly 
provided sera of C57Bl/6 mice collected at 2 days, 2 weeks and 12 weeks 
after folic acid administration (Long et al., 2008), together with sera of control 
mice injected with vehicle only, for assessment of β2m concentration of the 
different groups. 1 µl of each sample was run on an SDS-PAGE gel and 
probed with Dako polyconal anti-hβ2m antibody that recognises mouse as 
well as human β2m. No increase in β2m concentration was observed 
between the control and the folic acid treated mice (Figure 4.9). Because folic 
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acid induced chronic kidney failure in the hβ2mD76N transgenic mice would not 
lead to a significant increase in the plasma β2m concentration, this 
experimental procedure was not investigated any further. 
 
 
 
Figure 4.9: β2m concentration in chronic kidney disease mouse model 
1 µl of serum of non-induced C57Bl/6J mice (lanes 1 - 6) and of C57Bl/6J mice 
obtained 12 weeks after folic acid administration (lanes 8 – 14) was run on an SDS-
PAGE gel and probed with Dako polyclonal anti-hβ2m antibody recognising 13 kDa 
mouse β2m. No difference in β2m concentration was observed between the non-
induced and folic acid induced mice. β2m-KO serum (KO) was used as a negative 
control. Light and heavy chains of serum IgG were detected on the immunoblot. 
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4.2.4 Monitoring kidney function in hβ2mD76N 
transgenic mice 
In aged mice, the immunohistochemistry on the kidney revealed stronger 
signal of human β2m in the glomeruli, suggesting deposition of hβ2m. 
Although the kidney is not a site of amyloid deposition in Aβ2m amyloidosis 
patients, renal involvement is very common in systemic amyloidosis in 
humans and mice. 
β2m together with cystatin C (CysC) have been proposed as markers for the 
detection of kidney function due to their ability to pass freely through the 
glomerular barrier and due to the fact that both proteins are produced at a 
relatively constant rate without being affected either by muscle breakdown nor 
tubular secretion (unlike creatinine) (Randers et al., 1998, Randers et al., 
2000, Bianchi et al., 2001). Both proteins have also been shown to predict 
cardiovascular event and mortality (Shlipak et al., 2005, Joosten et al., 2014). 
In the folic acid-induced chronic kidney failure in mice discussed in the 
previous paragraph, plasma Cys C concentrations have been reported to rise 
(Wang et al., 2011). To evaluate whether kidney function was compromised 
due to possible pre-fibrillar deposition in the hβ2mD76N transgenic mice 
reaching 1 year of age, CysC serum levels were analysed by ELISA.  
The range of serum CysC concentration in C57Bl/6J mice is 0.6-0.8 g/ml (Xu 
et al., 2011, Sasabe et al., 2014).  No significant difference was seen 
between 8-11 months old high expressing line 2 hβ2mD76N transgenic mice on 
wild-type background and aged-matched non-transgenic controls with CysC 
levels 0.586 ± 0.070g/ml (n=14) and 0.640 ± 0.069g/ml (n=6), 
respectively, suggesting normal renal function in the transgenic mice (Figure 
4.10). The values are presented as mean ± standard deviation with numbers 
of mice (n) analysed. 
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Figure 4.10: Serum concentration of cystatin C in hβ2mD76N transgenic mice 
Concentration of serum cystatin C (CysC) in 8-11 months old line 2 hβ2mD76N 
transgenic mice (n=14) and age-matched non-transgenic controls (WT, n=6) were 
determined by ELISA and analysed as mean ± SD for number (n) of mice by Mann-
Whitney two-tailed test. No significant difference was found between the two groups 
showing no kidney impairment in hβ2mD76N transgenic mice. 
 
 
4.2.5 Amyloid fibril-induced amyloid deposition 
Although no spontaneous Aβ2m amyloid deposition was observed in the 
hβ2mD76N transgenic mice despite the fact that the mice present much higher 
concentrations of the β2mD76N in the circulation than is seen in Aβ2mD76N 
patients, accumulation of β2m in various organs including the liver, spleen, 
stomach and gut, which are the sites of Aβ2m deposition in the β2mD76N 
patients, was observed. The β2m deposits may represent non-Congophilic 
pre-fibrillar aggregates of the amyloidogenic variant, a pre-amyloid stage of 
an amyloidogenic protein described in amyloidosis patients (Sousa et al., 
2001). In the process of amyloid formation, there is always a lag phase 
between the first appearance of the potentially amyloidogenic protein and the 
deposition of clinically significant amyloid. In mice, the lag phase can be 
significantly shortened by administration of an extract of tissue containing 
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amyloid, called amyloid-enhancing factor (AEF) (Willerson et al., 1969, Baltz 
et al., 1986a). It has been shown in animals that administration of amyloid 
enhancing factor (AEF) acts as a seed for fibril formation and accelerates the 
appearance of amyloid fibrils. An extract of amyloidotic tissue and/or ex vivo-
isolated or in vitro-prepared amyloid fibrils can act as AEF.  (Axelrad et al., 
1982, Varga et al., 1986, Snel et al., 1989, Johan et al., 1998, Baltz et al., 
1986a). To test, whether the β2m deposition could be accelerated which 
would result in amyloid formation, the mice were seeded with pre-formed 
Aβ2mD76N amyloid fibrils.  
In vitro-prepared human Aβ2mD76N amyloid fibrils and ex vivo-isolated human 
Aβ2mD76N amyloid fibrils, both prepared by Dr Patrizia Mangione (Centre for 
amyloidosis and acute phase proteins, UCL), were used. Human ex-vivo 
Aβ2mD76N fibrils were isolated from spleen of an Aβ2mD76N amyloidosis 
patient with severe Aβ2m amyloid deposition. The availability of tissue of 
Aβ2mD76N amyloidosis patient was very limited and thus the amount of 
extracted fibrils for experimental work was limited.  On the other hand, using 
in vitro-prepared Aβ2mD76N fibrils for seeding had the advantage of essentially 
unlimited availability of the fibrils for experimental induction of amyloidosis. 
4 cohorts of amyloid fibril-seeded mice were set up to evaluate the possibility 
of accelerating amyloid deposition in hβ2mD76N transgenic mice:  
hβ2mD76N Cohort I was injected with 0.1 µg of in vitro-prepared human 
Aβ2mD76N amyloid fibrils,  
hβ2mD76N Cohort II was injected with 10 µg of in vitro-prepared human 
Aβ2mD76N amyloid fibrils,  
hβ2mD76N Cohort III was injected with 100 µg of in vitro-prepared human 
Aβ2mD76N amyloid fibrils, 
hβ2mD76N Cohort IV was injected with 10 µg of ex vivo-isolated human 
Aβ2mD76N amyloid fibrils. 
Outline of the seeding experiments is shown in Figure 4.11. 
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Figure 4.11: Timeline of seeding experiments of hβ2mD76N transgenic mice 
4 cohorts of hβ2mD76N transgenic and control mice were set up to prime amyloid 
deposition by injections with 0.1 µg (I), 10 µg (II) and 100 µg (III) of in vitro-prepared 
human Aβ2mD76N amyloid fibrils and 10 µg of ex vivo-isolated human Aβ2mD76N 
amyloid fibrils (IV). The timescale indicates number of weeks. Amyloid fibril injection 
(red arrow), blood sample collection (green arrow), 125I-human SAP whole body 
retention assay (blue arrow) and time-point when seeded animals were taken for 
analysis (black arrow) with the number of animals killed at each time point shown in 
brackets are indicated. 
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4.2.5.1 Outcomes of preliminary seeding experiments 
 
Monitoring an inflammatory response in fibril-seeded mice 
Before seeding the experimental hβ2mD76N transgenic animals, different 
doses of in vitro-prepared human Aβ2mD76N amyloid fibrils were tested in 
C57Bl/6J mice. The reason for this was to test if any remaining endotoxins of 
fibrils prepared in vitro from E.coli-expressed variant β2m would cause an 
inflammatory response. In the presence of severe inflammation, circulating 
levels of serum amyloid A protein (SAA), an acute phase plasma protein, rise 
up to 1000-fold almost immediately and fall down to baseline when 
inflammation clears. In chronic inflammation, when SAA levels are 
persistently elevated, the SAA protein can deposit as amyloid causing  AA 
amyloidosis (Hoffman et al., 1984). 
SAA levels were monitored prior to fibril injections and at 24 and 72 hours 
following intravenous injection of 0.2 µg, 2 µg and 20 µg of fibrils in 6 mice for 
each group. 6 mice injected with PBS only were used as a control group. The 
baseline level of SAA was < 20 µg/ml in all mice. 24 hours after injections, the 
SAA levels in PBS group and 0.2 µg group stayed < 20 µg/ml and increased 
in 2 µg group and 20 µg group reaching 498 ± 274 µg/ml and 1108 ± 348 
µg/ml, respectively (mean ± SD, n=6). At 72 hours, acute inflammation 
diminished with SAA production regressed back to its normal level <20 µg/ml 
in all four groups (Figure 4.12). This result confirmed that administration of the 
fibrils is safe for the animals and that fibril injection did not cause chronic 
inflammation. 
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Figure 4.12: Monitoring inflammatory response after fibril administration 
Levels of serum SAA were monitored in C57Bl/6J mice to evaluate the inflammatory 
response following injections of in vitro-prepared human β2mD76N amyloid fibrils (0.2 
µg, 2 µg, 20 µg) and PBS as a vehicle. Each group consisted of 6 mice. Blood 
samples were collected prior to the injection and 24 and 72 hours after the injection. 
Baseline serum SAA level was <20 µg/ml for each mouse. Acute inflammatory 
response was detected at 24 hours when > 2 µg of fibrils was administered but the 
SAA levels fell back to normal levels by 72 hours. The values are shown as mean ± 
SD (n=6).  
 
 
Evaluation of the seeding method 
To evaluate the persistence of injected amyloid fibrils within the organism, 2 
β2m-KO mice injected with 10 µg of in vitro-prepared human Aβ2mD76N 
amyloid fibrils and the mice were killed 72 hours after the seeding injections. 
At this time-point, Congo red positive stained material exhibiting green 
birefringence within liver, kidney, spleen, heart, lung and gut was not detected 
in the tissue sections. This result confirmed that any Congo red positive 
stained material exhibiting green birefringence in the experimental mice must 
be newly deposited material. 
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4.2.5.2 Monitoring amyloid deposition in vivo 
SAP, a normal plasma protein, binds avidly to all amyloid of human systemic 
amyloidoses and becomes concentrated at the sites of amyloid deposition. 
The fact that there is constant equilibrium between the circulating and the 
amyloid-bound SAP and that the amount of amyloid-bound SAP correlates 
with the quantity of amyloid present in the tissues (Baltz et al., 1986b) let to a 
development of a specific and quantitative in vivo tracing method for systemic 
amyloid deposition in mice and humans (Hawkins et al., 1988, Hawkins et al., 
1990a). This clinical method uses intravenously administered radiolabelled 
125I-human SAP (125I-hSAP) which is distributed between the plasma and the 
amyloid deposits. 125I-hSAP which retains in the body bound to amyloid then 
enables screening of the amyloid burden in amyloidosis patients. In mice, 
whole body retention of intravenously administered radiolabelled 125I-hSAP in 
the whole body of a live animal enables to evaluate the amyloid laden in 
amyloidotic mice in vivo and can be repeated. 
The injections and counts of radiolabelled material were performed by Dr 
Stephan Ellmerich (Centre for amyloidosis and acute phase proteins, UCL). 
The baseline level of 125I-hSAP retention 48 hours after injection of the 
radiolabelled tracer in untreated control mice was <10 %. Throughout the 
experiments, no change in 125I-hSAP retention was observed in any 
experimental groups suggesting that the mice were not heavily amyloidotic. 
However, the limiting sensitivity of the whole body count does not reveal the 
presence of small amounts of amyloid within the tissue. 
 
4.2.5.3 hβ2mD76N Cohort I 
3 – 6 months old mice were bled and tested for whole body 125I-hSAP 
retention prior to i.v. injection of 0.1 µg of in vitro-prepared human Aβ2mD76N 
amyloid fibrils. 9 hβ2mD76N transgenic mice on mouse β2m wild-type 
background (T/WT) and 3 non-transgenic controls (WT) were seeded, 5 T/WT 
mice and 3 non-transgenic mice were injected with vehicle only. All mice were 
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analysed with 125I-hSAP retention 3 and 14 weeks after fibrils administration 
with no animals showing amyloid deposition. The analysis of SAA 
concentration in the serum of the cohort I mice prior and 13 weeks after the 
fibril administration confirmed no chronic inflammation in the mice, with the 
SAA levels 26.6 ± 40.7 µg/ml (n=20) and 8.7± 10.0 µg/ml (n=20), 
respectively. 19 weeks after fibril injections, all mice (12 seeded, 8 non-
seeded) were killed and tissues were collected for histological analysis. The 
genotypes and the lines of experimental mice, the tissues analysed and the 
outcome of the analysis is shown in Table 4.4. Congo red stained sections of 
wax embedded tissue were negative for presence of amyloid in all mice. 
 
Cohort I 0.1 µg in vitro fibrils Non-seeded 
 Line 2 Line 4 Line 11 Controls Line 2 Line 11 
 T/WT T/WT T/WT -ve/WT T/WT T/WT 
Liver 0/4 - 0/5 0/3 0/3 0/2 
Kidney 0/4 - 0/5 0/3 0/3 0/2 
Spleen 0/4 - 0/5 0/3 0/3 0/2 
Heart 0/4 - 0/5 0/3 0/3 0/2 
Lung 0/4 - 0/5 0/3 0/3 0/2 
Salivary gland 0/4 - 0/5 0/3 0/3 0/2 
Adrenal 0/4 - 0/5 0/3 0/3 0/2 
Sciatic nerve 0/4 - 0/5 0/3 0/3 0/2 
Gut 0/4 - 0/5 0/3 0/3 0/2 
Stomach 0/4 - 0/5 0/3 0/3 0/2 
Muscle 0/4 - 0/5 0/3 0/3 0/2 
Fat 0/4 - 0/5 0/3 0/3 0/2 
Skin 0/4 - 0/5 0/3 0/3 0/2 
 
Table 4.4: Cohort I – lack of induction of amyloid deposition in seeded 
hβ2mD76N transgenic mice 
Summary of tissue analysed by Congo red in hβ2mD76N transgenic mice on mouse 
β2m wild-type background (T/WT) seeded with 0.1 µg of in vitro-prepared human 
Aβ2mD76N amyloid fibrils. 4 transgenic mice were from line 2 and 5 transgenic mice 
were from line 11. 3 seeded non-transgenic littermates (-ve/WT) and 5 non-seeded 
age-matched transgenic mice injected with vehicle only were also analysed at the 
same time as controls. The samples are scored as number of mice with amyloid / 
number of mice analysed for each tissue. 
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4.2.5.4 hβ2mD76N Cohort II 
The second cohort consisted of 40 mice 2 – 5 months old at the start of the 
experiment. 20 hβ2mD76N transgenic mice on mouse β2m-KO background 
(T/KO) and 10 β2m-KO controls were injected with 10 µg of in vitro-prepared 
human Aβ2mD76N amyloid fibrils. 8 T/KO mice and 2 β2m-KO mice were also 
followed as non-seeded controls. All mice were bled prior to and 72 hours 
after fibril injection to monitor serum SAA concentration as an inflammation 
marker. The analysis of SAA concentration in the serum confirmed no 
prolonged inflammatory response after the injections, with SAA level 31.8 ± 
39.5 µg/ml (n=38) prior to, and 22.1 ± 31.9 µg/ml (n=30) 72 hours after fibril 
injections. 12 weeks after fibril injections, all remaining mice were screened 
for whole body 125I-hSAP retention showing background levels of retention 
only. 
Amyloid deposition was examined by analysing mice at 19 weeks (4 seeded 
T/KO and 2 seeded β2m-KO mice), 36 weeks (5 seeded T/KO mice and 3 
T/KO and 2 β2m-KO non-seeded controls), 40 weeks (8 T/KO and 5 β2m-KO 
seeded mice, 3 T/KO and 2 β2m-KO non-seeded controls) and 46 weeks (3 
T/KO and 3 β2m-KO seeded mice, 2 T/KO non-seeded controls) after fibril 
administration. Liver, kidney, spleen, heart, lung, salivary gland, tongue, 
adrenal, stomach, gut, sciatic nerve, skeletal muscle, skin and fat were fixed 
and embedded in wax blocks. No amyloid deposition was detected by Congo 
red staining in any tissues in all mice. The genotypes and the lines of 
experimental mice, the tissues analysed and the outcome of the analysis is 
shown in Table 4.5.  
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Cohort II 10 µg in vitro fibrils Non-seeded 
 Line 2 Line 4 Line 11 Controls Line 4 Line 11 
 T/KO T/KO T/KO -ve/KO T/KO T/KO 
Liver  -  0/10 0/10 0/10 0/3 0/5 
Kidney  -  0/10 0/10 0/10 0/3 0/5 
Spleen  -  0/10 0/10 0/10 0/3 0/5 
Heart  -  0/10 0/10 0/10 0/3 0/5 
Lung  -  0/10 0/10 0/10 0/3 0/5 
Salivary gland  -  0/10 0/10 0/10 0/3 0/5 
Adrenal  -  0/10 0/10 0/10 0/3 0/5 
Sciatic nerve  -  0/10 0/10 0/10 0/3 0/5 
Gut  -  0/10 0/10 0/10 0/3 0/5 
Stomach  -  0/10 0/10 0/10 0/3 0/5 
Muscle  -  0/10 0/10 0/10 0/3 0/5 
Fat  -  0/10 0/10 0/10 0/3 0/5 
Skin  -  0/10 0/10 0/10 0/3 0/5 
Tongue - 0/10 0/10 0/10 0/3 0/5 
Eye - 0/10 0/10 0/10 0/3 0/5 
Optic nerve - 0/10 0/10 0/10 0/3 0/5 
Lacrymal gland - 0/10 0/10 0/10 0/3 0/5 
 
Table 4.5: Cohort II – lack of induction of amyloid deposition in seeded 
hβ2mD76N transgenic mice 
Summary of tissue analysed by Congo red in hβ2mD76N transgenic mice on β2m-KO 
background (T/KO) seeded with 10 µg of in vitro-prepared human Aβ2mD76N amyloid 
fibrils. 10 transgenic mice of line 4, 10 transgenic mice of line 11 and 10 non-
transgenic littermates (-ve/KO) were seeded and 8 age-matched transgenics were 
non-seeded. The samples are scored as number of mice with amyloid / number of 
mice analysed for each tissue. 
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4.2.5.5 hβ2mD76N Cohort III 
6 hβ2mD76N T/KO mice from line 2 and 6 β2m-KO mice were injected with 100 
µg of in vitro-prepared human Aβ2mD76N amyloid fibrils at 4 months of age. 
Serum SAA levels 72 hours after fibril injection (56.6 ± 60.7 µg/ml, n=12) did 
not differ from concentrations prior to injections (49.8 ± 54.7 µg/ml, n=12), 
confirming no prolonged inflammation caused by the fibril administration. 
Whole body 125I-hSAP retention was performed at weeks 13 and 26 after fibril 
seeding with background levels of retention in all mice. All mice were 
terminated 29 weeks after seeding. Amyloid deposition was examined in liver, 
heart, kidney, spleen, colon and sciatic nerve embedded into wax blocks and 
stained with Congo red. No amyloid deposits were observed in any tissue 
analysed (Table 4.6). 
 
 
Cohort III 100 µg in vitro fibrils 
 Line 2 Line 4 Line 11 Controls 
 T/KO T/KO T/KO -ve/KO 
Liver  0/6  - -  0/6  
Kidney  0/6  - -  0/6  
Spleen 0/6 - - 0/6 
Heart 0/6 - - 0/6 
Gut 0/6 - - 0/6 
Sciatic nerve 0/6 - - 0/6 
 
 
Table 4.6: Cohort III – lack of induction of amyloid deposition in seeded 
hβ2mD76N transgenic mice  
Summary of tissue analysed by Congo red in line 2 hβ2mD76N transgenic mice on 
mouse β2m-KO background (T/KO) seeded with 100 µg of in vitro-prepared human 
Aβ2mD76N amyloid fibrils. The samples are scored as number of mice with amyloid / 
number of mice analysed for each tissue. 
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4.2.5.6 hβ2mD76N Cohort IV 
In the fourth cohort, 10 hβ2mD76N T/KO mice and 6 β2m-KO mice were 
seeded with 10 µg of ex vivo-isolated human Aβ2mD76N amyloid fibrils at 2 – 5 
months of age. 4 age-matched hβ2mD76N T/KO were used as non-seeded 
controls. SAA concentrations of the experimental mice were 26.0 ± 46.8 µg/ml 
(n=18) prior to and 35.3 ± 53.6 µg/ml (n=18) 72-hours after the fibril injection, 
showing no significant difference between the injected and non-injected mice 
and confirming no prolonged inflammation after the seeding. 26 weeks after 
fibril injections, 125I-hSAP retention was performed. At 48 h after the tracer 
administration, the retention was at base-line level <10 % in all mice 
suggesting that there were no considerable amounts of amyloid in the mice. 
39 weeks after seeding, all mice were analysed. Liver, kidney, spleen, heart, 
lung, tongue, salivary gland, adrenal, sciatic nerve, gut, stomach, muscle, fat 
and skin were collected into fix. Liver, kidney and spleen were also snap-
frozen in liquid nitrogen and stored at -80 oC. Congo red stained sections of 
wax embedded tissues did not reveal any amyloid in any mice (Figure 4.13). 
The genotypes and the lines of experimental mice, the tissues analysed and 
the outcome of the analysis is shown in Table 4.7. 
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Figure 4.13: Negative Congo red staining of tissue of Cohort IV seeded mice 
hβ2mD76N transgenic mice on mβ2m-KO background were seeded with 10 µg of ex 
vivo-isolated human Aβ2mD76N amyloid fibrils at 2 – 5 months of age (Cohort IV) and 
taken for analysis 9 months after seeding. Staining of wax embedded tissue with 
Dako polyclonal anti-hβ2m antibody confirmed substantial amount of the hβ2m 
variant within the tissue. However, Congo red staining did not show any green 
birefringence that would indicate amyloid deposits under polarized light. Only white 
birefringence of collagen and connective tissue reacting with Congo red was 
detected under polarized light around blood vessel and in the submucosa of 
stomach. 
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Cohort IV 10 µg ex vivo fibrils Non-seeded 
 Line 2 Line 4 Line 11 Controls Line 2 Line 4 
 T/KO T/KO T/KO -ve/KO T/KO T/KO 
Liver  0/7  0/3 - 0/6 0/3 0/2 
Kidney  0/7 0/3 - 0/6 0/3 0/2 
Spleen 0/7 0/3 - 0/6 0/3 0/2 
Heart 0/7 0/3 - 0/6 0/3 0/2 
Lung 0/7 0/3 - 0/6 0/3 0/2 
Salivary gland 0/7 0/3 - 0/6 0/3 0/2 
Adrenal 0/7 0/3 - 0/6 0/3 0/2 
Sciatic nerve 0/7 0/3 - 0/6 0/3 0/2 
Gut 0/7 0/3 - 0/6 0/3 0/2 
Stomach 0/7 0/3 - 0/6 0/3 0/2 
Muscle 0/7 0/3 - 0/6 0/3 0/2 
Fat 0/7 0/3 - 0/6 0/3 0/2 
Skin 0/7 0/3 - 0/6 0/3 0/2 
Tongue 0/7 0/3 - 0/6 0/3 0/2 
 
 
Table 4.7: Cohort IV – lack of induction of amyloid deposition in seeded 
hβ2mD76N transgenic mice 
Summary of tissue analysed by Congo red in Cohort IV of  hβ2mD76N transgenic mice 
on β2m-KO background (T/KO) seeded with 10 µg of ex vivo-isolated human 
Aβ2mD76N amyloid fibrils. 7 transgenic mice of line 2; 3 transgenic mice of line 4 and 
6 non-transgenic littermates (-ve/KO) were seeded. 5 age-matched transgenic 
littermates were analysed as non-seeded controls. The samples are scored as 
number of mice with amyloid / number of mice analysed for each tissue. 
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4.2.6 Search for amyloid in tissue homogenate 
Despite high concentrations of the amyloidogenic variant β2m circulating in 
the blood and despite noticeable age-related accumulation of the variant in 
some tissue of the hβ2mD76N transgenic mice, no amyloid was detected by 
Congo red staining in the tissue sections of aged and amyloid-fibril seeded 
mice. However, the signal provided by Congo red bound to disperse amyloid 
deposits may not be visible by polarized light microscopy. To test whether any 
insoluble β2m could be detected in the tissue of the transgenic mice, 
suggesting the presence of insoluble fibrillar material within the tissue, liver 
and spleen of hβ2mD76N transgenic mice were homogenised and the 
homogenate was centrifuged to concentrate the insoluble material. The pellet 
was then washed four times to remove any soluble material and run on an 
SDS-PAGE gel and subjected to Western blot analysis with anti-hβ2m 
antibody 14H3. Two 10 months old non-seeded hβ2mD76N transgenic mice on 
β2m-KO background (T/KO) from the high-expressing line 2 were compared 
with two age-matched T/KO mice seeded with 10 µg of ex vivo-isolated 
human Aβ2mD76N amyloid fibrils. Soluble hβ2m was detected in the tissue 
homogenate and in the supernatant collected after pelleting the homogenised 
material in the transgenic mice, as expected. No hβ2m was detected in the 
last wash aspirated from the pellet confirming removal of all soluble material 
from the pellet. However, no insoluble β2m was detected in the pellet of the 
tissue suggesting absence of β2m amyloid fibrils in the tissue. No β2m signal 
was detected in liver and spleen homogenates of β2m-KO mice that were 
used as negative controls (Figure 4.14).  
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Figure 4.14: hβ2m in the liver homogenate of hβ2mD76N transgenic mice  
Liver tissue of 10 months old β2m-KO mouse, 10 months old non-seeded line 2 
hβ2mD76N transgenic mouse on β2m-KO background (non-seeded T/KO) and 10 
months old line 2 hβ2mD76N transgenic mouse on β2m-KO background seeded with 
10 µg of ex-vivo isolated Ahβ2mD76N amyloid fibrils (seeded T/KO) were 
homogenised and the homogenate (H), supernatant (S1) aspirated from pelleted 
insoluble material, fourth wash of the pellet (S4) and the pellet (P) were run on an 
SDS-PAGE gel and probed with anti-hβ2m antibody 14H3. Only soluble hβ2m was 
detected in the liver homogenates and the supernatants S1 in transgenic mice. No 
insoluble hβ2m was detected in the pellet of the tissue. No β2m signal was detected 
in the liver homogenate of a β2m-KO mouse. 50 ng of purified recombinant hβ2mD76N 
protein (hβ2m, kindly provided by Dr Riccardo Porcari) and a size marker (M) were 
run alongside the samples. 
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4.2.7 Native hβ2m in the serum of hβ2mD76N 
transgenic mice 
In humans, β2m protein is released from the cell surface after the dissociation 
of the MHC I complex into the blood where it circulates as a monomer 
(Gagnon et al., 1988). However, it has been reported that β2m protein 
circulates in a complex in mouse plasma (Natori et al., 1976) and further it 
was shown in rats that human β2m protein injected into the animals circulated 
not only as a free monomer but also complexed with a plasma glycoprotein 
(Nguyen-Simonnet et al., 1982). In hemodialysis patients, proportion of 
plasma β2m was found to circulate in a complex with α2-macroglobulin (α2M), 
whereas no β2m-α2M complexes were observed in the healthy people 
(Motomiya et al., 2003).  
To analyse their native conformations, proteins can be run on an agarose gel 
in the absence of denaturing and reducing agents. Under the non-reducing 
and non-denaturing conditions, proteins run in the gel principally according to 
their native charge. In fact, the native wild-type human β2m protein and the 
native β2mD76N variant are distinguishable by their different electrophoretic 
mobilities with the wild-type β2m migrating faster than the variant (Mangione 
et al., 2013). On a denatured SDS PAGE gel, the β2mD76N variant from the 
plasma of the transgenic mice ran as a full-length, non-glycosylated human 
β2m protein. However, the hβ2mD76N transgenic mice did not develop 
spontaneous or amyloid fibril-seeded amyloidosis. The reason for this could 
be that the β2mD76N variant does not circulate only as a free monomer but 
also in a complex which may be protecting the β2mD76N variant from 
misfolding. 
I speculated that if: 1) native and denatured pure hβ2m co-migrate; 2) native 
and denatured pure hβ2mD76N co-migrate; 3) hβ2mD76N in denatured serum 
from hβ2mD76N transgenic mouse co-migrates with pure hβ2mD76N and 4) 
hβ2mD76N in native serum from hβ2mD76N transgenic mouse migrates 
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differently, this could imply that the β2mD76N variant in the hβ2mD76N 
transgenic mice circulates in a complex. 
Therefore, serum of the high expressing line 2 hβ2mD76N T/KO mouse was 
denatured in 6 M urea to disrupt any complexes and run alongside the native 
serum sample of the same mouse on an agarose gel. Purified recombinant 
human β2m protein and purified recombinant human β2mD76N variant used as 
controls were also run on the gel in their native form as well as after 
denaturation in 6 M urea to confirm that the denatured proteins co-migrated 
with the native proteins for both the wild-type β2m and β2mD76N variant. β2m-
KO and C57Bl/6J mouse sera were also treated with 6 M urea and run on the 
gel in denatured and native form. Native human serum was used a positive 
control. The gel was then blotted onto a membrane and probed with Dako 
polyclonal anti-hβ2m antibody which recognises both mouse as well as 
human β2m. 
The native and denatured pure hβ2mD76N variant co-migrated on the gel as 
did the native and denatured pure hβ2mD76N variant confirming that the 
denaturation does not interfere with the mobility of the proteins. However, 
while the hβ2mD76N variant in the denatured serum from hβ2mD76N transgenic 
mouse co-migrated with the pure monomeric hβ2mD76N variant, the hβ2mD76N 
variant in the native serum from hβ2mD76N transgenic mouse migrated faster. 
Similarly in the serum of C57Bl/6J mouse, mouse β2m in the denatured 
serum was migrating much slower than mouse β2m in the native serum. In 
native human serum, only a band co-migrating with recombinant non-mutated 
human β2m was observed. These results are shown in Figure 4.15. 
These results suggest that in mice, a β2m-binding component exists in the 
plasma and the majority of the circulating β2m is bound in a complex. Thus, 
only a small proportion of the hβ2mD76N variant in the transgenic mice may 
circulate as a free monomer available to convert into amyloid fibrils. 
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Figure 4.15: The comparison of β2m in native and denatured serum 
1 µl of native sera of C57Bl/6J (WT), β2m-KO (KO) and line 2 hβ2mD76N transgenic 
mouse on β2m-KO background (T/KO, black arrow) mice were run alongside 1 µl of 
6 M urea-denatured serum of the same mice on 1% agarose gel and probed with 
Dako polyclonal anti-hβ2m antibody which recognises both human and mouse β2m. 
In the denatured serum, only monomeric proteins were detected - monomeric 
hβ2mD76N variant in the transgenic mouse (white arrow) and monomeric mouse β2m 
(mβ2m) in the serum of a WT mouse. Native hβ2mD76N and mβ2m from the serum of 
the transgenic and wild-type mouse, respectively, were migrating faster compared to 
their denatured equivalents. Native and denatured recombinant wild-type human 
β2m (rhβ2m) co-migrated as did the native and denatured recombinant hβ2mD76N 
(rD76N) confirming that the denaturation does not interfere with the protein mobility 
of the monomers. β2m in native human serum (Hum) co-migrated  with recombinant 
wild-type human β2m (rhβ2m) confirming that β2m exists in human plasma as a 
monomer. 30 ng of each recombinant protein was loaded per well. 
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4.3 Discussion 
In this project, transgenic mice expressing the highly amyloidogenic D76N 
variant of β2m protein were generated. Surprisingly, despite the fact that the 
hβ2mD76N transgenic mice have high concentrations of the amyloidogenic 
protein exceeding the concentrations seen in Aβ2mD76N amyloidosis patients 
up to 35-fold, none of the mice developed spontaneous Aβ2m amyloid 
deposits even at the age of 2 years. 
Amyloid fibril formation in vivo is a time-dependent process. Normally soluble 
proteins take decades to convert into clinically recognisable amyloid deposits. 
In this lag phase, first amyloid fibrils develop, forming the so called “seeds”, 
which is a process that occurs stochastically in vivo (Jarrett and Lansbury, 
1993, Kelly, 1998). The seeds then act as a template for further amyloid 
deposition. Once amyloid deposition has been initiated, and with continuous 
production and abundance of the precursor protein, amyloid fibril formation is 
autocatalytic and the clinical disease is progressing. In vitro (Jahn et al., 
2008) and in experimental animals in vivo (Willerson et al., 1969, Snel et al., 
1989, Higuchi et al., 1998) , amyloid deposition can be induced by exogenous 
seeding with pre-formed amyloid material. In vitro-prepared and ex-vivo 
isolated amyloid fibrils as well as crude extract from an amyloidotic tissue 
which has not been yet fully characterised but the active compound of which 
are amyloid fibrils, can all serve as AEF (Axelrad et al., 1982, Baltz et al., 
1986a). The hβ2mD76N transgenic mice presented here were therefore 
injected with in vitro-prepared and ex vivo-isolated Aβ2mD76N amyloid fibrils. 
However, Aβ2m amyloid deposits detectable by Congo red were not found in 
the seeded transgenic mice. In a transgenic mouse model expressing wild-
type β2m, seeding of the transgenic mice with amyloid fibrils was also not 
sufficient in priming amyloid deposition (Zhang et al., 2010). However, the 
concentration of the wild-type human β2m in the plasma of these transgenic 
mice may have been overestimated, as it was discussed in the previous 
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chapter, and thus the low concentration of the human β2m may have been 
the limiting factor in developing amyloid deposits. 
In the dialysis related amyloidosis, Aβ2m deposits consist of wild-type human 
β2m protein and an isoform of the protein lacking the first six N-terminal 
residues (ΔN6β2m) (Bellotti et al., 1998). In vitro experiments have shown 
that although wild-type hβ2m does not form amyloid fibrils under physiological 
conditions (Calabrese and Miranker, 2009, Bellotti et al., 1998), ΔN6β2m 
forms amyloid fibrils and is capable of catalysing assembly of wild-type hβ2m 
into amyloid-like fibrils at physiological conditions (Bellotti et al., 1998, 
Stoppini et al., 2005, Piazza et al., 2006). On the other hand, in vitro 
experiments showed that under conditions which are favourable for amyloid 
fibril formation of hβ2m, mβ2m does not form amyloid fibrils (Ivanova et al., 
2004, Eichner et al., 2011). Moreover, the aggregation potential of ΔN6β2m 
and the wild-type hβ2m was abolished in the presence of mouse β2m in the 
solution (Eichner et al., 2011, Karamanos et al., 2014). To avoid the possible 
inhibiting effect of mβ2m on Aβ2m amyloid fibril formation, the hβ2mD76N 
transgenic mice were crossed with mouse β2m-KO mice to produce hβ2mD76N 
transgenics lacking the endogenous β2m. However, despite the lack of the 
murine β2m, spontaneous and amyloid-fibril seeded amyloid deposition was 
still not detected in the transgenic mice and thus the effect of the mouse β2m 
on amyloid-fibril formation could not be evaluated. 
In dialysis-related amyloidosis, poor correlation between the plasma β2m 
concentration and the extent of Aβ2m amyloidosis suggests that additional 
factors are responsible for the initiation of β2m aggregation (Gejyo et al., 
1986a). These observations are consistent with in vitro studies that have 
shown that production of wild-type human β2m amyloid-like fibrils in the 
absence of detergents, solvents or other additional factors, under 
physiological conditions have not been achieved (Myers et al., 2006a). In vivo 
models, in which human β2m was successfully expressed have been unable 
to demonstrate the deposition of typical Aβ2m amyloid fibrils (Zhang et al., 
2010, Diomede et al., 2012). Fukunishi et al. have reported a rat model 
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expressing human β2m, in which only rats with collagen-induced arthritis, but 
not untreated rats, developed some amyloid in the knee joints. However, the 
amyloid deposits were not typed and thus not known whether the rats 
developed Aβ2m amyloid. Also, the number of animals that developed 
amyloid was not specified and the amyloid deposition was not further 
investigated (Fukunishi et al., 2007). On the other hand, in vitro biochemical 
studies showed that the human β2mD76N variant is highly amyloidogenic. The 
rapid fibrillogenesis occurs within a few hours in physiological buffer when 
enhanced by fluid agitation and exposure to a hydrophobic surface. In 
contrast, fibrillogenesis of the wild-type human β2m is extremely slow under 
the same conditions, being minimal or absent after 100 days of incubation 
(Mangione et al., 2013). The fluid agitation relevance is explained by the 
similarity with the extracellular environment, a site of amyloid deposition in 
systemic amyloidosis, where interstitial fluid flows over the extensive surfaces 
of the fibrous network of elastin and collagen. The fibrous network provides 
these hydrophobic surfaces promoting unfolding of globular proteins. Indeed, 
elastin has been shown to promote amyloid fibrillogenesis of β2mD76N variant 
in solution (Mangione et al., 2013). Moreover, the β2mD76N variant is a much 
more potent promoter of amyloid fibril formation by wild-type human β2m 
when compared to ΔN6β2m (Mangione et al., 2013, Eichner et al., 2011). 
However, only full-length human β2mD76N variant is present in the amyloid 
deposits of hereditary Aβ2mD76N amyloidosis patients, with wild-type human 
β2m and ΔN6β2m being absent (Valleix et al., 2012).  
The failure of the hβ2mD76N transgenic mice to develop spontaneous and 
amyloid fibril-seeded Aβ2m amyloidosis despite the aggressive propensity of 
the β2mD76N variant to form amyloid, led to a question whether the human 
β2mD76N variant circulates in the system as a free monomer or whether it may 
be bound in a complex which would prevent the availability of the free β2m to 
form amyloid fibrils in the extracellular spaces. Indeed, electrophoresis of 
native non-denatured serum of hβ2mD76N transgenic mice revealed that the 
human β2m does not circulate as a free monomer in the serum of the mice. 
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Molecular chaperones are proteins involved in protein folding, unfolding and 
remodelling. They assist newly synthesized proteins to achieve their native 
fold, mediate assembly and disassembly of complexes and protect proteins 
from aggregation (Bukau et al., 2006, Doyle et al., 2013). Extracellular 
chaperones and their function to contribute to proteome stability in the 
biological fluids by capturing and leading misfolded proteins for lysosomal 
proteolysis via endocytosis, have been recently identified – namely α2-
macroglobulin (α2M) (French et al., 2008), haptoglobin (Yerbury et al., 2005) 
and clusterin (Humphreys et al., 1999).  
α2M is best known for its ability to trap a range of proteases via a cage-like 
quaternary  structure (Sottrup-Jensen, 1989). It has been shown that α2M can 
form complexes with misfolded proteins and promote their removal from the 
extracellular spaces and therefore protect against pathogenic misfolded 
proteins (Narita et al., 1997). α2M was identified as a potent chaperone of 
β2m – in vitro experiments showed that α2M binds β2m (Gouin-Charnet et al., 
1997, Gouin-Charnet et al., 2000) and α2M-β2m complexes have been found 
in vivo in the serum of DRA patients (Motomiya et al., 2003). Preliminary 
experiments investigating whether β2m circulates in the serum of hβ2mD76N 
transgenic mice bound to α2M suggest that α2M may not be the β2m-binding 
partner. 
Another extracellular chaperon identified to bind β2m is haptoglobin (Sultan et 
al., 2013), serum glycoprotein with main function to bind free haemoglobin. It 
has been shown in vitro that haptoglobin interacts with β2m oligomers, 
preventing Aβ2m amyloid fibril formation, however interaction with monomeric 
β2m was not observed (Sultan et al., 2013). Characterisation of the 
chaperone activity of haptoglobin in vivo is very limited. Clusterin is also 
present in all extracellular fluids and has diverse biological functions. In terms 
of amyloid, clusterin has been most studied in association with Alzheimer’s 
disease (AD) (Boggs et al., 1996, Lacour et al., 2016, Calero et al., 2012). It 
has been shown that clusterin, similarly to haptoglobin, does not bind to 
native or fibrillar proteins but interacts with oligomeric species and plays a 
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role in the control of extracellular protein misfolding (Kumita et al., 2007, 
Yerbury et al., 2007). No interactions of clusterin and β2m have been 
described. Other molecular chaperones may be involved in binding misfolded 
β2m in biological fluids and prevent its deposition in tissue as amyloid.  
In the serum of wild-type mice, native endogenous β2m was also observed to 
circulate in a complex whereas in native human serum, only monomeric β2m 
was detected. It is therefore possible that a murine specific molecule may 
chaperone β2m in the mouse serum. Nevertheless, if β2m has a binding 
partner in mouse serum, its identification would give a possibility to cross the 
hβ2mD76N transgenic mice with mice in which the gene coding for the specific 
protein has been knocked out. In such mice, the D76N variant β2m might be 
present in the serum as a monomer without the protection of its binding 
component, available to form amyloid fibrils in the extracellular spaces of the 
mice. 
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5 Generation and establishment of 
hTTR
S52P
 transgenic mice 
 
5.1 Introduction 
Transthyretin (TTR) is one of the proteins that can misfold from its normal 
globular configuration and convert into insoluble amyloid fibrils. The main 
source of plasma TTR is the liver (Holmgren et al., 1991), although TTR 
expression has been identified in the choroid plexus of the brain (Dickson et 
al., 1985) and retina (Cavallaro et al., 1990). In blood, TTR circulates as a 
homotetramer where it functions as a transporter of thyroid hormone 
thyroxine (T4) (Woeber and Ingbar, 1968) and retinol via retinol-binding 
protein (RBP) (Kanai et al., 1968). Besides its transport functions, TTR is a 
protease (Liz et al., 2004). The concentration of TTR in plasma of healthy 
humans is 170-400 µg/ml (Smith and Goodman, 1971, Maetzler et al., 2012).  
In pathological conditions, TTR is associated with wild-type ATTR 
amyloidosis, previously referred to as senile systemic amyloidosis, and with 
hereditary systemic ATTR amyloidosis caused by a mutation in the TTR 
gene. Wild-type ATTR amyloidosis is an under-recognised condition in the 
elderly that involves accumulation of the TTR as amyloid affecting 
predominantly the heart. Hereditary systemic ATTR amyloidosis presents with 
familial amyloid polyneuropathy and/or familial amyloid cardiomyopathy, in 
which the TTR amyloid fibrils are mainly deposited in the peripheral and 
autonomic nervous system and the heart, respectively. Over 100 TTR 
variants have been identified to date, with >80 of these variants causing 
amyloidosis (www.amyloidosismutations.com/attr.html).  
Several transgenic mice carrying a human TTR gene, including wild-type TTR 
and V30M and L55P variants, have been generated to study ATTR 
amyloidosis. TTRV30M is one of the most common variants in Europe (Ando et 
al., 2013) associated with familial amyloid polyneuropathy affecting peripheral 
and autonomic nerves as the main symptom, with progression of the disease 
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at a later stage into cardiac amyloidosis. TTRL55P variant is an aggressively 
amyloidogenic variant with an early onset of neurological and cardiac 
involvement (Jacobson et al., 1992).  
The first transgenic mice carrying human TTR were generated shortly after 
the discovery that V30M variant TTR is the amyloidogenic protein responsible 
for familial amyloid polyneuropathy. In 1986, Sasaki et al. generated 
transgenic mice expressing human TTRV30M. In an attempt to maximise the 
efficiency of the transgene expression, the human TTR gene was fused with a 
mouse metallothionein-I (MT) promoter, a promoter that contains sequence 
elements responsible for heavy metal inductions. Upon addition of ZnSO4 into 
drinking water, the transgenic mice expressed about 10 µg/ml human TTR in 
the serum, levels more than an order of magnitude lower than in humans 
(Sasaki et al., 1986). Amyloid deposition in these mice was not examined. A 
similar approach of MT-hTTRV30M transgene construct was conducted by Yi et 
al. The generated mice expressed 10-50 µg/ml of plasma human TTR and 
spontaneous amyloid deposition was observed from 12 months of age in 
gastrointestinal tract and kidneys with later deposition in heart, thyroid and 
possibly other organs in some animals (Yi et al., 1991). However, neither 
number of mice nor the consistency of amyloid deposition was reported. 
Moreover, these transgenic mice were never reported again as a model of 
ATTR amyloidosis. 
In order to examine the possibility of ATTR amyloid deposits in the nervous 
system, a different approach of generating human TTR transgenic mice was 
tested. To maintain the physiological sites of TTR expression, the TTR gene’s 
own promoter and sequences enhancing expression of the TTR were 
investigated by Nagata et al. (1995). Two different lengths of sequences 
upstream of the transcription initiation site of the human TTRV30M gene, 0.6 kb 
and 6.0 kb, were compared to identify the position of regulatory elements 
upstream of the TTR gene. The 6.0-hTTRV30M gene showed appropriate 
tissue specific expression in the liver, choroid plexus and yolk sac, whereas 
the 0.6-hTTRV30M gene was not expressed in the choroid plexus. The liver 
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expression and plasma TTR concentration in mice carrying the 0.6-hTTRV30M 
gene were much lower than in mice carrying the 6.0-hTTRV30M transgene 
which had ~150 µg/ml of hTTR in the plasma (Nagata et al., 1995). ATTR 
amyloid deposition was reported in some transgenic mice for both constructs 
in the gastrointestinal tract, kidney, heart and skin. Amyloid was also 
observed in liver and spleen in some animals however the amyloid protein 
was identified as SAA (Takaoka et al., 1997). Interestingly, when these 
transgenic mice were moved to a different animal facility with a different 
health status, the mice did not develop amyloid deposits (Sousa et al., 2002) 
suggesting that, at least in part, the amyloid observed was AA amyloid as a 
consequence of inflammation. 
Another two models of human TTR transgenic mice were simultaneously 
generated and compared, in which the mice carried 19.2 kb of genomic DNA 
of wild-type human TTR or of human TTRL55P (Teng et al., 2001). Both strains 
showed transgene expression in tissues similar to humans. Mice carrying the 
L55P variant had low serum concentration of the human TTR (10-30 µg/ml) 
and no amyloid deposits were observed in these mice even at the age of 2.5 
years. On the other hand, mice carrying 100 copies of the wild-type human 
TTR gene had concentration of the human TTR 100-fold higher than the mice 
expressing the L55P variant.  Amyloid deposits were observed in the heart of 
20 % of the transgenic mice at 18 months, increasing to 50 % at two years 
(Teng et al., 2001). TTR immunoreactivity was also observed in the hearts but 
the data presented did not show co-localisation with the amyloid deposits. 
The hearts were negative for SAA immunoreactivity but the possibility of 
ApoAII amyloid was not addressed. Spontaneous ApoAII amyloidosis 
(including in the heart) is common in old mice (Higuchi et al., 1991b, Higuchi 
et al., 1991a). Even if the amyloid in these mice was ATTR amyloid, the slow 
progression of the amyloid deposition in this model is not sufficiently 
consistent and robust for the use of the mice as a model of the disease. 
L55P variant was also used by Sousa et al. to examine the cytotoxic activity 
of TTR deposits. The transgenic mice obtained by microinjection of TTRL55P 
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cDNA under the control of sheep methallothionein promoter had plasma TTR 
concentration similar to humans (50-200 µg/ml). TTR deposition in the tissue 
of the transgenic mice was detected and progressed with age, however these 
deposits were non-Congophilic and TTR amyloid was not detected in these 
mice up to 2 years of age (Sousa et al., 2002). Non-Congophilic non-fibrillar 
deposits of TTR in nerves were detected in patients in early stages of ATTR 
amyloidosis (Sousa et al., 2001). Observations that non-Congophilic TTR 
deposits in the TTRL55P transgenic mice had a cytotoxic effect in sites related 
to TTR deposition in the TTRL55P transgenic mice (Sousa et al., 2002) suggest 
that pre-fibrillar deposits have pathological effect in the disease development. 
Although these models have provided valuable insight into TTR gene 
expression, TTR protein interactions and TTR deposition, none of them have 
been able to provide a consistent model of ATTR amyloidosis.  
In 1993, an extremely aggressive amyloidosis with very early onset caused by 
TTRS52P variant was reported in the UK (Booth et al., 1993). This mutation is 
characterised by widespread ATTR amyloid deposits by the third decade with 
fatal cardiac involvement within just a few years (Mangione et al., 2014, 
Gonzalez-Duarte et al., 2013). Recently, the S52P variant has been 
extensively studied in vitro and the biochemical analysis of the variant have 
provided new evidence that may play an important role in pathogenesis of 
ATTR amyloidosis. Cardiac TTR amyloid typically contains fragmented TTR, 
with the fragments being mostly cleaved between amino acids at the position 
48-49 (Bergstrom et al., 2005, Ihse et al., 2013). In vitro studies looking into 
proteolytic cleavage of TTR variants associated with cardiac amyloidosis 
showed that S52P variant is much more susceptible to cleavage in 
comparison with wild-type TTR, TTRV122I and TTRL55P (Mangione et al., 2014). 
While in vitro fibrillogenesis of wild-type TTR and other mutant forms of TTR 
require the use of very harsh conditions, not found in nature (Colon and Kelly, 
1992), the cleaved S52P variant very rapidly converts into amyloid fibrils in 
physiological conditions in vitro, whereas neither un-cleaved S52P nor other 
variants nor wild-type TTR formed amyloid under the same conditions 
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(Mangione et al., 2014). Moreover, the fibrils produced in vitro from cleaved 
S52P TTR have the characteristic appearance of genuine amyloid fibrils in 
electron micrographs (Mangione et al., 2014), in contrast with the insoluble 
material produced from wild-type TTR and other variants (Hurshman et al., 
2004, Bateman et al., 2011, Bonifacio et al., 1996). 
These new insights into the possible mechanisms foregoing amyloid 
deposition and the susceptibility of the TTRS52P to cleavage which makes the 
S52P variant extremely amyloidogenic suggest that expression of human 
TTRS52P in mice may be a promising approach in generating a new model of 
cardiac ATTR amyloidosis. 
The outcomes of TTR transgenic mice produced by other groups were 
assessed and, together with new ideas were used to design TTRS52P 
transgene. Similarly like in the β2-microglobulin project, the genomic 
sequence, including exons and introns were used as it was shown that introns 
enhance the efficiency of gene expression and thus play a role in facilitating 
transcription of genes (Brinster et al., 1988, Whitelaw et al., 1991). The 
clinical observations and results obtained from transgenic mice produced by 
other groups indicate that concentration of the precursor protein plays an 
important role in initiating amyloid deposition. To maximise the expression of 
the S52P variant but at the same maintain the main site of endogenous TTR 
expression, which is the liver, replacement of the TTR gene’s own promoter 
with an albumin promoter was considered. Mouse albumin is abundantly 
expressed in the mouse liver (Tilghman and Belayew, 1982) and the mouse 
albumin enhancer/promoter has been well characterized showing that it is 
liver-specific and that it stimulates production of a transgene mRNA at levels 
comparable to mouse albumin (Pinkert et al., 1987). 
The aim of this part of the project was to generate transgenic mice expressing 
high concentrations of the highly amyloidogenic hTTRS52P protein towards the 
development of a model of cardiac ATTR amyloidosis. 
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5.2 Results 
Transgenic mice carrying a highly amyloidogenic variant S52P of human 
transthyretin (hTTRS52P) were generated as a transgenic model of ATTR 
amyloidosis. The transgene was prepared by cloning a full length wild-type 
hTTR gene from human genomic DNA, in which the single base substitution 
c.214TC (TCT/CCT) was introduced, encoding replacement of serine 
residue at the position 52 of the mature protein with proline residue (S52P). 
To maximise the expression levels of the S52P variant in the liver, the 
transgene was expressed under the control of mouse albumin enhancer and 
promoter (Pinkert et al., 1987). 
 
5.2.1 Cloning of human transthyretin 
The TTR gene was PCR amplified from human genomic DNA. Although 
several primer pairs were tested, attempts to amplify the entire 15.8 kb hTTR 
sequence containing the 7.3 kb TTR gene, 7 kb 5’ flanking sequence and 1.5 
kb 3’ flanking sequence were not successful. For this reason, the 15.8 kb TTR 
sequence was split into two fragments, 8 kb hTTR-NS and 8 kb hTTR-SM 
and each fragment was cloned separately (Figure 5.1). 
8 kb long hTTR-NS fragment contained 7 kb of 5’ flanking sequence and exon 
1 of the human TTR gene. This fragment was PCR-amplified from genomic 
DNA with hTTR-NS-4-For and hTTR-NS-4-Rev primers (Table 2.2). This 
primer pair was designed so that NheI and SalI restriction sites were present 
within the amplified fragment. 
8 kb long hTTR-SM fragment contained exons 2, 3 and 4, and 1.5 kb 3’ 
flanking sequence of the human TTR gene. This fragment was PCR-amplified 
from genomic DNA using hTTR-SM-10-For and hTTR-SM-10-Rev primers 
(Table 2.2). The primer pair was designed to include the SalI and MluI 
restriction sites within the amplified fragment. 
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Figure 5.1: Schematic representation of cloning of human transthyretin 
Cloning of 15.8 kb hTTR containing the 7.3 kb hTTR gene with its 4 exons and 3 
introns, 7 kb 5’ flanking sequence and 1.5 kb 3’ flanking sequence was split into two 
parts:  
1) hTTR-NS fragment containing 7kb 5’ flanking sequence, exon 1 and intron 1 was 
PCR amplified with primers hTTR-NS4-For and hTTR-NS4-Rev, cut with NheI and 
SalI and cloned into pLitmus38ixNheIxSalI.  
2) hTTR-SM fragment containing exons 2, 3 and 4, introns and 1.5 kb 3’ flanking 
sequence was PCR amplified with primers hTTR-MS10-For and hTTR-MS10-Rev, 
cut with SalI and MluI and cloned into pLitmus38ixSalIxMluI. 
N.B. Primers are not drawn to scale. 
 
Both fragments were amplified using Phusion Hot Start II High-Fidelity DNA 
Polymerase. This thermostable polymerase has a proofreading capability and 
a very low error rate compared to other DNA polymerases. Purified NheI-SalI 
fragment of hTTR-NS was then cloned into 2.8 kb pLitmus38ixNheIxSalI and 
SalI-MluI fragment of hTTR-SM was cloned into pLitmus38ixSalIxMluI and the 
ligates were then transformed into competent cells. 
The identity of the sequence for both recombinant plasmids was verified by 
restriction digest. hTTR-NS/pLitmus38i recombinant plasmid digested with 
BamHI enzyme gave the expected restriction pattern of 3 fragments of 4.1 kb, 
3.7 kb and 2.0 kb (not shown). hTTR-SM/pLitmus38i digested with HindIII 
enzyme showed the expected 3 fragments of 6 kb, 2.6 kb and 1.8 kb (not 
shown).  
Four hTTR-NS/pLitmus38i recombinant plasmids and two hTTR-
SM/pLitmus38i recombinant plasmids were sequenced by Source BioScience 
(UK) to exclude sequence alterations due to PCR-introduced errors. All 
184 
 
exons, exon-intron boundaries, 5’ and 3’ ends and ligation sites were 
sequenced to ensure that correct transcription and splicing of the transgene 
would be maintained as well as no alterations in the amino acid coding 
sequence were present. Primers for sequencing were designed using 
NCBI/Primer-BLAST online software and are listed in Table 2.2. No mutations 
were detected in the coding and regulatory sequences of the recombinant 
plasmids and one hTTR-NS/pLitmus38i (plasmid number 8) and one hTTR-
SM/pLitmus38i (plasmid number 1) were used for further work. 
 
5.2.2  Mutagenesis of human transthyretin 
The S52P mutation was introduced into the human TTR gene sequence by 
site-directed mutagenesis. Because the mutation site is in exon 3 of the hTTR 
gene, which is in the hTTR-SM fragment, hTTR-SM/pLitmus38i recombinant 
plasmid was used as a template for the site-directed mutagenesis. This 
method involves designing a pair of primers which are partly complimentary to 
one another and also to the DNA to be mutated except that they contain the 
desired mutation. hTTR-S52P-mut-For and hTTR-S52P-mut-Rev (Table 2.2) 
were designed so that the c.214TC (TCT/CCT)  substitution was present in 
the short oligonucleotide sequences priming a PCR amplification of the hTTR-
SM/pLitmus38i recombinant plasmid (Figure 5.2). A 20-cycle PCR with the 
recombinant plasmid as a DNA template and Phusion Hot Start II High-
Fidelity DNA Polymerase was run. The advantage of using the high-fidelity 
polymerase is the minimal chance of unwanted mutations during the PCR and 
the hot-start formulation of the enzyme which ensures that the primers are not 
degraded by the enzyme’s exonuclease activity during the reaction set-up. 
The site-directed mutagenesis PCR reaction produces plasmids which carry 
the mutation on both strands, as it is described in mutagenesis of hβM gene. 
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   hTTR-S52P-mut-For     5’-AGTGAGCCTGGAGAGCTGCATGGGCTC-3’ 
                            |||||||||||||||||||  
      3’-GTGGAATATCCTTTTGGTCACTCGGACCTCTCGACG-5’   hTTR-S52P-mut-Rev 
 
Figure 5.2: hTTRS52P site-directed mutagenesis 
hTTR-S52P-mut-For and hTTR-S52P-mut-Rev primers were designed which are 
partly complimentary to each other and to the targeted hTTR gene, but containing 
TC mutation causing the S52P substitution. In the first round of PCR reaction, the 
double stranded template hTTR-SM/pLitmus38i DNA denatures, the primers anneal 
to the template and new DNA strands are extended, resulting in a plasmid with a 
single mismatch in the mutation site. Subsequent PCR cycles predominantly lead to 
double-stranded plasmids carrying the desired mutation on both strands. 
N.B. Primers are not drawn to scale. 
 
 
After transformation of the newly synthesized mutagenized plasmids, plasmid 
DNA of 8 different clones was purified and mapped with HindIII restriction 
digest to establish which clones carry the hTTR/pLitmus38i recombinant 
plasmid DNA and that the sequence of these plasmids has not been altered 
by major deletions or insertions. The mutation itself does not interfere with the 
restriction sites for HindIII and so the same pattern of 3 restriction fragments 
of 6 kb, 2.6 kb and 1.8 kb as in the hTTR-SM/pLitmus38i template DNA were 
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expected and confirmed in all 8 mutated recombinant plasmids tested (Figure 
5.3). 
 
 
 
Figure 5.3: Mutated hTTR-SM/pLitmus38i x HindIII 
HindIII restriction analysis of mutated hTTR-SM/pLitmus38i recombinant plasmids 
(m1 – m8) showed 3 fragments of expected sizes 6.0 kb, 2.6 kb and 1.8 kb in all 
clones. Non-mutated template plasmid hTTR-SM/pLitmus38i digested with HindIII 
enzyme (T) was used as a control and run alongside the samples in which the same 
restriction pattern is obtained as the introduced mutation does not interfere with the 
HindIII restriction sites. λ-DNAxHindIII (M) was used as a size marker. 
 
 
5 of the 8 clones were sequenced by Source BioScience (UK) using the 
hTTR-SM-seq3F and hTTR-SM-seq3R primers (Table 2.2) to determine 
which clones carry the S52P mutation in the exon 3 of the human TTR 
sequence (hTTRS52P). All 5 clones were confirmed to carry the mutation 
(Figure 5.4). 
  
187 
 
 
 
Figure 5.4: Partial-sequence chromatograms of the human TTR gene 
Wild-type human TTR coding sequence (WT hTTR) and amyloidogenic variant of 
human TTR (hTTRS52P) show the c.214TC single base substitution (arrows) which 
encodes replacement of a charged serine (TCT) residue at position 52 of the mature 
protein with a proline residue (CCT). The S52P mutation, introduced into the wild-
type human coding sequence by site-directed mutagenesis was confirmed in all 5 
clones analysed. 
 
One hTTR-SMS52P/pLitmus38i clone (plasmid number 1) was then sequenced 
further to exclude sequence alterations due to PCR-introduced errors. All 3 
exons of this fragment of the hTTR sequence, exon-intron boundaries, 3’ end 
and ligation sites were verified to ensure that correct transcription and splicing 
of the transgene mRNA would be maintained and that no alterations in the 
amino acid coding sequence (except for the S52P substitution) were present. 
The same primers as for sequencing of the non-mutated hTTR-
SM/pLitmus38i were used (Table 2.2). No sequence alterations were 
detected in the coding and regulatory regions of the hTTR-SMS52P/pLitmus38i 
and this clone was used to assemble the full hTTRS52P transgene. 
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5.2.3 Gibson assembly of Alb-hTTR
S52P
 transgene 
The final step in the construct preparation was to join the mouse albumin 
enhancer and promoter, the hTTR-NS fragment carrying exon 1 of the hTTR 
gene and the hTTR-SMS52P fragment carrying exons 2, 3 and 4 of the hTTR 
gene with the S52P mutation in exon 3 to create the final Alb-hTTRS52P 
transgene. This was achieved by Gibson assembly. 
Gibson Assembly allows in a single reaction insertion of one or more DNA 
fragments into virtually any position of a linearized vector and does not rely on 
the presence of restriction sites within a particular sequence to be 
synthesized or cloned (Gibson et al., 2009). This method requires DNA 
fragments with 15-25 nucleotides overlaps with adjacent DNA fragment. To 
achieve this, DNA fragments and a linearised vector to be assembled are 
PCR amplified using specifically designed primers to generate fragments with 
overlapping ends. Exonuclease, DNA polymerase and DNA ligase enzymes 
combined in the Gibson assembly mastermix then create single stranded 3’ 
overhangs to facilitate the annealing of fragments that are complimentary to 
one another, fill the gaps within each annealed fragment and anneal nicks in 
the assembled DNA, respectively. 
The linearised mouse albumin enhancer/promoter in pBSIISK(-) vector 
(Pinkert et al., 1987, Gorski et al., 1986) was PCR amplified with TTRass6 
and TTRass1 primers which created a 5.2 kb Alb/pBSIISK(-) fragment. NheI 
linearised hTTR-NS/pLitmus38i was amplified with TTRass2 and TTRass3 
primers which created a 0.9 kb 5’-UTR – SalI fragment of hTTR-NS carrying 
exon 1 of the hTTR gene. hTTR-SMS52P/pLitmus38i linearised with EcoRV 
was PCR amplified with TTRass4 and TTRass5 primers which created a 7.7 
kb SalI – MluI fragment of hTTR-SMS52P carrying exon 2, exon 3 (with the 
S52P mutation), exon 4 and a 1.5 kb 3’ flanking sequence of the hTTR gene. 
The PCR amplifications were performed using Phusion Hot Start II High-
Fidelity DNA Polymerase. Each of the PCR amplified fragments had short 
sequence overlaps with the adjacent fragments (Table 2.2). These three 
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fragments were then joined together in Gibson assembly to make up the Alb-
hTTRS52P/pBSIISK(-) recombinant plasmid in which the mouse albumin 
enhancer/promoter is linked to the full length of hTTRS52P gene with 1.5 kb of 
3’ flanking sequence in pBSIISK(-) vector (Figure 5.5). 
 
 
 
Figure 5.5: Gibson assembly of Alb-hTTRS52P fragment in pBSIISK(-) 
890 bp 5’UTR-SalI fragment of hTTR-NS, 7.7 kb SalI-MluI fragment of hTTR-
SMS52P and mouse albumin enhancer/promoter in pBSIISK(-) were PCR amplified 
using specifically design primers with nucleotide overlaps (1-6). These fragments 
were then assembled together to make up Alb-hTTRS52P transgene in which the full 
length hTTRS52P gene with its 1.5 kb 3’ flanking sequence is joined together with 
mouse albumin enhancer/promoter in pBSIISK(-) vector. 
 
 
The assembled reaction was then transformed into competent cells. The 
predicted size of correctly assembled Alb-hTTRS52P/pBSIISK(-) recombinant 
plasmid was 13.7 kb (Figure 5.6). Five out of twelve analysed and linearised 
recombinant plasmids suggested the correct assembly. These five plasmids 
were digested with HindIII to verify the identity of the assembled clones and 
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all five recombinants showed the predicted fragments of 6.4 kb, 5.5 kb and 
1.8 kb (Figure 5.7). Two of these five Alb-hTTRS52P/pBSIISK(-) plasmids were 
sequenced by Source BioScience (UK) to verify all coding sequences, correct 
assembly of fragments and exon-intron boundaries of the construct to ensure 
that correct transcription and splicing of the transgene mRNA would be 
maintained and that no alterations in the coding sequence were present. After 
the sequences verification, one Alb-hTTRS52P/pBSIISK(-) recombinant was 
used to prepared the Alb-hTTRS52P microinjection fragment (Figure 5.8). 
 
 
 
Figure 5.6: Map of assembled Alb-hTTRS52P fragment in pBSIISK(-) vector.  
HindIII, used for identification of recombinant plasmids obtained by Gibson 
assembly, cuts the 13.7 kb Alb-hTTRS52P/pBSIISK(-) plasmid into 3 fragments of 6.4 
kb, 5.5 kb and 1.8 kb. NotI and BssHI were used for excision of the 10.9 kb Alb-
hTTRS52P microinjection fragment from the plasmid. 
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Figure 5.7: HindIII restriction analysis of Alb-hTTRS52P/pBSIISK(-) 
HindIII restriction analysis of five assembled Alb-hTTRS52P/pBSIISK(-) clones showed 
predicted restriction pattern of three fragments of 6.4 kb, 5.5 kb, 1.8 kb in all five 
clones (1, 5, 7, 9, 10). λ-DNAxHindIII was run alongside the samples as a size 
marker. 
 
 
 
 
 
Figure 5.8: Schematic representation of the assembled Alb-hTTRS52P fragment 
The 10.9 kb NotI – BssHI fragment excised from the Alb-hTTRS52P/pBSIISK(-) was 
used for microinjections to generate hTTRS52P transgenic mice. 
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5.2.4 Generation of hTTR
S52P
 transgenic mice 
The 10.9 kb Alb-hTTRS52P fragment was cut out of the circular Alb-
hTTRS52P/pBSIISK(-) plasmid with BssHII and NotI (Figure 5.8). The fragment 
was gel purified to remove the plasmid vector sequence, quantified and used 
for pronuclear injection. The microinjections into C57Bl/6J embryos and 
embryo transfers into pseudo-pregnant recipient female mice were performed 
by Dr Raya Al-Shawi and Dr Paul Simons. 
27 pups were born from the pronuclear microinjections. Ear and tail biopsies 
were collected and used for genotyping at 5 weeks of age. Transgenic mice 
were identified by PCR using primers hTTRg-3U and hTTRg-3D (Table 2.2) 
that amplify a 689 bp fragment of the transgene. Two females showed 
integration of the hTTRS52P transgene, and the PCR clearly distinguished the 
transgenic mice from non-transgenic mice (Figure 5.9). Both transgenic 
females were bred with C57Bl/6J mice to identify germline transmitters. 1 
female proved to transmit the transgene to the first generation, establishing 
line 5. 
 
 
Figure 5.9: Identification of hTTRS52P transgenic animals 
hTTRS52P transgenic mice born from microinjected embryos were identified by PCR 
using hTTRg-3U and hTTRg-3D primers. Two transgenic animals (mice number 5 
and 10) were distinguished from their negative littermates (mice numbers 1, 2, 3, 4, 
8, 9, 11) by an amplification of a 689 bp fragment of the transgene. Human genomic 
DNA (H) was used as a positive control and run alongside the samples together with 
a 100 bp marker (M). 
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In hTTR transgenic mice carrying L55P variant produced by Sousa et al. 
(2002) and Tagoe et al. (2007), a difference in deposition of human TTR 
protein was noticed between mice expressing the endogenous mouse TTR 
and mice in which the murine TTR gene was silenced (TTR-KO). Although no 
ATTR amyloid was detected in any TTRL55P transgenic mice, increased TTR 
deposition was observed in transgenic mice on TTR-KO background in 
comparison with transgenic mice with the murine TTR present (Sousa et al., 
2002, Tagoe et al., 2007). This observation suggested that the murine TTR 
may interfere with hTTR deposition in the hTTR transgenic mice. TTR is a 
homotetramer and presence of the murine TTR in hTTR transgenic mice 
leads to a formation of TTR heterotetramers composed of both, murine and 
human TTR monomers (Tagoe et al., 2007). It was then shown that in the 
transgenic mice the murine/human TTR heterotetramers are more stable to 
denaturation (Tagoe et al., 2007) and in vitro experiments looking at the 
dissociation rates and kinetic stability of murine/human heterotetramers 
suggested that the presence of murine subunit in the murine/human TTR 
heterotetramers may prevent human TTR fibrillogenesis (Reixach et al., 
2008). For this reason, the hTTRS52P transgenic mice were bred on mouse 
TTR-KO background (Episkopou et al., 1993) as well as on mouse TTR wild-
type background to evaluate the effect of the mouse endogenous TTR in the 
transgenic mice. 
 
5.2.5 Expression of hTTR mRNA in the hTTR
S52P
 
transgenic mice 
TTR is normally expressed mostly by hepatocytes and by the choroid plexus 
of the brain (Dickson et al., 1985) and minor synthesis has also been 
identified in the retinal and ciliary pigment epithelia of the eye, visceral yolk 
sac, placenta and other organs (Soprano et al., 1985, Soprano et al., 1986, 
Cavallaro et al., 1990, McKinnon et al., 2005). In the hTTRS52P transgenic 
mice, the hTTR transgene is expressed under the control of mouse albumin 
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promoter which has been shown to be liver-specific (Pinkert et al., 1987). 
Thus the transgene expression was expected exclusively in the liver. 
Liver, spleen, heart, kidney, tongue, skeletal muscle and brain of hTTRS52P 
transgenic mice lacking the endogenous mouse TTR were analysed for the 
transgenic hTTR mRNA expression by reverse transcription PCR (RT-PCR). 
RNA was isolated from mouse tissue and any contaminating DNA in the 
samples was eliminated by DNase (gDNA wipe-out buffer, QIAGEN). The 
isolated RNA was then transcribed into cDNA by reverse transcriptase using 
a mix of primers which ensured cDNA synthesis from all regions of RNA 
transcripts. 
The obtained cDNA from the hTTRS52P transgenic tissues was PCR amplified 
using human TTR specific primers hTTR RT-PCR 5’ and hTTR RT-PCR 3’ 
(Table 2.2) each of which is complementary to a sequence from different 
exons. The PCR-amplified product was a 226 bp fragment. As expected, the 
hTTR mRNA was detected only in the liver (Figure 5.10 A). The specificity of 
the human TTR primers was confirmed by RT-PCR of mRNA obtained from 
tissue of control TTR-KO mice, in which no amplification with hTTR RT-PCR 
5’ and hTTR RT-PCR 3’ primers was detected (Figure 5.11 A). 
As a positive control, RT-PCR of the mouse house-keeping gene GAPDH 
which is ubiquitously expressed in all tissue was simultaneously performed. 
Using msGAPDHf and msGAPDHr primers (Table 2.2), a 133 bp PCR 
product was amplified from obtained cDNA in all analysed tissues of hTTRS52P 
transgenic mice as well as of TTR-KO mice (Figure 5.10 B and 5.11 B). This 
result confirmed that the extracted RNA is of a good quality and that no 
amplification of cDNA in the tissue with hTTR primers in the RT-PCR 
reactions is due to the fact that the gene of interest is not expressed and not 
due to lack of total RNA itself in the analysed samples or failure of cDNA 
synthesis.  
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Figure 5.10: Expression of transgene-encoded hTTR mRNA 
hTTR transgene mRNA expression in tissue of hTTRS52P transgenic mice on TTR-
KO background was analysed by RT-PCR. RNA isolated from liver, kidney, spleen, 
heart, tongue, skeletal muscle and brain was used for cDNA synthesis using reverse 
transcriptase (RT) and a mixture of oligo-dT primers and random primers to ensure 
cDNA synthesis from all regions of RNA transcripts. The synthesized cDNA was then 
amplified by 25 cycle PCR using Taq polymerase. hTTR expression (A) was 
detected as a 226 bp fragment in the liver only as expected as the transgene was 
under the control of liver-specific albumin promoter. Successful RNA extraction and 
cDNA synthesis was confirmed by control RT-PCR reactions using primers specific 
for mouse GAPDH, an ubiquitously expressed gene, amplifying a 133 bp fragment in 
all tissue analysed (B). When no RT was added into the tissue RNA, no PCR 
amplification was detected in any tissue with either hTTR (C) or GAPDH (D) primers 
confirming specificity of the PCR reaction to cDNA synthesized from the tissue-
extracted RNA. 25 bp DNA ladder (M) was run alongside the samples. 
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To exclude the possibility of false positive signal by genomic DNA 
contamination, a control reaction prepared without the addition of reverse 
transcriptase enzyme into the RNA isolated from tissues of hTTRS52P 
transgenic mice was also run. Using primers amplifying hTTR cDNA and 
GAPDH cDNA, no amplification after the PCR was detected, confirming that 
the amplification of hTTR and mouse GAPDH fragments was specific to the 
extracted RNA from the mouse tissue (Figure 5.10 C, D).  
 
 
 
Figure 5.11: Negative control RT-PCR of hTTR transgene-encoded mRNA 
RNA isolated from liver, kidney, spleen, heart, tongue, skeletal muscle and brain of 
non-transgenic control mice lacking the endogenous mouse β2m (mβ2m-KO) was 
used for cDNA synthesis using reverse transcriptase and subjected to PCR 
amplification with hTTR primers (A) amplifying a 226 bp fragment in hTTR positive 
samples and mouse GAPDH primers (B) detecting a ubiquitously expressed GAPDH 
house-keeping gene. While the GAPDH primers amplified a 133 bp fragment, 
confirming successful extraction of RNA from the tissue as well as cDNA synthesis 
by reverse transcriptase, no amplification using the hTTR primers was detected 
confirming the specificity of the assay. 
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5.2.6 hTTR in the serum of hTTR
S52P
 transgenic mice 
Presence of hTTR in the serum of hTTRS52P transgenic mice was evaluated 
by Western blot analysis. Human serum was used as a positive control of the 
protein migration and for estimation of the amount of the hTTR protein in the 
mouse serum. 
0.2 µl of serum of hTTRS52P of transgenic mice, C57Bl/6J mice, TTR-KO 
mice, as well as 0.2 µl of human serum were separated on an SDS-PAGE gel 
and blotted onto a PVDF membrane which was probed with antibodies 
against human TTR. Two antibodies were tested: Dako rabbit polyclonal anti-
human TTR and sheep polyclonal anti-human TTR from Binding site. Both 
antibodies recognized human TTR as a 14 kDa band migrating together with 
the TTR in the human serum. From the signal intensity given by the TTR in 
the human serum and hTTR signal in the transgenic mice, the hTTR 
concentration in the transgenic mice was equivalent to the concentration of 
the TTR in the human sample. Both antibodies also reacted with mouse TTR 
(mTTR) which migrated faster as a 13 kDa band and was clearly 
distinguishable from the human TTR protein in the serum of the transgenic 
mice carrying both alleles (T/WT) or one allele (T/Het) of the murine TTR. As 
expected, no signal was detected in the serum of TTR-KO mice. No 
difference in the hTTR signal was observed in the serum of T/WT and T/Het 
mice and in the serum of mice lacking the mouse TTR (T/KO). These results 
are shown in Figure 5.12. 
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Figure 5.12: hTTR in serum of hTTRS52P transgenic mice 
Western blot analysis showing expression of human TTR in the serum of hTTRS52P 
transgenic mice carrying one (T/Het) or two (T/WT) alleles of endogenous mouse 
TTR and hTTRS52P transgenics on mouse TTR knock-out background (T/KO) using a 
sheep polyclonal anti-human TTR antibody (Binding site) recognising both, human 
and mouse TTR. Human TTR (14 kDa) is distinguishable from mouse TTR which 
migrates faster as a 13 kDa band. No signal was detected in mouse TTR knock-out 
serum (KO). Human serum was used as a positive control (Hum), wild-type C57Bl/6J 
serum as a negative control (Wt) and 100 ng and 50 ng of recombinant human TTR 
per well were used for a concentration estimate. 0.2 µl of serum was loaded per well 
for each sample analysed. 
 
 
5.2.7 Quantitation of serum hTTR in the hTTR
S52P
 
transgenic mice 
To quantify the concentration of circulating hTTR in hTTRS52P transgenic 
mice, mouse serum was assayed by rocket immunoelectrophoresis. 
No rocket was formed when sera of C57Bl/6J mice and TTR-KO mice were 
analysed, showing that the Dako anti-hTTR antibody, which recognizes both 
human and murine TTR in their denatured form, is specific for human TTR 
only in its native conformation. hTTRS52P transgenic mice carrying one or two 
alleles of the endogenous mouse TTR (T/Het or T/WT, respectively) showed 
higher measured concentration of serum hTTR in the rocket analysis than 
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transgenic mice lacking the endogenous murine TTR (T/KO) (Figure 5.13). 
Moreover, sex difference was observed in the serum levels of hTTR with 
males expressing higher levels than females.  
The measured concentrations were 1736 ± 447 µg/ml (n=13) in T/WT males, 
1231 ± 137 µg/ml (n=6) in T/WT females, 1109 ± 255 µg/ml (n=8) in T/Het 
males, 799 ± 98 µg/ml (n=7) in T/Het females, 596 ± 128 µg/ml (n=12) in 
T/KO males and 361 ± 175 µg/ml (n=9) in T/KO females (Figure 5.14). 
 
 
 
 
 
Figure 5.13: Quantitation of serum hTTR by rocket immunoelectrophoresis 
Serum of hTTRS52P transgenic mice was analysed by rocket assay. Human serum 
(Hum) was used as a positive control (panel A) and undiluted mouse sera of 
C57Bl/6J (WT) and mTTR-KO (KO) mice were used as negative controls (panel B). 
The assay is specific for hTTR. Note that different range of dilutions of transgenic 
sera were tested. Known concentrations of hTTR in human serum were used to 
prepare standard curve. The gels were stained with Coomassie blue. 
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Figure 5.14: Quantitation of serum hTTR in hTTRS52P transgenic mice 
The concentration of human TTR in the serum of hTTRS52P transgenic mice was 
quantified using rocket immunoelectrophoresis. A difference between males and 
females was observed, with the serum levels of hTTR significantly higher in males 
than females. Native TTR is tetrameric – while in the hTTRS52P transgenic mice on 
mTTR-KO background the homotetramers are formed of human TTR only, 
heterotetramers between human and mouse TTR are formed in mice carrying one or 
two alleles of mouse TTR (mTTR-Het and mTTR-WT, respectively). The values are 
expressed as mean ± standard deviation for number of mice analysed (n). Mann-
Whitney two-tailed test was used to analyse the differences between males and 
females with statistical significance showed as p<0.05 (*) and p<0.01 (**). 
 
 
Although a significant difference was seen in the serum hTTR concentrations 
between transgenic mice expressing or lacking murine TTR, such difference 
was not observed in the denatured serum run on an SDS-PAGE gel. Native 
TTR is tetrameric and it has been shown that in transgenic mice carrying 
human and mouse TTR, heterotetramers composed of human and murine 
subunits are formed (Tagoe et al., 2007, Zhao et al., 2008). In hTTRS52P 
transgenic mice on mouse TTR-KO background, the TTR is a homotetramer 
formed only by the human subunits. In transgenic mice in which the murine 
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TTR is present, human/mouse TTR heterotetramers can be formed as it is 
illustrated in Figure 5.15. As no rocket was formed when serum of C57Bl/6J 
mice was analysed, the rocket analysis is human TTR specific. Thus, one or 
more human subunits present in a mouse/human TTR heterotetramer may 
react with the anti-human TTR antibody in the gel, contributing to the 
precipitate in the rocket. The concentration of tetramers containing at least 
one human TTR subunit in transgenic mice on wild-type background is higher 
than the concentration of homotetramers in transgenic mice on TTR-KO 
background. The concentrations of hTTR containing tetramers are 
intermediate in hTTR transgenics on mTTR heterozygous background. These 
considerations probably explain the apparent discrepancies between the 
concentrations measured by rockets in the serum of transgenic mice on 
knock-out background and those carrying the endogenous mouse TTR, given 
that no differences were observed by Western blotting. 
 
 
 
Figure 5.15: TTR tetramers 
Native TTR is a tetramer composed of four TTR monomers. In transgenic 
mice expressing human TTR (hTTR; red subunit) as well as mouse TTR 
(mTTR; white subunit), five different compositions of the TTR tetramer can 
occur: homotetramers when the TTR is composed of the same monomers, or 
heterotetramers when both, mouse and human TTR monomers are present.  
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5.2.8 Body weight of hTTR
S52P
 transgenic mice 
A difference was observed between the transgenic and non-transgenic 
animals in the body weight and the size of the body, from birth and throughout 
their life span, regardless the presence of endogenous murine TTR. The 
hTTRS52P transgenic mice were smaller and had significantly lower body 
weight than their non-transgenic littermates (Table 5.2). No difference was 
seen in body weights between non-transgenic mice wild-type, heterozygous 
and knock-out for endogenous mouse TTR-KO throughout their life (Table 
5.1). 
 
 
Non-transgenic control mice 
      
[Weight] g  Males (n) Females (n) 
mTTR Wild-type  19.81 ± 1.71 (6) 17.92 ± 1.31 (6) 
mTTR Heterozygous  20.06 ± 2.38 (12) 18.24 ± 1.50 (8) 
mTTR Knock-out  19.01 ± 2.18 (10) 19.17 ± 0.96 (3) 
P value  ns  ns  
 
 
Table 5.1: Body weight of non-transgenic mice on different mTTR backgrounds 
Comparison of weights of 5 weeks old non-transgenic males and females that are 
wild-type, heterozygous or knock-out for endogenous murine TTR (mTTR). Values 
are shown as mean ± SD for number (n) of mice analysed. One way ANOVA 
(Kruskal-Wallis test) was used for statistical analysis. Presence or absence of 
expression of mTTR did not affect the weights of the mice. 
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[Weight] g  Males (n) Females (n) 
Non-transgenic controls  19.86 ± 2.23 (28) 18.29 ± 1.36 (17) 
hTTRS52P transgenics  13.59 ± 2.58 (20) 14.44 ± 2.18 (13) 
P value  < 0.0001 
 
< 0.0001 
   
Table 5.2: Body weight of transgenic and non-transgenic mice 
Weights of hTTRS52P transgenic mice at 5 weeks of age are shown as mean ± SD for 
number (n) of mice analysed. Mann-Whitney two-tailed test was used for statistical 
analysis. The difference in body weight between transgenic mice and the non-
transgenic littermates was observed from birth and throughout the life span of the 
mice, regardless of presence of murine TTR. 
 
 
Such phenotype of the transgenic mice could be related to the expression of 
the TTRS52P transgene itself or it could be due to a position effect (Al-Shawi et 
al., 1990) of the randomly integrated transgene causing a disruption of a 
normal gene sequence in the mouse genotype. Because only one line of the 
hTTRS52P transgenic mice has been characterised so far, the position effect of 
the transgene has not been evaluated yet. 
 
5.2.9 TTR
S52P
 variant binds thyroxine T4 in hTTR
S52P
 
transgenic mice 
TTR is the main carrier of thyroxine hormone T4 in rodents (Davis et al., 
1970). T4 is synthesized exclusively in the thyroid gland and is distributed via 
circulation bound to T4 carriers to target tissue where it is converted to 
biologically active T3 form by 5’-deiodinase enzymes (Balfour and Tunnicliffe, 
1960, Braverman et al., 1970, Jennings et al., 1979). In TTR-KO mice, total 
T4 levels in serum were reported to be almost 3-fold lower than in wild-type 
mice (Episkopou et al., 1993) but the mice are healthy and viable. To analyse 
the potential of hTTRS52P to bind T4, total T4 levels were measured in the 
hTTRS52P transgenic mice and non-transgenic controls by ELISA. 
The concentration of total T4 in wild-type mice was 0.049 ± 0.005 µg/ml (n=4), 
whereas in the TTR-KO mice, the concentration was 0.028 ± 0.009 µg/ml 
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(n=4). Lower levels of T4 have been reported in transgenic mice in which the 
mouse TTR was knocked-out (Episkopou et al., 1993, Zhao et al., 2008). In 
the hTTRS52P transgenic mice on mouse TTR knockout background, the 
presence of the hTTRS52P variant rescued the total T4 in the plasma, with 
measured concentration 0.050 ± 0.011 µg/ml (n=9). The concentrations of T4 
in hTTRS52P transgenic mice on wild-type background (0.063 ± 0.027 µg/ml, 
n=4) were equivalent with non-transgenic wild-type controls. In the non-
transgenic mice heterozygous for mTTR, the concentration of T4 was 
intermediate between wild-type and TTR knock-out mice (0.037 ± 0.003 
µg/ml, n=6), and the concentration increased in the presence of the hTTRS52P 
variant (0.062 ± 0.014 µg/ml, n=10). The results are shown in Figure 5.16. 
These results confirm that the S52P variant expressed in the transgenic mice 
forms functional tetramers able to bind T4. 
 
 
 
Figure 5.16: Serum thyroxine (T4) levels in hTTRS52P transgenic mice 
T4 concentration in the serum of hTTRS52P transgenic (Tg) and non-transgenic (-ve) 
mice with both alleles (wild-type), one allele (heterozygous) or no allele (knock-out) 
of mouse TTR (mTTR) was measured by ELISA. Mann-Whitney two-tailed test was 
used for result analysis with statistical significance of p<0.05 (*) and p<0.01 (**). 
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5.2.10 Presence of glycosylated TTR in serum of 
hTTR
S52P
 transgenic mice 
In serum of all hTTRS52P transgenic mice tested, a slower migrating band was 
consistently detected on immunoblots in addition to the 14 kDa monomeric 
hTTR. This band was a minor component and was absent from the serum of 
non-transgenic mice and normal human serum. TTR is not normally secreted 
as a glycoprotein. However, presence of glycosylated TTR in plasma of 
carriers of the V30M variant of TTR was reported in both, humans and 
transgenic mice (Teixeira and Saraiva, 2013).  
To identify whether the slower migrating band seen in the serum of hTTRS52P 
transgenic mice was glycosylated TTR, serum of transgenic mice was treated 
with PNGase F, an enzyme that cleaves carbohydrate residues from N-
glycoproteins. Indeed, the enzymatic treatment led to a loss of the slower 
migrating band on the immunoblot as documented in Figure 5.17. 
The specificity of the enzymatic treatment under the reaction conditions was 
tested in serum samples of the same transgenic mice by subjecting the serum 
to the same reaction conditions but without the addition of PNGase F enzyme 
into the reaction. After this treatment, the slower migrating band was still 
detected in these samples confirming that the reaction conditions had no 
effect on the TTR in the serum and its mobility. 
Non-treated transgenic serum and human serum were used as positive 
controls and serum of C57Bl/6J mice and TTR-KO mice were used as 
negative controls for detection of the human TTR.  
Overall, these results confirm that a fraction of the human S52P variant 
circulating in the transgenic mice is N-glycosylated. 
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Figure 5.17: Glycosylated TTR in the serum of hTTRS52P mice 
Treating serum of hTTRS52P transgenic mice with PNGase F, an enzyme that cleaves 
carbohydrate residues from glycoproteins, results in a loss of a slower migrating 
band on western blot (+PNGase F), showing that a fraction of the human protein 
circulating in the transgenic mice is N-glycosylated. The deglycosylation reaction 
conditions had no effect on the serum TTR when no enzyme was added into the 
reaction mix (no PNGase F). Human TTR (hTTR) only was detected as a 14 kDa 
band in human serum (Hum). Mouse TTR (mTTR) only was detected as a 13 kDa 
band in serum of C57Bl/6J mouse. hTTR, mTTR and glycosylated hTTR were 
detected in non-treated serum of hTTRS52P transgenic serum (T/WT). No signal was 
detected in the serum of TTR-KO mice (KO). Sheep anti-hTTR antibody (Binding 
site, UK) was used for TTR detection. The film was deliberately over-exposed in 
order to show clearly the glycosylated TTR band. 
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5.3 Discussion 
Despite many attempts to model ATTR amyloidosis in mice, no or very little 
and inconsistent ATTR amyloid deposition has been achieved in the 
transgenic mice to date. hTTRS52P is the most highly amyloidogenic TTR 
variant described so far. Here, transgenic mice expressing hTTRS52P have 
been generated as a potential new model of ATTR amyloidosis. Although 
TTR is also synthesized in the choroid plexus of the brain, the liver is 
effectively the sole source of plasma TTR (Holmgren et al., 1991). To 
maintain the liver as the physiological site of expression but at the same 
maximise the expression levels of the S52P hTTR variant in the transgenic 
mice, the hTTRS52P transgene was expressed under the control of mouse 
albumin enhancer-promoter, which has been well characterised (Pinkert et 
al., 1987). Albumin in abundantly expressed in the liver and the concentration 
of albumin in plasma is about 100-times higher than of TTR in mice (Champy 
et al., 2008). 
Transgenic mice produced to study the control sequences located upstream 
of mouse albumin gene, transgenes with up to 12 kb of mouse albumin 5’-
flanking sequences fused to human growth hormone gene were tested 
(Pinkert et al., 1987). In those mice, 8.5 – 10.4 kb region located upstream of 
the albumin promoter acted as an enhancer essential for high levels of the 
transgene expression as well as determining the hepatic-specific expression, 
with the region in between -8.5 and -0.3 kb shown to be disposable  (Pinkert 
et al., 1987). This enhancer/promoter was successfully used (Johnson et al., 
1995, Heckel et al., 1990). Indeed, in the hTTRS52P transgenic mice presented 
here, the hTTR mRNA expression was confirmed exclusively in the liver as 
expected, consistent with the characterisation of the albumin enhancer-
promoter used to drive the transgene expression. Moreover, the hTTRS52P 
transgenic mice have serum concentration of the human TTR higher than 
typical in healthy humans. The high concentration of circulating human TTR in 
the hTTRS52P transgenic mice, which is one of the highest reported in TTR 
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transgenic mice generated world-wide so far, is an important prerequisite for 
priming formation of amyloid fibrils. Although the data presented above relate 
to a single transgenic line, four new transgenic mice generated with the same 
construct have similarly high levels of expression showing that this construct 
contained all regulatory elements necessary for consistently high levels of 
liver-specific expression. 
In this context, it is interesting to note that TTR knock-in transgenic mice 
generated by Zhao et al. (2008) by knock-in of human TTR cDNA with rabbit 
β-globin intron into the mouse TTR locus only gave 10 % of the TTR 
expression levels observed in the hTTRS52P transgenic mice presented here, 
using the same assay (data not shown). Although this allele has all of the 5’ 
and 3’ regulatory sequences in the chromosomal context of the mouse Ttr 
gene, the expression is low. Against this background, the data in this chapter 
show that the combination of using the genomic sequence, including the 
introns, and a strong liver-specific promoter is a successful strategy in driving 
high level liver-specific expression of human TTR. 
The clinical disease of amyloidosis occurs when the rate of amyloid 
deposition exceeds its continuing rate of reabsorption by natural clearance 
mechanisms, resulting in accumulation of substantial amyloid deposits in 
various organs. Once the process of amyloid formation has begun, amyloid 
deposition and its progress depend only on a continuing supply of the 
respective amyloid fibril precursor protein. This was very clearly demonstrated 
in AA amyloidosis patients by Lachmann et al. (2007) and confirmed by 
Simons et al. (2013) in a transgenic mouse model of AA amyloidosis with a 
doxycycline-inducible system of expression of an amyloidogenic mouse SAA 
protein. In patients, AA amyloidosis derives from sustained overproduction of 
SAA associated with chronic inflammation. The plasma SAA concentration in 
healthy humans is 3 µg/ml, but the concentration can increase to more than 
2000 µg/ml during acute phase inflammation response (Ledue et al., 1998, 
Lachmann et al., 2007). Spleen, adrenal glands, gut and liver are affected 
with amyloid deposits in AA amyloidosis but the dominant feature is renal 
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dysfunction caused by amyloid deposits. Upon successful anti-inflammatory 
treatment which decreased the production of SAA, the amyloid deposits in the 
patients remained stable or regressed and the survival of the patients 
improved (Lachmann et al., 2007). When the SAA transgenic mice were 
exposed to doxycycline in drinking water, SAA production dramatically 
increased to values only seen in severe inflammation in humans and the mice 
developed systemic amyloid deposits within 4-16 weeks. However, after the 
doxycycline withdrawal, the SAA transgene expression was switched off 
immediately leading to base-line, very low concentration of circulating mouse 
SAA and the amyloid load in the tissue of the amyloidotic transgenic mice 
slowly regressed (Simons et al., 2013). 
Therefore, the high serum concentration of the extremely amyloidogenic 
S52P variant TTR in the transgenic mice presented here should be sufficient 
for amyloid deposition. 
Interestingly, the hTTRS52P transgenic males have almost twice as much of 
the TTR variant in the serum than transgenic females. Sex difference in TTR 
serum levels is also seen in humans with men having higher plasma levels of 
TTR than women although the difference is not so marked (Maetzler et al., 
2012, Smith and Goodman, 1971, Ingenbleek and De Visscher, 1979, 
Ingenbleek and Bernstein, 2015). Importantly, cardiac ATTR amyloidosis is 
almost exclusively seen in men (Ng et al., 2005, Rapezzi et al., 2008, Pinney 
et al., 2013b). The sex-dependent mechanisms in male prevalence of ATTR 
cardiac amyloidosis are yet unexplained and the sex difference of TTR 
concentration in the hTTRS52P mice may be a useful characteristic for 
investigating the correlation between TTR concentration, sex hormones and 
amyloid deposition. There is no difference in albumin expression and albumin 
plasma concentration between men and women and between male and 
female mice suggesting that the activity of the albumin promoter used for the 
TTRS52P transgene expression is unlikely to explain the sex difference in TTR 
concentrations. 
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Although TTR is not secreted as a glycoprotein, fraction of the circulating 
hTTR was found to be N-glycosylated in the serum of hTTRS52P transgenic 
mice. N-glycosylation is a mainly co-translational, highly conserved process 
characterized by addition of a sugar complex to the nascent polypeptide chain 
as soon as it is translocated into ER, with functions such as accelerating 
protein folding  (Jitsuhara et al., 2002), increasing protein stability (Culyba et 
al., 2011, Shental-Bechor and Levy, 2008) and reducing aggregation by 
increasing solubility (Sato et al., 2012). Proteins that are correctly folded and 
assembled pass the ER-quality control system and are trafficked to Golgi 
apparatus and their final destination through the secretory pathway. Proteins 
that are not folded correctly enter a process called endoplasmic reticulum-
associated degradation (ERAD) (Lippincott-Schwartz et al., 1988, McCracken 
and Brodsky, 1996). ERAD facilitates the translocation of proteins targeted for 
degradation from ER into cytosol, where these proteins enter the ubiquitin-
proteasome machinery and are degraded (Baldridge and Rapoport, 2016, 
Vembar and Brodsky, 2008). Most of secreted proteins are glycoproteins and 
the glycosylation pattern and N-glycan interactions play an important role in 
recognition of the protein folding status in the ER (Liu et al., 1999, Helenius 
and Aebi, 2004, Kapoor et al., 2004). ER-quality control of non-glycosylated 
proteins is not that well characterised yet. Recently, studies done by Sato et 
al. on TTR as an example of non-glycosylated protein, whose pathological 
variants escape the ER-quality control and aggregate into amyloid fibrils in 
the extracellular spaces, provided an insight into the process of ER-quality 
control and ERAD of non-glycosylated proteins (Sato et al., 2012). It was 
shown that unfolding of unstable TTR variants (D18G, V30M, L55P) exposes 
a cryptic N-glycosylation site near the C terminus at the asparagine side chain 
at the position 98 of TTR and that N-glycan is transferred to TTR post-
translationally. The authors suggest that this may increase its solubility and 
prevent aggregation of the aggregation-prone variant in the ER in order to 
maintain cellular homeostasis (Sato et al., 2012). Further it was shown that 
post-translational N-glycosylation of TTR is the molecular switch that targets 
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the misfolded protein for degradation by proteasomes (Sato et al., 2012). 
N-glycosylated TTR was detected in serum of the hTTRS52P transgenic mice 
presented in this project. In consistency with the finding presented here, it 
was recently reported that N-glycosylated TTR was detected in human 
plasma of TTRV30M carriers as well as in plasma of hTTRV30M transgenic mice 
(Teixeira and Saraiva, 2013). Thus it seems that the TTR variants escape 
from the ER-quality control and ERAD systems with mechanisms not known 
yet. 
In summary, transgenic mice expressing a highly amyloidogenic human 
TTRS52P have been successfully generated. These mice present with high 
plasma levels of the human TTR, one of the pre-requisites of amyloid 
formation in vivo. Moreover, fraction of the hTTR in serum of the transgenic 
mice was found to be N-glycosylated, a feature recently detected in human 
plasma of V30M variant carriers (Teixeira and Saraiva, 2013), suggesting that 
a fraction of the human protein in these mice has escaped ER-associated 
degradation, a quality control mechanism that prevents secretion of misfolded 
proteins. This result indicates that TTRS52P in the transgenic mice has the 
propensity to misfold and potentially to form amyloid.  
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6 Assessment of amyloid deposition in 
hTTR
S52P
 transgenic mice 
 
6.1 Introduction 
Cardiac involvement is the leading cause of morbidity and mortality in 
amyloidosis (Falk, 2005, Dubrey et al., 1998). It is characterised by 
extracellular amyloid infiltration throughout the heart, with amyloid deposits 
occurring in ventricles and atria, within the vessels, in the valves and in the 
conduction system, causing restrictive cardiomyopathy and progressing to 
heart failure. Cardiac amyloidosis occurs in about 50 % of patients with AL 
amyloidosis (Merlini, 2012), is a dominant feature in patients with wild-type 
ATTR amyloidosis and hereditary systemic ATTR amyloidosis, although in the 
most common type of hereditary systemic amyloidosis associated with 
TTRV30M, cardiac involvement is not so common (Rapezzi et al., 2006, Pinney 
et al., 2013b, Rapezzi et al., 2010), and is often found in AApoAI amyloidosis 
(Mucchiano et al., 2001, Eriksson et al., 2009). In AA amyloidosis, amyloid 
cardiomyopathy is rare, affecting about 1 % of AA patients (Lachmann et al., 
2007). 
In non-hereditary cardiac ATTR amyloidosis, which results from deposition of 
wild-type TTR as amyloid, the prevalence of the disease increases with age. 
In post-mortem analyses, wild-type TTR cardiac amyloid was found in 25 % of 
individuals over the age of 85, with moderate or severe deposits in >5 % 
(Tanskanen et al., 2008). Such findings suggest that cardiac ATTR 
amyloidosis is much more common than is currently diagnosed and that many 
older people with cardiac ATTR amyloidosis are not identified, perhaps 
because the cause of heart failure is not thoroughly investigated. 
In hereditary ATTR amyloidosis, associated with ~85 pathogenic TTR 
variants (Benson and Kincaid, 2007, Dubrey et al., 2011), amyloid can occur 
in various organs and tissues. In most cases of hereditary ATTR amyloidosis, 
the hallmark is peripheral and autonomic nerve neuropathy associated with 
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clinical syndrome of familial amyloid polyneuropathy, in which cardiac 
amyloidosis can occur at a later stage of the disease (Rapezzi et al., 2010). 
Some TTR variants are associated exclusively with familial amyloid 
cardiomyopathy. Among the TTR variants predominantly targeting the heart, 
TTRV122I is the most common type affecting 3-4 % of people of Afro-
Caribbean descent (Jacobson et al., 1997, Yamashita et al., 2005, Buxbaum 
et al., 2010). It is estimated that about 1.5 million African Americans carry the 
TTRV122I mutation and are at risk of development of ATTR cardiac 
amyloidosis (Ruberg and Berk, 2012), which is clinically indistinguishable 
from the wild-type non-hereditary amyloidosis. 
Diagnosis of cardiac amyloidosis is usually delayed but increasing availability 
of cardiovascular magnetic resonance imaging in recent years has led to a 
greater recognition of the disease (Patel and Hawkins, 2015). Currently, 
about 100 new British patients per year are diagnosed in the NHS National 
Amyloidosis Centre (NAC) and the reported pattern of referral in the last 20 
years showed that wild-type ATTR amyloidosis-related cardiomyopathy has 
increased greatly (from 0.2 % to more than 6.4 %) (Wechalekar et al., 2016). 
The prognosis for patients with cardiac amyloidosis is poor, although with new 
emerging treatment strategies the survival has been improved. AL cardiac 
amyloidosis has the worst prognosis with more than 50 % mortality within 6 
months of the initial diagnosis (Kumar et al., 2011), while ATTR cardiac 
amyloidosis prognosis is ~3 to 5 years (Ruberg et al., 2012, Pinney et al., 
2013b). Interestingly, cardiac ATTR amyloidosis is remarkably gender-
specific and almost exclusively occurs in men (Rapezzi et al., 2008, Pinney et 
al., 2013b, Ng et al., 2005). The reasons for this gender difference are not 
known. 
Amyloid fibrils isolated from hereditary ATTR amyloidosis patients 
heterozygous for a TTR mutation showed that cardiac deposits (Dwulet and 
Benson, 1986) and deposits in the vitreous body of eye (Thylen et al., 1993) 
consist of wild-type as well as mutated TTR and the mutated protein makes 
up about two thirds of the ATTR amyloid deposits. Moreover, a major 
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component of the myocardial and vitreous ex vivo ATTR amyloid fibrils is a 
49-127 C-terminal fragment of the TTR monomer, regardless of the presence 
or position of any amyloidogenic mutation (Dwulet and Benson, 1986, Thylen 
et al., 1993, Bergstrom et al., 2005). These findings and follow up in vitro 
experiments suggested that a selective proteolytic cleavage between amino 
acids 48-49 of TTR may have an important role in destabilising the TTR 
tetramers (Marcoux et al., 2015, Mangione et al., 2014). Destabilisation of the 
TTR tetramer leads to a release of the 49-127 truncated monomers that are 
highly amyloidogenic (Marcoux et al., 2015). 
To date, despite many attempts there is no animal model of cardiac 
amyloidosis suitable for studying the molecular mechanism of the disease, for 
testing emerging innovative treatments of cardiac amyloidosis, or new 
diagnostic imagining technologies.  
In the previous chapter, generation and establishment of a new transgenic 
model expressing a highly amyloidogenic human TTRS52P variant have been 
presented. Amyloidosis caused by TTRS52P is a devastating disease with a 
clinical picture of rapidly progressing amyloid cardiomyopathy (Booth et al., 
1993, Mangione et al., 2014). Amyloid deposits are also found in the nerves, 
causing autonomic dysfunction and peripheral neuropathy, in thyroid, spleen, 
liver, kidneys and adrenal glands. ATTRS52P amyloidosis typically leads to 
death in early to mid-adult life, within five years of the onset of symptoms 
(Booth et al., 1993, Stangou et al., 1998, Mangione et al., 2014). The clinical 
phenotype is among the most severe ever described in ATTR amyloidosis. 
The S52P variant TTR is the least stable known variant (Marcoux et al., 2015, 
Mangione et al., 2014). In vitro experiments examining the amyloidogenic 
potential of wild-type TTR and five of the naturally occurring variants – 
TTRS52P, TTRV30M, TTRL55P, TTRV122I and TTRT119M demonstrated that none of 
the full-length proteins formed amyloid fibrils under stirring in physiological 
conditions (Mangione et al., 2014, Marcoux et al., 2015). However, the wild-
type protein and all the variants except the non-amyloidogenic TTRT119M were 
susceptible to trypsin cleavage with the 49-127 fragment being released from 
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the proteolysed tetramer in each case and  typical Congophilic fibrillar 
structures were rapidly formed (Marcoux et al., 2015). The non-pathogenic 
TTRT119M, expression of which actually protects carriers of amyloidogenic 
mutations from developing amyloidosis (Hammarstrom et al., 2001), was 
resistant to proteolysis and did not form amyloid (Marcoux et al., 2015). The 
TTRS52P was substantially more susceptible to cleavage that all the other 
variants and wild-type TTR (Marcoux et al., 2015). 
The susceptibility to proteolytic cleavage of the TTRS52P and other 
amyloidogenic variants and the effect of cleavage on conversion to amyloid 
provide strong evidence that cleavage precedes amyloid formation and is a 
key pathogenic event, as cleaved TTR is found in cardiac amyloid. Although it 
is not known yet which protease(s) catalyse the cleavage of TTR, nor the 
anatomical site at which this cleavage occurs, the hypothesis was that 
expression of the extremely amyloidogenic TTRS52P in mice may lead to a 
new model of cardiac ATTR amyloidosis. The hTTRS52P transgenic mice 
generated and described in the previous chapter present with high serum 
levels of the human TTR, one of the pre-requisites of amyloid formation in 
vivo, with evidence that fraction of the human protein in these mice has 
escaped ER-associated degradation, a quality control mechanism that 
prevents secretion of misfolded proteins suggesting propensity of the TTRS52P 
in the transgenic mice to misfold and potentially form amyloid.  
The aims in support of the hypothesis were to assess spontaneous amyloid 
deposition in the human TTRS52P transgenic mice in the heart and other 
tissues in which ATTR amyloid deposition may occur in ATTR amyloidosis, by 
histological analysis using Congo red staining and immunohistochemistry. 
hTTRS52P transgenic mice on both, wild-type murine TTR and TTR-KO 
backgrounds were analysed to evaluate the effect of the mouse TTR on 
human TTR deposition and amyloid formation in the mice. The possibility of 
accelerating amyloid deposition by seeding the mice with amyloid-enhancing 
factor of ATTR amyloid tissue and/or amyloid fibrils was also investigated, 
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together with determining whether any cleavage of the S52P variant could be 
detected in the tissues of the transgenic mice. 
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6.2 Results 
 
6.2.1 Assessment of spontaneous amyloid deposition 
in hTTR
S52P
 transgenic mice 
In humans, the TTRS52P variant is responsible for the most severe known 
ATTR amyloidosis with onset as early as the third decade. It is characterised 
by widespread ATTR amyloid deposits with prominent cardiac involvement 
and with deposits also found in autonomic and peripheral nerves, liver, 
spleen, kidney, adrenal and thyroid (Mangione et al., 2014).  
In the hTTRS52P transgenic mice, spontaneous amyloid deposition was 
assessed by Congo red staining of sections of fixed and wax embedded 
tissue and light microscopy with polarised light. Because of the extremely 
aggressive amyloidogenicity of the TTRS52P in patients, and the potential for 
deposition in many sites, the assessment involved a wide variety of tissues. 
The examined tissues were liver, heart, spleen, kidney, lung, tongue, 
stomach, gut, thyroid, submandibular gland, sublingual gland, parotid gland, 
adrenal, lacrymal gland, sciatic nerve, trigeminal ganglion, brain, skin, muscle 
and fat in hTTRS52P transgenic mice on both, wild-type and TTR-KO 
backgrounds. Because of the age-dependence in amyloid deposition typical 
for amyloidosis, the analysis was performed on mice 4 weeks old up to 24 
months old. Age-matched non-transgenic wild-type and TTR-KO mice were 
also analysed as negative controls.  
Although the transgenic mice had high levels of the aggressively 
amyloidogenic TTRS52P variant circulating in the plasma, no spontaneous 
amyloid deposition was detected in the transgenic mice, despite a thorough 
search of extensive tissue samples. The results of these analyses are 
summarised in Table 6.1. 
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 Spontaneous amyloid deposition 
Age 1-2 months 6-12 months 12-18 months 18-24 months 
Genotype T/WT T/KO T/WT T/Het T/KO T/WT T/KO T/WT T/KO 
Heart 0/1 0/3 0/4 0/2 0/2 0/4 0/2 0/5 - 
Liver 0/1 0/3 0/4 0/2 0/2 0/4 0/2 0/5 - 
Spleen 0/1 0/3 0/4 0/2 0/2 0/4 0/2 0/5 - 
Kidney 0/1 0/3 0/4 0/2 0/2 0/4 0/2 0/5 - 
Lung 0/1 0/3 0/4 0/2 - 0/3 - 0/5 - 
Tongue 0/1 0/3 0/3 - 0/1 0/3 0/2 0/5 - 
Adrenal 0/1 0/3 0/4 0/2 0/1 0/3 - 0/5 - 
Brain - 0/3 0/4 - 0/1 0/3 - 0/5 - 
Trigeminal g. - 0/3 - - - 0/3 - 0/5 - 
Sciatic nerve 0/1 0/3 0/4 0/2 0/1 0/4 0/2 0/5 - 
Thyroid - 0/1 0/4 0/2 0/1 0/3 - 0/5 - 
Salivary gland 0/1 0/3 0/4 0/2 0/1 0/3 - 0/5 - 
(Submandibular) - - 0/4 0/2 0/1 0/3 - 0/5 - 
(Sublingual) - - 0/4 - 0/1 0/3 - 0/5 - 
(Parotid) - - 0/4 0/2 0/1 0/3 - 0/5 - 
Gut 0/1 0/3 0/4 0/2 0/2 0/3 - 0/5 - 
Stomach 0/1 0/3 0/3 - 0/1 0/3 - 0/5 - 
Muscle - - 0/4 0/2 0/1 0/3 - 0/5 - 
Fat - - 0/4 0/2 0/1 0/4 - 0/5 - 
Skin - - 0/4 0/2 0/1 0/3 - 0/5 - 
Eye - 0/3 0/4 0/2 - 0/1 - - - 
Lacrymal gland - 0/3  - - - 0/2 - 0/5 - 
Sex of mice 0♂ 1♀ 2♂ 1♀ 0♂ 4♀ 0♂ 2♂ 2♂ 0♀ 4♂ 0♀ 1♂ 1♀ 2♂ 3♀ - 
 
 
Table 6.1: Analysis of spontaneous amyloid deposition in hTTRS52P transgenic 
mice 
Summary of tissue analysed by Congo red in hTTRS52P transgenic mice with both 
alleles of the murine TTR (T/WT), with one allele of the murine TTR (T/Het) and 
transgenic mice lacking the endogenous TTR (T/KO) at age groups 1-2 months old, 
6-12 months old, 12-18 months old and 18-24 months old. The samples are scored 
as number of mice with amyloid / number of mice analysed for each tissue analysed. 
Because the transgenic males have higher concentrations of circulating hTTR than 
females, the sex of analysed mice in each age group for each genotype is also 
stated. 
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6.2.2 TTR deposition in hTTR
S52P
 transgenic mice 
In ATTR amyloid patients, non-fibrillar deposits in early stages of disease 
have been identified (Sousa et al., 2001) suggesting that pre-amyloid forms of 
TTR may play a role in the pathogenesis of amyloidosis. Because no amyloid 
was found in the hTTRS52P transgenic mice, immunohistochemistry of wax 
embedded tissue was used to analyse TTR expression and TTR deposition in 
the transgenic mice on both, wild-type and TTR-KO background. 
In the transgenic mice, the TTRS52P variant is expressed in the liver and 
therefore TTR signal was expected in the liver only. Some signal 
corresponding to plasma TTR was also expected in the tissues, but a different 
pattern, or more intensive and localised signal in the extracellular space, 
would also result from TTR deposition, pre-fibrillar aggregation or small 
amounts of TTR amyloid. 
Because the anti-human TTR antibodies cross-reacted with denatured mouse 
TTR on Western blots, the specificity of Dako polyclonal anti-human TTR 
antibody (Table 2.3) to human TTR in fixed and wax embedded tissue was 
tested. Tissue of 6 months old transgenic mice on both wild-type and TTR-KO 
background (3 transgenic males and 1 transgenic female on TTR wild-type 
background, 2 transgenic males and 1 transgenic female on TTR-KO 
background) was immunostained together with tissues of 1 non-transgenic 
WT male and 1 non-transgenic TTR-KO male used as negative controls. 
No signal was detected in the tissues of non-transgenic WT or TTR-KO mice 
showing that the antibody did not react with the mouse TTR in the fixed tissue 
of wild-type mice and thus confirming the specificity of the antibody to human 
TTR. 
In the transgenic mice, strong human TTR signal was detected in the liver as 
expected. Notably, much stronger TTR signal was observed in the liver of six 
months old transgenic mice on wild-type background (n=4) in comparison 
with transgenic mice on TTR-KO background (n=3) and the observed TTR 
appeared to be localised intracellularly (Figure 6.1). 
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Figure 6.1: TTR localisation in the liver of hTTRS52P transgenic mice 
TTR signal in the liver was detected in 6-months old hTTRS52P transgenic mice 
(hTTRS52P-Tg) on both backgrounds, mouse TTR wild-type (mTTR-WT) and mouse 
TTR knock-out (mTTR-KO), with hTTRS52P-Tg/mTTR-WT mice (n=4) showing 
stronger TTR signal compared to hTTRS52P-Tg/mTTR-KO mice (n=3). TTR appears 
to be localised intracellularly in the hepatocytes. The Dako anti-human TTR antibody 
used for the immunohistochemical analysis was confirmed to be human TTR-specific 
in fixed and wax embedded tissue as no TTR reactivity was detected in 
non-transgenic mTTR-WT mice. Liver of non-transgenic mTTR-KO mouse was used 
as a negative control. The figure shows representative images of 6 months old mice. 
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In the heart of hTTRS52P transgenic mice, it was not possible to clearly 
distinguish whether the TTR signal observed on the muscle fibres of the heart 
originated from plasma TTR or whether the signal was due to genuine TTR 
deposition. However, some non-uniform concentration of signal was observed 
along the heart muscle fibres in the transgenic mice on both backgrounds. As 
expected, plasma TTR was detected within the blood vessels of the 
transgenic mice. (Figure 6.2). 
Immunohistochemistry of the kidneys of hTTRS52P transgenic mice suggested 
that TTR may be depositing around the glomeruli in the transgenics on 
TTR-KO background, whereas no TTR deposition was detected in the 
kidneys of the transgenics on wild-type background. As expected, plasma 
TTR was detected within the blood vessels of the transgenic mice. No signal 
was observed in the kidneys of non-transgenic mice (Figure 6.3). No TTR 
deposition was detected in the spleen of transgenic mice. Some background 
non-specific signal was observed in the spleen of transgenic mice as well as 
non-transgenic controls (Figure 6.4). 
Although none of the TTR deposits were Congophilic, these results 
suggested that TTR may be accumulating in extracellular spaces. This is 
consistent with reports of pre-fibrillar aggregates. 
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Figure 6.2: TTR localisation in the heart of hTTRS52P transgenic mice 
TTR signal in the heart was detected in 6-months old hTTRS52P transgenic mice 
(hTTRS52P-Tg) on both backgrounds, mouse TTR wild-type (mTTR-WT) and mouse 
TTR knock-out (mTTR-KO) by immunohistochemistry with Dako anti-human TTR 
antibody. The TTR signal in hTTRS52P-Tg/mTTR-KO mice (n=3) seemed more 
wide-spread than in hTTRS52P-Tg/mTTR-WT mice (n=4). TTR signal is also seen in 
blood vessels within the heart in the hTTRS52P-Tg/mTTR-WT mice, shown in the 
insert (400x). Heart of non-transgenic mTTR-WT mouse and non-transgenic 
mTTR-KO mouse were used as negative controls. The figure shows representative 
images of 6 months old mice. 
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Figure 6.3: TTR localisation in the kidney of hTTRS52P transgenic mice 
Immunohistochemistry of the kidney of hTTRS52P transgenic mice (hTTRS52P-Tg). 
TTR signal was detected in the hTTRS52P-Tg mice on TTR knock-out (mTTR-KO) 
background, notably around the glomeruli (G). Plasma TTR was observed within the 
blood vessels in transgenic mice on both backgrounds. Kidney of non-transgenic 
wild-type mouse (mTTR-WT) and non-transgenic mTTR-KO mouse were used as 
negative controls. The figure shows representative images of 
hTTRS52P-Tg/mTTR-WT (n=4) and hTTRS52P-Tg/mTTR-KO (n=3) mice. 
 
224 
 
 
 
Figure 6.4: TTR in the spleen of hTTRS52P transgenic mice 
Immunohistochemistry of the spleen of the hTTRS52P transgenic mice (hTTRS52P-Tg). 
No TTR signal was detected in the hTTRS52P-Tg mice as well as in the non-
transgenic controls. Some non-specific background staining was seen in the spleens 
of all mice analysed. The figure shows representative images of 
hTTRS52P-Tg/mTTR-WT (n=4) and hTTRS52P-Tg/mTTR-KO (n=3) mice. 
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Because amyloid deposition is time dependent, immunohistochemistry for 
hTTR was performed on tissues of 4-week old hTTRS52P transgenic mice on 
wild-type background (n=3) and compared with 22-months old hTTRS52P 
transgenic mice on wild-type background (n=3). Although in most cases the 
patterns of staining were broadly similar, some consistent differences were 
evident. The tissues analysed included heart, liver, kidney, spleen, salivary 
gland, tongue, lung, intestine, adrenal and sciatic nerve. As TTR is expressed 
in the liver, TTR signal was detected in the hepatocytes of young transgenic 
mice with the signal evenly distributed throughout the tissue. In the liver of 
aged mice, the pattern of expression was different from the young mice, with 
the TTR signal concentrated around portal veins. TTR signal was also 
detected in the muscle tissue of heart and tongue in both young and aged 
transgenic mice. However, in the aged mice, the TTR was concentrated 
around the blood vessels within heart and tongue. Similarly, in the kidney 
cortex, salivary gland and sciatic nerve, TTR signal was detected around 
blood vessels in the aged transgenic animals, whereas no TTR signal was 
detected in the equivalent sites in young transgenic mice. In the kidney, TTR 
signal was detected in the collecting ducts in both, the young and aged mice. 
Interestingly, TTR signal was observed in the kidney glomeruli in old 
transgenic mice on TTR-KO background but not in transgenic mice on wild-
type background. Some TTR signal was seen in the adrenal gland of young 
and aged transgenic mice but no difference in the signal was observed 
between young and aged animals. No TTR signal was seen in the intestine in 
either young or old mice. The results are shown in Figures 6.5 and 6.6. 
The increased TTR signal in aged transgenic mice was observed mostly 
around blood vessels, a site of amyloid deposition commonly observed in 
systemic amyloidosis. As the TTRS52P expression was confirmed exclusively 
in the liver, the observed increase in TTR signal in the analysed tissues 
suggested that with advancing age, the TTR was accumulating in the tissues, 
an observation consistent with very low levels of amyloid deposition and/or 
pre-fibrillar aggregation. 
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Figure 6.5: Comparison of hTTR localisation between young and old hTTRS52P 
transgenic mice 
Immunohistochemistry of hTTRS52P transgenic mice on wild-type background using 
Dako anti-human TTR antibody. Representative images of three 4-week old 
transgenic mice and three 22-months old transgenic mice are shown. In the aged 
mice, strong hTTR signal was detected around portal veins (PV). In the kidney, 
hTTR was observed in the collecting ducts (CD) in young and aged mice but no TTR 
signal was observed in the glomeruli (G). Strong TTR signal was detected around 
blood vessels (BV) in the heart of aged mice. 
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Figure 6.6: Comparison of hTTR localisation between young and old hTTRS52P 
transgenic mice 
Immunohistochemistry of hTTRS52P transgenic mice on wild-type background using 
Dako anti-human TTR antibody. Representative images of three 4-week old 
transgenic mice and three 22-months old transgenic mice are shown. Strong TTR 
signal was detected in the muscle tissue of the tongue in both, young and aged 
transgenic mice, but the aged mice also showed hTTR localisation around the blood 
vessels (BV) in the tongue. Some hTTR is also seen around blood vessels in the 
sciatic nerve (SN). 
 
228 
 
6.2.3 Priming of amyloid deposition in hTTR
S52P
 
transgenic mice 
Although no spontaneous ATTR amyloid deposition was observed in the 
hTTRS52P transgenic mice despite their high concentration of the TTRS52P in 
the circulation, TTR accumulation in various organs including the heart, a 
prominent site of ATTR deposition in the TTRS52P patients, was observed. The 
TTR deposits may represent non-Congophilic pre-fibrillar aggregates of the 
amyloidogenic variant. In the process of amyloid formation, there is always a 
lag phase between the first appearance of the potentially amyloidogenic 
protein and the deposition of clinically significant amyloid. In mice, the lag 
phase can be significantly shortened by administration of an extract of tissue 
containing amyloid, called amyloid-enhancing factor (AEF) (Willerson et al., 
1969). AEF serves to seed fibril formation and accelerates amyloid deposition 
of the respective amyloid fibril precursor protein (Axelrad et al., 1982). 
Amyloid fibrils extracted from amyloidotic tissue and in vitro prepared amyloid 
fibrils have shown to have the same effect in vivo as AEF (Ganowiak et al., 
1994, Johan et al., 1998). Therefore, the possibility of priming the TTR 
amyloid deposition in the hTTRS52P transgenic mice by seeding the transgenic 
mice with an extract of ATTRS52P amyloidotic spleen and/or ex vivo-isolated 
ATTRS52P amyloid fibrils was investigated.  
Spleen from an ATTRS52P amyloidosis patient with abundant infiltration of 
amyloid was provided by Dr Glenys Tennent (Centre for amyloidosis and 
acute phase proteins, UCL) from Amyloid Research Tissue bank and used to 
prepared tissue extract for AEF-injections. Ex-vivo ATTRS52P fibrils were 
isolated from the spleen by Dr Patrizia Mangione (Centre for amyloidosis and 
acute phase proteins, UCL). 
 
3 experimental cohorts of amyloid-seeded mice were set up to evaluate the 
possibility of accelerating amyloid deposition in the hTTRS52P transgenic mice: 
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hTTRS52P Cohort I was injected with 10 µg of human ATTRS52P ex vivo-
isolated amyloid fibrils;  
hTTRS52P Cohort II was injected with ATTRS52P AEF prepared from human 
spleen;  
hTTRS52P Cohort III was injected with the combination of both, 10 µg of 
human ATTRS52P ex vivo-isolated amyloid fibrils followed by ATTRS52P AEF. 
Outline of the seeding experiments is shown in Figure 6.7. 
Similarly like in the hβ2mD76N project (section 4.2.5.2), whole body retention of 
intravenously administered radiolabelled 125I-hSAP was carried out in all 
experimental mice to monitor amyloid deposition in vivo (Hawkins et al., 
1988). The injections and counts of radiolabeled material were performed by 
Dr Stephan Ellmerich (Centre for amyloidosis and acute phase proteins, 
UCL). The baseline level of 125I-hSAP retention 48 hours after administration 
of the radiolabelled tracer in untreated control mice was <10 %. 
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Figure 6.7: Timeline of seeding experiments of hTTRS52P transgenic mice 
3 cohorts of hTTRS52P transgenic and control mice were set up to prime amyloid 
deposition by intravenous injections of 10 µg of human ATTRS52P ex vivo-isolated 
amyloid fibrils (I), ATTRS52P spleen extract AEF (II) and combination of both, ex-vivo 
fibrils and AEF (III). The timescale indicates numbers of weeks. Amyloid seeding 
injections (red arrow), blood sample collection (green arrow), 125I-human SAP whole 
body retention assay (blue arrow) and time-point when seeded animals were taken 
for analysis (black arrow) with the number of animals killed at each time point shown 
in the brackets are indicated. 
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hTTRS52P Cohort I 
Cohort I consisted of transgenic (T) and non-transgenic mice on mTTR wild-
type background (WT), mTTR heterozygous background (Het) and TTR-KO 
background (KO). The mice were seeded by intravenous injection of 10 µg of 
human ATTRS52P ex vivo-isolated amyloid fibrils when they were 3-4 months 
old. The group of seeded mice was as follows: 1 T/WT male, 1 T/WT female, 
1 T/Het male, 1 T/Het female, 2 T/KO males, 2 T/KO females, with 2 WT 
females and 1 KO male as non-transgenic controls. Blood samples were 
collected from all mice prior and 72 hours after the fibril injections to measure 
plasma SAA concentration to check that the mice did not develop persistent 
inflammation after the administration of the fibrils. In all mice, no difference in 
the measured concentrations of SAA was seen between pre- and post-fibril 
injection time-points (39.43 ± 71.5 µg/ml (n=14), 23.36 ± 43.3 µg/ml (n=14), 
respectively). 14 weeks after the seeding, the results of the 125I-hSAP 
retention assay did not indicate amyloid deposition in the animals. 18 weeks 
after the seeding, two transgenic females (T/Het and T/KO) and one T/WT 
male were killed, the tissues were harvested and analysed by histochemistry 
for amyloid deposition. The analysed tissues included: liver, heart, kidney, 
spleen, tongue, lung, sciatic nerve, adrenal, thyroid, salivary gland dissected 
into submandibular, sublingual and parotid glands, lachrymal gland, intestine, 
stomach, brain, eye, optic nerve, trigeminal ganglion, skin, muscle and fat. 
Amyloid was found in the tongue of the seeded transgenic male mouse. No 
amyloid was found in the tissues of transgenic females. The remaining mice 
were kept and monitored by 125I-hSAP whole body retention at weeks 32 and 
45 after seeding with no amyloid detected by this assay. The experiment was 
terminated 48 weeks after seeding and liver, heart, kidney, spleen, tongue, 
sciatic nerve and adrenal were collected for analysis. Congo red staining and 
polarized light microscopy were used for amyloid detection. In the three 
remaining fibril-seeded transgenic males, amyloid was detected in the heart 
(3/3) and tongue (2/3) (Figure 6.8). One T/KO female also had amyloid in the 
heart and tongue. In one T/WT female, no amyloid was detected. No amyloid 
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was detected in seeded non-transgenic controls. The numbers and genotypes 
of the experimental mice, tissues analysed and the outcome of the 
experiment are summarised in Table 6.2. 
 
 
 
 
Figure 6.8: Amyloid deposition in fibril-seeded mice (Cohort I) 
Amyloid deposits were detected in the heart and the tongue of fibril-seeded hTTRS52P 
transgenic mice by Congo red. Amyloid (arrows) is stained red and exhibits green 
birefringence under polarised light. (The figure shows 14 months old transgenic male 
on mTTR-KO background analysed 11 months after seeding.) 
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 Cohort I - Amyloid deposition 
Genotype T/WT T/Het T/KO -ve/KO -ve/WT 
Sex ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ 
Heart 0/1 0/1 1/1 0/1 2/2 1/2 0/1 0/2 
Tongue 1/1 0/1 1/1 0/1 1/1 1/2 0/1 0/2 
Liver 0/1 0/1 0/1 0/1 0/2 0/2 0/1 0/2 
Kidney 0/1 0/1 0/1 0/1 0/2 0/2 0/1 0/2 
Spleen 0/1 0/1 0/1 0/1 0/2 0/2 0/1 0/2 
Sciatic nerve 0/1 0/1 0/1 0/1 0/2 0/2 0/1 0/2 
Adrenal 0/1 0/1 0/1 0/1 0/2 0/2 0/1 0/2 
Brain 0/1 - - 0/1 - 0/1 - - 
Trigeminal g. 0/1 - - 0/1 - 0/1 - - 
Lung 0/1 - - 0/1 - 0/1 - - 
Thyroid 0/1 - - 0/1 - 0/1 - - 
Salivary gland 0/1 - - 0/1 - 0/1 - - 
(Submandibular) 0/1 - - 0/1 - 0/1 - - 
(Sublingual) 0/1 - - 0/1 - 0/1 - - 
(Parotid) 0/1 - - 0/1 - 0/1 - - 
Intestine 0/1 - - 0/1 - 0/1 - - 
Stomach 0/1 - - 0/1 - 0/1 - - 
Muscle 0/1 - - 0/1 - 0/1 - - 
Fat 0/1 - - 0/1 - 0/1 - - 
Skin 0/1 - - 0/1 - 0/1 - - 
Eye 0/1 - - 0/1 - 0/1 - - 
Optic nerve 0/1 - - 0/1 - 0/1 - - 
Lacrymal gland 0/1 - - 0/1 - 0/1 - - 
 
 
Table 6.2: Cohort I – Primed amyloid deposition in hTTRS52P transgenic mice 
Summary of tissues analysed by Congo red in hTTRS52P transgenic (T) mice on 
mTTR wild-type (WT), mTTR heterozygous (Het) and mTTR-KO background (KO) 
seeded with 10 µg of human ATTRS52P ex vivo-isolated amyloid fibrils. Amyloid 
deposition was observed in all 4 seeded transgenic males and in 1 seeded 
transgenic female. The amyloid deposits were localised in the heart and tongue. 3 
non-transgenic controls were injected with the fibrils as negative controls. The 
samples are scored as number of mice with amyloid / number of mice analysed for 
each tissue analysed. 
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hTTRS52P Cohort II 
Cohort II consisted of transgenic (T) and non-transgenic mice on mTTR wild-
type background (WT), mTTR heterozygous background (Het) and TTR-KO 
background (KO). 6-8 months old mice were intravenously injected with 200 
µl of amyloid enhancing factor (AEF) prepared from a spleen of an ATTRS52P 
amyloidosis patient (AEF). The group of seeded mice was as follows: 3 T/WT 
males, 2 T/WT females, 3 T/Het males, 2 T/Het females, 3 T/KO males, 1 
T/KO female and 2 KO males and 3 KO females as non-transgenic controls. 
Blood samples were collected from all mice prior and 72 hours after the AEF 
injections to measure plasma SAA levels concentration which showed that 
the mice did not develop persistent inflammation after the administration of 
the AEF. 14 weeks after the seeding, the results of the 125I-hSAP retention 
assay did not indicate amyloid deposition in the animals. 17 weeks after the 
seeding, one T/WT male and one T/KO female were killed and the tissues 
were harvested and analysed by histochemistry for amyloid deposition. The 
analysed tissues included: liver, heart, kidney, spleen, tongue, lung, sciatic 
nerve, adrenal, thyroid, salivary gland dissected into submandibular, 
sublingual and parotid glands, lachrymal gland, intestine, stomach, brain, eye, 
optic nerve, trigeminal ganglion, skin, muscle and fat. Amyloid was detected 
in the heart and tongue of the seeded transgenic male, no amyloid was 
detected in the T/KO seeded female. 
27 weeks after the AEF injection, the remaining mice were analysed with 125I-
hSAP whole body retention and none of the mice showed retention over the 
baseline 10 %. At week 30 after the AEF, the experiment was terminated, all 
mice were killed and heart, liver, kidney, spleen, tongue and sciatic nerve 
were collected for analysis. Congo red staining and polarized light microscopy 
were used for amyloid detection. Of the 9 hTTRS52P transgenic males seeded 
with AEF, 8 had amyloid in the heart and 8 had amyloid in the tongue (Figure 
6.9). 2 of the 5 hTTRS52P transgenic females seeded with AEF had amyloid in 
the tongue. No amyloid was detected in the 5 non-transgenic mice seeded 
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with AEF. The numbers and genotypes of the experimental mice, tissues 
analysed and the outcome of the experiment are summarised in Table 6.3. 
 
 
 
 
Figure 6.9: Amyloid deposition in AEF-seeded mice (Cohort II) 
Amyloid deposits were detected in the heart and the tongue of AEF-seeded 
hTTRS52P transgenic mice by Congo red. Amyloid (arrows) is stained red and exhibits 
green birefringence under polarised light. (The figure shows the heart of a 14 months 
old transgenic male on mTTR-KO background analysed 7 months after seeding, and 
the tongue of a 10 months old old transgenic male on wild-type background analysed 
4 months after seeding). 
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 Cohort II – Amyloid deposition 
Genotype T/WT T/Het T/KO -ve/KO -ve/KO 
Sex ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ 
Heart 3/3 0/2 3/3 0/2 2/3 0/1 0/2 0/3 
Tongue 3/3 2/2 2/3 0/2 3/3 0/1 0/2 0/3 
Liver 0/3 0/2 0/3 0/2 0/3 0/1 0/2 0/3 
Kidney 0/3 0/2 0/3 0/2 0/3 0/1 0/2 0/3 
Spleen 0/3 0/2 0/3 0/2 0/3 0/1 0/2 0/3 
Sciatic nerve 0/3 0/2 0/3 0/2 0/3 0/1 0/2 0/3 
Adrenal 0/3 0/2 0/3 0/2 0/3 0/1 0/2 0/3 
Brain 0/1 - - - - - - - 
Trigeminal g. 0/1 - - - - - - - 
Lung 0/1 - - - - 0/1 - - 
Thyroid 0/1 - - - - - - - 
Salivary gland 0/1 - - - - 0/1 - - 
(Submandibular) 0/1 - - - - - - - 
(Sublingual) 0/1 - - - - - - - 
(Parotid) 0/1 - - - - - - - 
Intestine 0/1 - - - - 0/1 - - 
Stomach 0/1 - - - - 0/1 - - 
Muscle 0/1 - - - - 0/1 - - 
Fat 0/1 - - - - 0/1 - - 
Skin 0/1 - - - - - - - 
Eye 0/1 - - - - - - - 
Optic nerve 0/1 - - - - - - - 
Lacrymal gland 0/1 - - - - 0/1 - - 
 
 
Table 6.3: Cohort II – Primed amyloid deposition in hTTRS52P transgenic mice 
Summary of tissues analysed by Congo red in hTTRS52P transgenic (T) mice on 
mTTR wild-type (WT), mTTR heterozygous (Het) and mTTR-KO background (KO) 
seeded with ATTRS52P spleen extract (AEF). Amyloid deposition was observed in all 
9 seeded transgenic males and 2 seeded transgenic females. The amyloid deposits 
were localised in the heart and tongue. 5 non-transgenic controls were also injected 
with the fibrils as negative controls. The samples are scored as number of mice with 
amyloid / number of mice analysed for each tissue analysed. 
 
 
hTTRS52P Cohort III 
In cohort III, 3-4 months old transgenic (T) and non-transgenic mice on mTTR 
wild-type background (WT), mTTR heterozygous background (Het) and TTR-
KO background (KO) were intravenously injected with combination of 10 µg of 
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human ATTRS52P ex vivo-isolated amyloid fibrils, and ATTRS52P spleen AEF. 
The experimental group consisted of 1 T/WT male, 1 T/WT female, 1 T/Het 
male, 2 T/Het females, 3 T/KO males, 1 T/KO female and 2 wild-type mice 
and 2 KO mice as non-transgenic controls. The mice were seeded at week 1 
with 10 µg of human ATTRS52P ex vivo-isolated amyloid fibrils and bled prior 
and 72 hours after the fibril injections to measure plasma SAA levels 
concentration. The SAA concentrations before and after the seeding (33.2 ± 
38.6 µg/ml (n=13) and 30.9 ± 31.0 µg/ml (n=13), respectively) showed that 
the mice did not develop prolonged inflammation after the administration of 
the fibrils. 14 weeks after the seeding, 125I-hSAP retention did not indicate 
amyloid deposition in the animals. At week 17, the mice were seeded again 
but this time with ATTRS52P spleen AEF. Again, blood samples prior and 72 
hours after the AEF injections were collected to measure SAA concentration 
which confirmed that the mice were not persistently inflamed after the 
seeding, with the SAA concentrations 22.7 ± 31.5 µg/ml (n=13) prior to AEF 
seeding and 40.8 ± 38.2 µg/ml (n=13) after AEF seeding. At week 32, 125I-
hSAP retention did not indicate amyloid deposition in the animals. One 
double-seeded T/KO male was taken for analysis at week 34. The tissue 
analysed included : liver, heart, kidney, spleen, tongue, lung, sciatic nerve, 
adrenal, thyroid, salivary gland dissected into submandibular, sublingual and 
parotid glands, lachrymal gland, intestine, stomach, brain, eye, optic nerve, 
trigeminal ganglion, skin, muscle and fat. Amyloid deposits were detected in 
the heart and tongue by Congo red staining. The amounts of amyloid 
observed in the tissue did not differ from the amounts of amyloid found in the 
seeded males in the other two cohorts. 
45 weeks from the start of the experiment, the remaining mice were analysed 
with125I-hSAP whole body retention and none of the mice showed retention 
over the baseline 10 %. At week 48, all 12 remaining mice were killed and 
heart, tongue, liver, kidney, spleen and sciatic nerve were collected for 
analysis. Congo red staining and polarized light microscopy were used for 
amyloid detection. All 4 seeded transgenic males had amyloid deposits in the 
238 
 
heart and the tongue (Figure 6.10) and 1 of the 4 seeded transgenic females 
had amyloid in the tongue only. No amyloid was detected in the seeded non-
transgenic controls. The data are summarised  in Table 6.4. 
 
 
 
 
Figure 6.10: Amyloid deposition in double-seeded mice (Cohort II) 
Amyloid deposits were detected in the heart and the tongue of double-seeded 
hTTRS52P transgenic mice by Congo red. Amyloid is stained red and exhibits 
orange/green birefringence under polarised light. (The figure shows the heart and 
the tongue of a 13 months old transgenic male on mTTR-KO background analysed 
10 months after the first seeding). 
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 Cohort III – Amyloid deposition 
Genotype T/WT T/Het T/KO -ve/WT -ve/KO 
Sex ♂ ♀ ♂ ♀ ♂ ♀ ♂+♀ ♂+♀ 
Heart 1/1 0/1 1/1 0/2 3/3 0/1 0/2 0/2 
Tongue 1/1 1/1 1/1 0/2 3/3 0/1 0/2 0/2 
Liver 0/1 0/1 0/1 0/2 0/3 0/1 0/2 0/2 
Kidney 0/1 0/1 0/1 0/2 0/3 0/1 0/2 0/2 
Spleen 0/1 0/1 0/1 0/2 0/3 0/1 0/2 0/2 
Sciatic nerve 0/1 0/1 0/1 0/2 0/3 0/1 0/2 0/2 
Adrenal 0/1 0/1 0/1 0/2 0/3 0/1 0/2 0/2 
Brain - - - - 0/1 - - - 
Trigeminal g. - - - - 0/1 - - - 
Lung - - - - 0/1 - - - 
Thyroid - - - - 0/1 - - - 
Salivary gland - - - - 0/1 - - - 
(Submandibular) - - - - 0/1 - - - 
(Sublingual) - - - - 0/1 - - - 
(Parotid) - - - - 0/1 - - - 
Intestine - - - - 0/1 - - - 
Stomach - - - - 0/1 - - - 
Muscle - - - - 0/1 - - - 
Fat - - - - 0/1 - - - 
Skin - - - - 0/1 - - - 
Eye - - - - 0/1 - - - 
Optic nerve - - - - 0/1 - - - 
Lacrymal gland - - - - 0/1 - - - 
 
 
Table 6.4: Cohort III – Primed amyloid deposition in hTTRS52P transgenic mice 
Summary of tissues analysed by Congo red in hTTRS52P transgenic (T) mice on 
mTTR wild-type (WT), mTTR heterozygous (Het) and mTTR-KO background (KO) 
seeded with combination of ATTRS52P ex-vivo fibrils and ATTRS52P spleen extract 
(AEF). Amyloid deposition was observed in all 5 seeded transgenic males and 1 
seeded transgenic female with the amyloid deposits localised in the heart and 
tongue. 4 non-transgenic controls were also seeded as negative controls. The 
samples are scored as number of mice with amyloid / number of mice analysed. 
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6.2.4 Nature of the amyloid deposits in the hTTR
S52P
 
transgenic mice 
To identify the amyloid protein co-localised with the amyloid deposits of the 
hTTRS52P transgenic mice, adjacent sections of the tissues were analysed by 
immunohistochemistry in all seeded transgenic mice. The amyloid was 
expected to be human ATTR amyloid and for its identification Dako anti-
human TTR antibody was used. In old or inflamed mice, amyloid deposits of 
ApoAII or SAA, respectively, can be naturally formed (Higuchi et al., 1991b, 
Hoffman et al., 1984). To analyse whether this was the case in the hTTRS52P 
transgenic mice, the sections were also immunostained with anti-mouse 
ApoAII antibody and anti-mouse SAA antibody. One set of the adjacent tissue 
sections of all seeded transgenic mice was stained with Congo red for exact 
co-localisation of the amyloid with the amyloid protein. 
In the amyloidotic hTTRS52P transgenic mice, in each case (e.g. Figures 6.11 
and 6.12) the amyloid in the heart and the tongue was found to be 
immunoreactive with anti-human TTR antiserum, and negative when stained 
for ApoAII or for SAA. This shows that the mice have ATTR amyloidosis. 
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Figure 6.11: Typing of amyloid deposits in the heart of seeded hTTRS52P 
transgenic mice 
Amyloid deposits in the heart of seeded hTTRS52P transgenic mice were localised 
with Congo red staining, exhibiting green birefringence under polariser light. Co-
localisation of the amyloid with human TTR, mouse ApoAII and mouse SAA was 
analysed on adjacent sections. Positive immunohistochemical staining for human 
TTR and negative immuno-staining for mApoAII and mSAA confirmed ATTR amyloid 
deposits in the hearts of amyloidotic mice. 
 
 
242 
 
 
 
Figure 6.12: Typing of amyloid deposits in the tongue of seeded hTTRS52P 
transgenic mice 
Amyloid deposits in the tongue of seeded hTTRS52P transgenic mice were localised 
with Congo red staining, exhibiting green birefringence under polariser light. Co-
localisation of the amyloid with human TTR, mouse ApoAII and mouse SAA was 
analysed on adjacent sections. Positive immunohistochemical staining for human 
TTR and negative immuno-staining for mApoAII and mSAA confirmed ATTR amyloid 
deposits in the hearts of amyloidotic mice. 
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6.2.5 Investigation of the presence of cleaved TTR in 
the cardiac amyloid of hTTR
S52P
 transgenic mice 
In ATTR cardiac amyloidosis, the deposits typically contain fragmented TTR 
(Cornwell et al., 1988, Bergstrom et al., 2005, Ihse et al., 2013) which 
suggests that proteolytic cleavage may be important in the pathogenesis of 
ATTR amyloidosis. In vitro biochemical characterisation of wild-type TTR and 
pathogenic TTR variants, all associated with ATTR cardiac amyloidosis 
showed that trypsin-induced proteolytic cleavage results in rapid conversion 
into amyloid fibrils under physiological conditions, whereas un-cleaved TTR 
and TTR variants did not form amyloid under the same conditions (Mangione 
et al., 2014, Marcoux et al., 2015). Moreover, the cleavage occurred between 
amino acids 48 and 49 of the mature proteins, the same position at which 
cardiac TTR is cleaved in ATTR cardiac amyloidosis patients (Marcoux et al., 
2015). Importantly, the S52P variant was much more susceptible to cleavage 
at this site than wild-type TTR and any other TTR variant analysed (Mangione 
et al., 2014, Marcoux et al., 2015).  
To determine whether the amyloid in the hTTRS52P transgenic mice contained 
cleaved TTR, insoluble material from the hearts of two amyloidotic transgenic 
mice were homogenised, the homogenate was centrifuged to concentrate the 
insoluble material and washed 4 times to remove all soluble material and the 
washed pellet was analysed by Western blot. Sheep anti-human TTR 
antibody (Binding site, UK) was used in the analysis as this antibody 
recognises the 49-127 fragment of TTR as well as the full-length TTR. Full-
length TTR was detected in the soluble supernatant of the tissue homogenate 
as expected. However, in the insoluble material of both hearts, only full-length 
TTR was detected and the predicted cleaved fragment of TTR was not 
detected (Figure 6.13). This finding suggests that the failure to cleave the 
TTRS52P in the transgenic mice may have limited the spontaneous amyloid 
deposition in the animals which was only achieved after provision of 
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exogenous seeds. These observations also suggest that cleavage of the TTR 
may accelerate the initial formation of amyloid seeds. 
 
 
 
   
 
Figure 6.13: TTR deposited in the heart of amyloidotic hTTRS52P transgenic 
mice 
Western blot analysis of insoluble material pelleted from the hearts of two 
amyloidotic hTTRS52P transgenic mice showed that the TTR deposited in the hearts is 
un-cleaved full length protein. One transgenic mouse was on mouse TTR wild-type 
background seeded with AEF and one transgenic mouse was on mouse TTR-KO 
background seeded with fibrils and AEF. The hearts were homogenised and the 
supernatant containing the soluble material (lane 1) was removed. The pellet (P) was 
washed three times to remove the remaining soluble proteins. The supernatants 
collected from the three washes (lanes 2, 3 and 4 – respectively) were also run on 
the gel to check no carry-over of soluble proteins in the pellet. Recombinant 
hTTRS52P cleaved with trypsin (R), showing the full-length hTTR (1-127 hTTRS52P) 
and the released 49-127 fragment (49-127 hTTRS52P) which was kindly provided by 
Dr Riccardo Porcari,  was run alongside the samples as a control. 
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6.2.6 Summary of the results of amyloid deposition in 
the hTTR
S52P
 transgenic mice 
No spontaneous ATTR amyloid was observed in the hTTRS52P transgenic 
mice despite high levels of plasma human TTRS52P variant and despite 
thorough search of up to 22 different tissues in which ATTR amyloid may 
occur in ATTR amyloidosis. However, upon seeding with ex vivo-isolated 
ATTRS52P fibrils and/or AEF of ATTRS52P spleen extract, amyloid was found 4-
11 months after seeding in 22 out of 31 transgenic mice analysed, and no 
amyloid was found in 12 seeded non-transgenic control mice. Strikingly, all 18 
seeded males were amyloidotic, in marked contrast to only 4 out of the 13 
females having detectable amyloid deposits. Cardiac amyloid was present in 
16 of the 18 males, but in only 1 of the 4 amyloidotic females. Amyloid was 
also detected in the tongue in the seeded mice (16/18 amyloidotic males; 4/4 
amyloidotic females). Interestingly, the amyloid deposits developed in mice on 
all genetic backgrounds – mouse TTR wild-type, heterozygous and knock-out, 
and no difference was seen in the onset and/or the amount of amyloid 
deposited in the tissues in these mice. The deposited TTR in two hearts of 
amyloidotic mice analysed was full-length TTR. 
 
  
246 
 
6.3 Discussion 
Despite many attempts to model ATTR amyloidosis in mice, no or very little, 
inconsistent ATTR amyloid deposition has been achieved in transgenic mice 
to date. In this thesis, transgenic mice expressing highly amyloidogenic 
human TTRS52P variant have been generated and the data presented here 
demonstrate that the hTTRS52P transgenic mice develop consistent amyloid 
deposition in the heart, the site of amyloid deposition in cardiac ATTR 
amyloidosis in humans. Furthermore, hTTRS52P amyloid deposits were found 
in the tongues of the transgenic mice which were more extensive than those 
found in the heart. Although amyloid in the tongue has not often been 
documented in ATTR amyloidosis patients, macroglossia caused by ATTR 
amyloid has been reported (Cowan et al., 2011). Without macroglossia, the 
presence of amyloid in the tongue is unlikely to be investigated in the 
patients. 
Although others have reported cardiac amyloid in hTTR transgenic mice, the 
data presented did not unequivocally demonstrate that the amyloid was TTR 
amyloid as outlined previously. The analysis reported here demonstrate that 
the amyloid in this model is composed of hTTR because in adjacent sections 
the Congo red positive amyloid was coincident with hTTR immunoreactivity 
and did not react with anti-mouse SAA or anti-mouse ApoAII. Furthermore, 
recent proteomic analysis of amyloid from the hearts of amyloidotic hTTRS52P 
transgenic mice by laser-capture microdissection and mass spectrometry 
confirmed that the amyloid was hTTRS52P (Dr Graham Taylor, Dr Nigel 
Rendell and Janet Gilbertson – personal communication). No mouse TTR 
was detected by this assay in the amyloid deposits in a transgenic mouse on 
mouse TTR wild-type background. 
In amyloidosis, pathological amyloid fibrils form from normally soluble proteins 
which are present in an organism for a long time before the disease develops. 
In this lag phase, which in case of ATTR amyloidosis can take decades, first 
amyloid fibril assemblies, “seeds”, are formed (Jarrett and Lansbury, 1993, 
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Kelly, 1998) which act as a template for further deposition. This process 
occurs stochastically in vivo. In the hTTRS52P transgenic mice, amyloid 
deposition was achieved only after a provision of exogenous seeds containing 
ATTR amyloid fibrils despite high production of the hTTRS52P. Together, these 
observations show that the endogenous formation of amyloid seeds was 
limiting and therefore spontaneous amyloid deposition was not observed. 
In wild-type ATTR amyloidosis patients, the amyloid in the heart contains 
cleaved TTR as well as full-length protein (Dwulet and Benson, 1986, 
Bergstrom et al., 2005). The highly amyloidogenic S52P variant was found to 
be cleaved in the spleen of a patient carrying this variant and in vitro cleaved 
human S52P TTR readily forms amyloid under physiological conditions 
(Mangione et al., 2014). Against this background, it was expected that any 
TTR amyloid deposits in the transgenic mice would contain cleaved TTR. 
Unexpectedly, in the mice presented here, the cardiac ATTR amyloid 
deposits consisted of the full-length TTRS52P, and the predicted cleaved 
product was not detected. The best evidence suggests that proteolytic 
cleavage precedes amyloid deposition in ATTR amyloidosis. However, it is 
not known yet, which protease(s) catalyse the cleavage of TTR in humans. 
Differences in the selectivity or efficiency between human and murine 
proteases in TTR processing or absence of proteases involved in TTR 
cleavage in mice could explain why ATTR amyloidosis does not naturally 
occur in mice and why it has been so difficult to model ATTR amyloidosis in 
mice. The lack of proteolytic cleavage of the hTTR in the hTTRS52P transgenic 
mice could also explain why the mice did not develop spontaneous amyloid 
deposits despite very high concentrations of the hTTRS52P in the plasma.  
Although fragmented TTR is normally present in cardiac TTR amyloid, in 
some patients carrying V30M variant TTR, amyloid deposits in the heart are 
composed of purely full length TTR (Bergstrom et al., 2005), demonstrating 
that cleavage is not an essential prerequisite for cardiac TTR amyloid. 
Amyloid deposits in the hTTRS52P transgenic mice presented here were 
observed regardless of the presence or absence of murine TTR in these 
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mice. Other groups that generated hTTR transgenic mice (hTTRV30M or 
hTTRL55P transgenics) reported that the presence of murine TTR delays 
deposition of human TTR in the transgenic mice (Sousa et al., 2002, Tagoe et 
al., 2007). It was then shown that in the transgenic mice in which both, murine 
and human TTR were present, hybrid TTR heterotetramers composed of 
mouse and human TTR monomers were formed and that in the presence of 
mouse TTR, circulating human TTR was much more stable to denaturation 
(Tagoe et al., 2007). In vitro experiments than showed that mouse TTR and 
mouse/human TTR heterotetramers are much more kinetically stable than 
human TTR and a subunit exchange that is normally observed in human TTR 
in vitro was not observed between mouse and human TTR over time 
(Reixach et al., 2008). From these observations, the authors concluded that in 
transgenic mice expressing human TTR, the presence of mouse TTR may 
prevent dissociation of the mixed TTR heterotetramers and thus prevent 
human TTR fibrillogenesis and amyloid deposition. In the hTTRS52P transgenic 
mice presented here, the expression of mouse TTR did not have a major 
effect on the onset or the amount of hTTR amyloid deposits in the transgenic 
mice. This demonstrates that the presence of mouse TTR does not prevent 
amyloid formation in transgenic mice expressing both human and mouse 
TTR.  
Interestingly, the hTTRS52P transgenic mice recapitulate the yet unexplained 
male prevalence of clinical cardiac ATTR amyloid (Rapezzi et al., 2008, 
Pinney et al., 2013b). In people and in the mice presented here, the sex 
difference in susceptibility to ATTR amyloidosis might reflect the higher TTR 
concentration in males (Ingenbleek and De Visscher, 1979, Ingenbleek and 
Bernstein, 2015), although in healthy humans this difference is only modest. 
The minor difference of TTR abundance suggests that other sex-dependent 
mechanisms may be involved in the male predisposition to cardiac ATTR 
amyloidosis. Therefore, the hTTRS52P transgenic mice can be a valuable tool 
in investigating these differences. One approach to investigate this would be 
to make the female mice homozygous for the TTRS52P transgene which could 
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lead to double dose of the TTRS52P variant in the plasma. Hemizygous 
transgenic males and homozygous transgenic females would then be 
expected to have similar circulating concentrations of the human TTR variant. 
If the male prevalence remains despite similar measured serum TTR 
concentrations, it will be an indicator of sex-difference mechanisms involved 
in susceptibility to ATTR amyloidosis. If the male prevalence disappears when 
the measured plasma hTTR concentration is equalised between transgenic 
males and females, it will be an indicator that the TTR concentration is a 
critical determinant of susceptibility to ATTR amyloidosis. 
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7 Final Discussion 
 
Two transgenic mouse models have been generated expressing extremely 
amyloidogenic variants of human proteins associated with severe phenotypes 
of hereditary systemic amyloidoses in people – Aβ2mD76N amyloidosis and 
ATTRS52P amyloidosis. Although both variants are highly penetrant in humans 
with an early onset in mid-adult life, the transgenic mice did not develop 
spontaneous amyloidosis, despite high plasma concentrations of the variants. 
It is important to emphasize that phenotypic variations in people exist 
between individuals and populations due to genetic and environmental 
factors. In the carriers of V30M variant TTR, the age of onset of the disease is 
on average 56 years in the Swedish population, whereas the average age of 
onset is 34 years in the Portuguese population. In addition, at 40 years of 
age, 5 % of the Swedish and French V30M population will have developed 
symptomatic disease compared to 55-90 % of the Portuguese V30M 
population (Hellman et al., 2008, Sousa et al., 1993, Sousa et al., 1995). It 
was also reported that the penetrance of the V30M variant in Swedish 
population is higher when the mutation is inherited from the mother than the 
father (Hellman et al., 2008).  This phenomenon was partly explained by an 
effect of mitochondrial DNA polymorphism on the expression of the TTR 
mutation (Bonaiti et al., 2010) and partly it could be due to DNA imprinting 
(Bonaiti et al., 2010).  Phenotypic variation has even been described between 
monozygotic twins (Holmgren et al., 2004). These observations indicate that 
genetic and environmental factors play an important role in amyloidosis. 
Because such phenotypic variations are seen among humans, it is not 
surprising that differences exist between humans and mice. Thus, differences 
between humans and mice, e.g. genetic background, proteome and 
extracellular matrix will have an effect, at least to some extent, on amyloid 
protein processing, metabolism, turnover, fibrillogenesis and deposition. 
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In amyloidosis, concentration of the precursor protein is a limiting factor in 
amyloid formation in both humans (Lachmann et al., 2007) and mice (Simons 
et al., 2013), affecting the dynamics of the protein deposition as amyloid and 
amyloid regression. In fact, reducing the concentration of the precursor 
protein is one of the most important strategies in therapy of amyloidoses 
(Lachmann et al., 2007, Comenzo et al., 2012, Weiss et al., 2016, Nakamura, 
2011, Adams, 2013). In both transgenic mouse models presented here, the 
plasma concentrations of the human proteins, β2m and TTR, were similar or 
higher than the concentrations of equivalent proteins seen in patients of 
Aβ2mD76N and ATTRS52P amyloidoses, respectively, and among the highest 
ever reported in transgenic mice expressing these human proteins. Although 
the hβ2mD76N transgenic mice did not develop Aβ2m amyloid deposits, the 
hTTRS52P transgenic mice did develop ATTR amyloidosis when the amyloid 
deposition was primed by seeding. Given the background knowledge of the 
propensity of both variants to aggregate into amyloid fibrils in people and in 
vitro, other factors related to differences between human and murine 
physiology may have influenced the conversion of the soluble proteins into 
amyloid fibrils, some of which are discussed below. 
The role of proteolysis in protein fibrillogenesis has been intensively studied 
(Westermark et al., 1996, Marcoux et al., 2015). In cardiac ATTR amyloidosis, 
cleaved TTR is a major component of ATTR amyloid fibrils (Dwulet and 
Benson, 1986, Bergstrom et al., 2005), in Aβ2m amyloidosis, truncated 
species of β2m missing the first six N-terminal residues are a component of 
Aβ2m amyloid deposits (Gorevic et al., 1986, Stoppini et al., 2005). In AA 
amyloidosis, the amyloid proteins in the deposits are also fragmented 
(Rocken et al., 2005) and studies have shown that cathepsin B may 
contribute to the conversion of SAA protein to AA amyloid fibrils (Yamada et 
al., 1995, Rocken et al., 2005). Interestingly in the same study, while some 
proteases may contribute to protein fibrillogenesis, other proteases have a 
protective role over amyloid fibril formation (Stix et al., 2001, Rocken et al., 
2005).  
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In a patient of ATTRS52P amyloidosis, ATTR amyloid deposits in the spleen 
have been shown to consist of fragmented TTR as well as the full-length 
protein (Mangione et al., 2014) and the S52P variant has been shown to be 
highly susceptible to proteolytic cleavage in vitro and the cleaved variant was 
readily amyloidogenic (Marcoux et al., 2015). However, in the hTTRS52P 
transgenic mice presented here, only full-length S52P variant TTR was 
detected in the cardiac ATTR amyloid deposits. Differences in proteases 
concentrations, turnover, recognition and inhibition between humans and 
mice could explain this observation. The fact that cardiac ATTR amyloidosis 
was achieved in the hTTRS52P transgenic mice only after provision of 
exogenous seeds and not spontaneously could be explained by the lack of 
proteolytic cleavage of TTR in the animals, which may have limited the initial 
formation of endogenous seeds and thus limit the spontaneous development 
of ATTR deposits. The lack of proteolytic cleavage of TTR observed in the 
hTTRS52P transgenic mice could also be explained by a difference in protease 
inhibitors between humans and mice. Interestingly, in the hβ2mD76N 
transgenic mice, the β2m protein was found to circulate in a complex with a 
component that has not been identified yet. Complexed β2m has been 
observed in plasma of mice (Natori et al., 1976) and rats (Nguyen-Simonnet 
et al., 1982) but in humans, >98 % of plasma β2m circulates as a free 
monomer (Plesner and Bjerrum, 1980). Although a fraction of β2m may 
circulate in the plasma of the transgenic mice complexed with MHC class I 
heavy chain, as about 2 % of β2m was found to be bound to MHC class I 
heavy chain in human plasma (Plesner and Bjerrum, 1980), majority of β2m 
in mouse plasma was found to be complexed with a different, non-identified 
molecule (Natori et al., 1976). The observation that the β2m is complexed in 
the plasma of the transgenic mice raises a question whether extracellular 
chaperones may be the partners of β2m in the plasma of mice. As it was 
discussed earlier, identification of chaperons and their role in protein 
fibrillogenesis have been recently studied (French et al., 2008, Lashley et al., 
2006). 
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A common feature in all types of amyloidosis in humans is the presence of 
SAP in amyloid deposits (Pepys et al., 1979). Although SAP is a plasma 
protein in both humans and mice, it was shown that human SAP binds much 
more avidly to amyloid in vivo than mouse SAP (Hawkins et al., 1988). Given 
the stabilising role of SAP on amyloid deposits by preventing proteolysis of 
the amyloid fibrils (Tennent et al., 1995), the lower affinity of mouse SAP to 
amyloid deposits may play an important role on the dynamic of the turnover of 
amyloid in mice, when the amyloid deposition is not exceeding the gradual 
rate of resorption of the amyloid fibrils. Thus, spontaneous amyloid deposition 
of a precursor protein in mice may require relatively longer time than in 
humans, taking the time scale of the life span of both species into 
consideration. Indeed, in transgenic mice lacking mouse SAP, induced AA 
amyloid deposition was delayed and the quantity of the deposits was reduced 
in the SAP knock-out mice compared to mice expressing SAP, despite equal 
elevated production of SAA (Botto et al., 1997). It would be interesting to see 
whether expression of human SAP in the two transgenic mouse models 
presented here would have an effect on amyloid deposition. 
Another factor that may influence the aggregation of amyloidogenic proteins 
is the composition of extracellular matrix. The main components are elastic 
fibres, fibrillar collagens and glycosaminoglycans and a role of these 
components on amyloid fibril formation has been studied in vitro (Stevens and 
Kisilevsky, 2000, Relini et al., 2006) as the glycosaminoglycan heparan 
sulphate is found co-localised with amyloid deposits in humans. In vivo 
evidence that the glycosaminoglycan heparan sulphate can affect the 
development of amyloidosis was provided in transgenic mice which 
selectively overexpressed heparanase in the liver and in the kidney, but not in 
the spleen (Li et al., 2005). The overexpression of heparanase caused 
shortening of heparan sulphate chains in the liver and the kidney, which led to 
inhibition of induced AA amyloid deposition in these organs but not in the 
spleen of the transgenic mice (Li et al., 2005).  
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Histological identification of amyloid in tissues by green birefringence under 
cross-polarised light following Congo red staining is the golden standard for 
confirmation of amyloid deposition (Puchtler H, 1962). Although binding of 
Congo red to amyloid is specific, it is not very sensitive and requires an 
adequate amount of amyloid. When patients are diagnosed for presence of 
amyloid by Congo red staining of tissue biopsy, this usually means that there 
is a clinical evidence of a disease which suggests that substantial amounts of 
amyloid may be present within certain tissues. In the hTTRS52P transgenic 
model presented here, Congophilic amyloid deposits were detected in the 
heart and the tongue of the seeded transgenic mice. However, no 
spontaneous amyloid deposition was detected by Congo red in these mice 
and no amyloid was detected in the hβ2mD76N transgenic mice. The 
requirement for an adequate amount of amyloid within the tissue in order to 
provide a detectable signal by Congo red may not have been met in the non-
amyloidotic transgenic mice. However, this does not necessarily mean that 
amyloid deposits were not present. The deposits may have been of a diffused 
nature within tissues in amounts in which the bound Congo red dye is of 
limited quantity to exhibit detectable signal. In fact, a difference in the signal 
provided by Congo red bound to cardiac amyloid deposits was reported in 
wild-type ATTR and ATTRV30M amyloidosis patients (Bergstrom et al., 2005). 
The comparative study revealed that ATTR amyloid seems to occur in two 
morphologically, histochemically and structurally distinguishable forms in 
these patients. One form of the amyloid deposits consisted of full-length 
TTRV30M, was more compact and strongly Congophilic and birefringent. The 
other form of the amyloid deposits consisted of either fragmented wild-type 
TTR or a mixture of fragmented wild-type TTR and TTRV30M, was more 
diffused, homogeneous and widespread and showed weak Congo red signal 
and birefringence (Bergstrom et al., 2005). However, for modelling 
amyloidosis in mice, sufficient amounts of amyloid in the tissues are 
necessary to resemble the human disease. 
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To date there are no reports of any animal model of cardiac amyloidosis 
ideally suited to test the functional efficacy or safety of any treatment for 
cardiac amyloidosis, or for new diagnostic imaging technologies. Modelling of 
AA amyloidosis in mice enabled an invention and clinical development of SAP 
scintigraphy (Hawkins et al., 1988, Hawkins et al., 1990b, Hawkins et al., 
1990a) for diagnosis and management, which was commissioned by the NHS 
in 1999. The SAP scan is highly specific and quantitative in vivo method 
which enables to evaluate the visceral amyloid burdens and response to 
treatment, it is unable to evaluate amyloid in the moving heart. Cardiac MRI 
has been recently used as a novel tool to monitor amyloid load in the heart 
showing a high specificity for diagnosis of cardiac amyloidosis (Maceira et al., 
2005, Fontana et al., 2015). Recently, 99m-technetium (99mTc) labelled 
phosphate derivative (99mTc-DPD) used as a nuclear bone scintigraphy tracer 
was found to localise in hearts of all patients with cardiac ATTR amyloidosis 
and in a small proportion of patients with AL amyloidosis (Puille et al., 2002, 
Perugini et al., 2005, Hutt et al., 2014). The mechanisms by which 99mTc-DPD 
localises to amyloidotic hearts and the reason for a difference seen in its 
reactivity with cardiac amyloid among AL patients are completely unknown 
which limits the clinical value of this diagnostic technique. The novel hTTRS52P 
transgenic model of cardiac amyloidosis presented here will be a valuable 
tool for elucidation of the mechanisms of 99mTc-DPD localisation and for 
investigation of the outcomes of serial monitoring of the course of the 
disease. 
At present, no specific treatment is available for cardiac ATTR amyloidosis. 
Two small molecules, Tafamidis and non-steroidal inflammatory drug 
Diflunisal, which kinetically stabilize the native TTR tetramer and thus inhibit 
its dissociation and TTR amyloid formation, are under investigation in clinical 
trials (Bulawa et al., 2012, Coelho et al., 2012, Castano et al., 2012). 
Approaches to reduce TTR production through nucleic acid intervention – 
anti-sense oligonucleotide targeting TTR (Ackermann et al., 2012) and 
anti-TTR small interfering RNA (Coelho et al., 2013) are also in clinical trials. 
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Both strategies may decrease the rate of amyloid deposition, with potential to 
slow down or stop disease progression. Indeed, in a mouse model expressing 
TTRV30M, TTR knockdown by small interfering RNA was recently reported to 
decrease non-fibrillar deposits of transgenic human TTR (Butler et al., 2016). 
In the TTRV30M mouse model used, the mice were reported to have TTR 
deposits, however these were not ATTR amyloid deposits (Santos et al., 
2010). Although the TTR deposits regressed after the interfering RNA 
intervention, the influence of pre-formed amyloid deposits in tissues and the 
regression of amyloid could not be evaluated. In the hTTRS52P transgenic 
mice presented here, both the gene silencing effect of TTR expression and its 
effect on amyloid deposits could be investigated. It has been seen in patients 
(Gillmore et al., 2001, Lachmann et al., 2007) and confirmed in transgenic 
mice (Simons et al., 2013) that an increase in concentration of precursor 
protein after regression of amyloid deposition can lead to a rapid development 
of amyloid deposits, probably due to remaining templates of amyloid within 
the tissue. In the inducible AA transgenic model, increased SAA 
concentrations led to a development of heavy AA amyloid deposits in the 
liver, the spleen and a minor amyloid deposition in the heart. However, after 
re-induction of SAA expression in the transgenic mice in which amyloid had 
previously been induced and spontaneously regressed, renal failure 
developed very rapidly due to amyloid deposits in kidney (Simons et al., 
2013). This response closely resembled the rapid onset of renal failure 
precipitated by flares of inflammation in some AA amyloidosis patients in 
remission (Gillmore et al., 2001, Lachmann et al., 2007) suggesting that 
glomeruli amyloid deposits may be responsible (Simons et al., 2013). This 
observation points out the importance of a different pattern in amyloid 
re-accumulation following regression, possibly due to different distribution of 
amyloid template after the regression (Simons et al., 2013). 
An immunotherapeutic approach targeting directly amyloid deposits for 
removal is under investigation in clinical trials. Antibodies to SAP, a universal 
constituent of human systemic amyloid deposits is used to activate 
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complement of the deposits thereby attracting and engaging macrophages 
which have the capability to engulf and destroy amyloid load (Bodin et al., 
2010). This approach was tested in AA amyloid mouse model in which the 
anti-SAP antibody led to clearance of abundant visceral amyloid deposits 
(Bodin et al., 2010). In fact, the first human phase 1 clinical trial of anti-SAP 
antibody treatment has shown very promising results (Richards et al., 2015), 
but cardiac amyloidosis was excluded from the phase 1 trial for safety 
reasons. Although there is an AA amyloidosis mouse model which presents 
with minor cardiac amyloid deposits, the mice predominantly develop heavy 
amyloid deposits in the liver and the spleen (Simons et al., 2013). Although 
the anti-SAP antibody treatment showed significant reduction of the cardiac 
amyloid in the heart in the AA mouse model, this was achieved only after a 
second dose of the treatment because of the abundant amyloid deposits in 
the liver and the spleen. The overabundance of amyloid in the viscera may 
complicate the functional studies of the heart and thus the model is not ideally 
suitable for evaluation of treatment targeting cardiac amyloidosis. The 
hTTRS52P transgenic mice which closely resemble the amyloid deposition in 
ATTR cardiac amyloidosis patients provide a great advantage for further 
testing of the mechanisms and safety of emerging treatments and 
development of new treatments of cardiac amyloidosis. 
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8 Future work 
 
The established hβ2mD76N and hTTRS52P transgenic mouse models will be 
further investigated to understand the disease mechanisms, to elucidate 
some molecular mechanisms of amyloid formation and to test possibilities of 
inhibition of amyloid formation. This chapter summarises future work 
discussed in previous sections. 
 
hβ2mD76N transgenic mouse model: 
 Identification of a molecule complexed with circulating β2m protein. 
 Attempt of priming of amyloid deposition by repeated administration of 
amyloid-fibril seeds. 
 Investigation of the effects of amyloid-associated molecules (human SAP, 
glycosaminoglycans) on the conversion of the β2mD76N protein into amyloid 
by manipulation of the extracellular environment (e.g. crossing with hSAP 
transgenic mice). 
 Evaluation of β2m protein levels in chronic kidney disease mouse models 
and the use of such models to increase the concentration of circulating 
β2mD76N variant which may lead to deposition of the β2mD76N protein as 
amyloid. 
 Breeding of the hβ2mD76N transgenic mice on different backgrounds (e.g. 
Balb/c background) to investigate whether different mouse strain 
phenotypes may influence the conversion of the β2mD76N protein into 
amyloid. 
 
hTTRS52P transgenic mouse model: 
 Evaluation of the age-effect on amyloid deposition by seeding 2 months old 
mice and 12-18 months old mice and comparison of the amyloid load in the 
mice at specific time points. 
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 Investigation of male preponderance of cardiac ATTR amyloidosis by 
producing homozygous females which will have a double dose of the 
transgene and comparing them with hemizygous males. Hemizygous 
males and homozygous females are expected to produce similar amounts 
of hTTR. If the male preponderance remains despite the fact that the males 
and females express similar levels of the hTTR, it will clearly suggest that 
other gender differences influence ATTR amyloid deposition. 
 Investigation of the mechanisms of 99mTc-DPD localisation in the heart and 
other organs of ATTR amyloidotic animals. 
 Suppression of TTR (e.g. by RNA inhibition) and its effect on amyloid 
deposition in the hTTRS52P transgenic mice. 
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